Branched payload-linker compounds for manufacture of targeting molecule-drug-conjugates

Branched payload-linker compounds with reactive groups and cleavable linkers address low drug-to-targeting molecule ratios and stability issues, enabling efficient and controlled payload release at the target site, improving therapeutic efficacy and serum stability.

WO2026234635A1PCT designated stage Publication Date: 2026-11-12DEBIOPHARM RESEARCH & MANUFACTURING SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/054577
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing targeting molecule-drug conjugates, particularly antibody-drug conjugates, face challenges with low drug-to-targeting molecule ratio (DAR), inefficient drug release at the target site, and stability issues in serum, leading to systemic toxicity and reduced efficacy.

Method used

The development of branched payload-linker compounds with reactive groups that form covalent bonds with targeting molecules, incorporating branching groups and cleavable linkers to enhance drug loading and controlled release, ensuring high drug-to-targeting molecule ratios and improved serum stability, even for poorly soluble payloads.

Benefits of technology

The compounds achieve efficient delivery and release of payloads in their active state at the target site, enhancing therapeutic effects while maintaining serum stability and reducing off-target effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2026054577_12112026_PF_FP_ABST
    Figure IB2026054577_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to a compound comprising at least two payloads, linkers, and a reactive group having the ability to react with a functional group in a targeting molecule, as well as to a targeting molecule-drug conjugate, such as an antibody-drug conjugate comprising at least two payloads. Furthermore, the present disclosure relates to a method of manufacturing a targeting molecule-drug conjugate using a compound according to the present disclosure. Additionally, the present disclosure relates to a targeting molecule-drug conjugate as disclosed herein, such as an antibody-drug conjugate as disclosed herein, for use in medicine, such as for use in a method of treating or diagnosing cancer, an autoimmune disease, a bacterial infection, or a viral infection.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] BRANCHED PAYLOAD-LINKER COMPOUNDS FOR MANUFACTURE OF TARGETING MOLECULE-DRUG-CONJUGATES Technical Field

[0002] The present disclosure relates to a compound comprising at least two payloads, linkers, and a reactive group having the ability to react with a functional group in a targeting molecule, as well as to a targeting molecule-drug conjugate, such as an antibody-drug conjugate comprising at least two payloads. Furthermore, the present disclosure relates to a method of manufacturing a targeting molecule-drug conjugate using a compound according to the present disclosure. Additionally, the present disclosure relates to a targeting molecule-drug conjugate as disclosed herein, such as an antibody-drug conjugate as disclosed herein, for use in medicine, such as for use in a method of treating or diagnosing cancer, an autoimmune disease, a bacterial infection, or a viral infection.

[0003] Background of the invention

[0004] In recent years, research and development of targeting molecule-drug conjugates, such as antibody-drug conjugates (ADCs), have been actively conducted. Such conjugate, as implied by the name, comprises a targeting molecule and a drug or similar compound, e.g. a labelling agent or a diagnostic agent, which are connected to each other via a linker. Methods to conjugate targeting molecules are applied in various fields, including medicine, diagnostics, biocatalysis and materials.

[0005] Upon administration of such targeting molecule-drug conjugate to a patient, e.g. to a patient in need of a treatment of a disease, each of the components of the targeting moleculedrug conjugate fulfils a specific purpose:

[0006] The targeting molecule, such as an antibody, comprised in the targeting molecule-drug conjugate directs the targeting molecule-drug conjugate to its site of action. For instance, the targeting molecule or antibody may be specifically selected in that it binds to a specific type of cell associated with the disease to be treated, such as a cancer cell. Therefore, the targeting molecule-drug conjugate can be delivered to said specific target cells.

[0007] After delivery of the targeting molecule-drug conjugate to the target cells, the linker of the targeting molecule-drug conjugate that connects the drug (or other payload) to the targeting molecule may be cleaved thus releasing the drug (or other payload), such as an anticancer agent or a radionuclide, is released at the target site.

[0008] Therefore, the action of the drug or other payload at off-target sites is reduced. For example, when the drug is an anticancer agent, its damage to healthy cells / non-cancerous tissue and the systemic effects are reduced. At the same time, the potency of such anticancer agent may be considerably increased when compared to the respective anticancer agent when given systemically when given on its own.

[0009] DV: MHOAn example of an antibody-drug conjugate is trastuzumab emtansine, also known as T-DM1 (trade name: Kadcyla®).

[0010] Targeting molecule-drug conjugates including T-DM1 have had the problem of their low loading with the payload, such as a therapeutic agent. In other words, the drug / targeting molecule ratio or drug / antibody ratio (DAR) is low.

[0011] Furthermore, one of the biggest technical hurdles for targeting molecule-drug conjugates in general and antibody-drug conjugates specifically is effective and controlled drug release at the target site. A linker is the chemical bridge that connects the targeting molecule or antibody (the targeting part) to the payload (the therapeutic or diagnostic part). Said linker needs a “Goldilocks balance” — stable in the bloodstream but easily broken in or near the target site, such as a tumor. Thereby, it is understood that the payload must also not be altered upon release but released in its most active state - in other words, the payload is released in its native state.

[0012] If the linker is too unstable, the payload leaks into circulation potentially resulting in systemic toxicity or the like. Thus, a linker needs to be chemically resistant to serum proteases, pH changes, and glutathione levels found in normal circulation of a subject to avoid premature release of the payload.

[0013] If the linker is too stable, the payload cannot be released in its native state at the target site, reducing efficacy. Therefore, the linker may not use non-cleavable chemistry or include sterical hindrance.

[0014] In other words, the linker has to be stable against various conditions, but unstable at the target site where it is to be cleaved, such as by enzymes (e.g. cathepsin B as in Brentuximab vedotin, trade name: Adcetris® or a fibroblast activation protein) or by lysosomal degradation (e.g. T-DM1, Kadcyla).

[0015] Summary of the invention

[0016] Therefore, there is a high need for targeting molecule-drug conjugates and antibodydrug conjugates that address the issues above.

[0017] In particular, the present disclosure provides targeting molecule-drug conjugates, in particular antibody-drug conjugates, that release the payload in or close to the target site in an improved manner thereby not altering the payload, and compounds for manufacturing such targeting molecule-drug conjugates. Thus, the payload may be delivered and released in its most active state more efficiently thus increasing the therapeutic effect and / or other benefits of the payload and targeting molecule. Furthermore, the present disclosure provides targeting molecule-drug conjugates, in particular antibody-drug conjugates, with superior serum stability.

[0018] Furthermore, the present disclosure solves the problem of low drug / targeting molecule ratio and drug / antibody ratio (DAR) by providing the compounds comprising payload, a branching group, linkers, and a reactive group having the ability to react with a functional group in a targeting molecule, preferably yielding a high DAR of 16 even for poorly soluble lipophilicpayloads, with resulting conjugates demonstrating high serum stability. Additionally, the present disclosure provides payload combinations with different mode of action (e.g. resistance to efflux, bystander effect) as well as synergistic payload combinations.

[0019] In a first aspect, the present disclosure relates to a compound of formula (I)

[0020] A-L-B(-E)e(I)

[0021] wherein A is a reactive group having ability to react with a functional group in a targeting molecule; L is a divalent linker group; B is a branching group; e is an integer of 2 or more; and each E is independently a group of formula (IE)

[0022]

[0023] wherein the wavy line in formula (IE) means bond to B; each Leis independently a divalent linker group; each f is independently an integer of 0 or 1; each Pep independently comprises 1 to 6 amino acid groups; each T is independently a solubilizing group; each CL is independently a cleavable linker group; and each group P-X1is a payload, wherein each X1is independently O, S, NR1, or N+R1R11, wherein R1and R11are each independently a hydrogen or an organic residue.

[0024] In a second aspect, the present disclosure relates to a targeting molecule-drug conjugate of formula (V)

[0025] Ab[-A’-L-B(-E)e]d (V)

[0026] wherein Ab is a targeting molecule; d is at least 1; A’ is a group formed by a reaction between A and a functional group in Ab; and wherein L, B, E, and e are as defined herein with regard to the first aspect of the present disclosure.

[0027] In a third aspect, the present disclosure relates to method of manufacturing a targeting molecule-drug conjugate of formula (V) according to the second aspect of the present disclosure, the method comprising the steps of providing a compound of formula (I) according to the first aspect of the present disclosure, providing a targeting molecule Ab, and reacting said compound of formula (I) according to the first aspect of the present disclosure with the targeting molecule Ab to provide the targeting molecule-drug conjugate according to the second aspect of the present disclosure.

[0028] According to a fourth aspect, the present disclosure relates to a targeting molecule-drug conjugate prepared by the method according to the third aspect of the present disclosure.

[0029] According to a fifth aspect, the present disclosure related to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in medicine, such as for use in a method of treating cancer, or an autoimmune disease, or a bacterial infection, or a viral infection; or for use in a method of diagnosing cancer, or an autoimmune disease, or a bacterial infection, or a viral infection.Brief Description of the Drawings

[0030] Fig. 1 shows the results of in vivo studies according to example 35. Compound 34 as disclosed herein prevents tumor growth efficiently.

[0031] Fig. 2 shows the results of in vivo studies according to example 36. Compound 41 as disclosed herein prevents tumor growth efficiently.

[0032] Fig. 3 shows the results of in vitro mouse and human plasma stability of compounds 58 and 137 according to example 38.

[0033] Fig. 4 shows the results of in vivo pharmacokinetic study conducted on compounds 41 and 135 according to example 39.

[0034] Fig. 5 shows the results of in vivo pharmacokinetic study conducted on compounds 58 and 137 according to example 39.

[0035] Fig. 6 shows the results of in vivo studies according to example 41. Compound 58 as disclosed herein prevents tumor growth efficiently.

[0036] Detailed description of the invention

[0037] Although the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodologies, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0038] In the following, the elements of the present invention will be described. These elements are listed with specific embodiments; however, it should be understood that they may be combined in any manner and in any number to create additional embodiments. The variously described examples and preferred embodiments should not be construed to limit the present invention to only the explicitly described embodiments. This description should be understood to support and encompass embodiments which combine the explicitly described embodiments with any number of the disclosed and / or preferred elements. Furthermore, any permutations and combinations of all described elements in this application should be considered disclosed by the description of the present application unless the context indicates otherwise.The compound of formula (I)

[0039] In a first aspect, the present disclosure relates to a compound of formula (I)

[0040] A-L-B(-E)e(I)

[0041] wherein A is a reactive group having ability to react with a functional group in a targeting molecule; L is a divalent linker group; B is a branching group; e is an integer of 2 or more; and each E is independently a group of formula (IE)

[0042]

[0043] wherein the wavy line in formula (IE) means bond to B; each Leis independently a divalent linker group; each f is independently an integer of 0 or 1; each Pep independently comprises 1 to 6 amino acid groups; each T is independently a solubilizing group; each CL is independently a cleavable linker group; and each group P-X1is independently a payload, wherein each X1is independently O, S, NR1, or N+R1R11, wherein R1and R11are each independently a hydrogen or an organic residue.

[0044] In that, it is understood that each group E of formula (IE) may be selected independently of each other. In other words, according to a preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) comprises 2 or more different groups E. In that, at least one of groups Le, Pep, T, CL, and P-X1are not the same in each of the 2 or more groups E. In particular, the payload P-X1are not the same in the 2 or more groups E, wherein groups Le, Pep, and T are identical.

[0045] According to another preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) comprises 2 or more identical groups E. In that, all groups Le, Pep, T, CL, and P-X1are the same in each of the 2 or more groups E.

[0046] According to a further preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) has the formula (la)

[0047]

[0048] wherein A, L, B, Le, f, Pep, T, CL, and P-X1are as disclosed herein.According to a further preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) has the formula (lb)

[0049]

[0050] wherein A, L, B, Pep, T, CL and P-X1are as disclosed herein.

[0051] In the following, preferred embodiments of the first aspect and / or the second aspect of the present disclosure are described. It is understood that all following preferred embodiments apply to the third aspect of the present disclosure.

[0052] Furthermore, it is understood that the following preferred embodiments of L, B, Le, Pep, T, CL, X1, and P also apply to the second, fourth, and fifth aspect of the present disclosure.

[0053]

[0054] According to the first aspect of the present disclosure, the compound of formula (I) as disclosed herein comprises a reactive group A that has the ability to react with a functional group in a targeting molecule. Said group A is an essential component of the compound of formula (I) as it enables the compound to react with a targeting molecule during formation of a targeting molecule-drug conjugate, such as an antibody-drug conjugate. During the reaction of the group A with a reactive functional group of a targeting molecule, such as an amino acid reacting side-chain (such as -SH of cysteine, -NH₂ of lysine, or -N₃ of a non-canonical amino acid), a covalent bond is formed between said reactive functional group of the targeting molecule, such as an amino acid reacting side-chain, and the group A thus forming a group A’.

[0055] Herein, the terms “A is a reactive group having ability to react with a functional group in a targeting molecule” and “reactive group A”, “A”, and “reactive group A having ability to react with a functional group in a targeting molecule” are used interchangeably. The term “reactive group”, as used herein, is a functional group capable of forming a covalent bond with a functional group of a targeting molecule, such as an antibody or an antibody fragment.

[0056] As used herein, the reactive group A is not particularly limited as long as A is a reactive group having ability to react with a functional group in a targeting molecule. In other words, A is suitable for bioconjugation. Techniques for bioconjugation may be known to the skilled person. Typically, strategies of bioconjugation involve forming a stable covalent link between the targeting molecule and a second molecule, such as a small molecule drugs, biotin, fluorescent or phosphorescent dyes or the like.

[0057] Various bioconjugation reactions have been developed to chemically modify proteins. Common types of bioconjugation reactions on proteins are coupling of lysine, cysteine, andtyrosine amino acid residues, as well as modification of tryptophan residues and of the N- and C-terminus.

[0058] A further strategy may be to first install a unique functional group into a targeting molecule, such as via introducing a non-native amino acid into the targeting molecule, and then a bioorthogonal reaction is used to couple said modified targeting molecule with this unique functional group. The bioorthogonal reactions targeting non-native functional groups are widely used in bioconjugation chemistry. Some important reactions are modification of ketone and aldehydes, Staudinger ligation with organic azides, copper-catalyzed Huisgen cycloaddition of azides, and strain promoted Huisgen cycloaddition of azides.

[0059] It is also possible that the targeting molecule is a small molecule and the reactive group A has the ability to react with a reactive functional group of the small molecule, such as a thiol, amine, hydroxyl, azide, unsaturated alkene or alkyne or carboxylate group of the small molecule. In other words, the group A of the compound of formula (I) as disclosed herein may have the ability to react with a -SH group, an amine group (such as -NH₂), an alcohol group (-OH), a ketone, an aldehyde, or an azide group in a targeting molecule

[0060] According to a preferred embodiment of the present disclosure, the group A is a reactive group having ability to react with a functional group in a targeting molecule. According to another preferred embodiment of the first aspect of the present disclosure, the reactive group A has the ability to react with a -SH group of a cysteine side chain in a targeting molecule.

[0061] According to another preferred embodiment of the first aspect of the present disclosure, the reactive group A has the ability to react with a thiol, amine, azide, unsaturated alkene or alkyne, hydroxyl or carboxylate group of a targeting molecule.

[0062] In other words, according to a preferred embodiment of the first aspect of the present disclosure, A is a reactive group having the ability to react with an -SH group of a cysteine group in a targeting molecule.

[0063] According to another preferred embodiment of the first aspect of the present disclosure, the reactive group A having the ability to react with an -SH group of a cysteine group in a targeting molecule Ab is a maleimide group, or a haloacetamide group, or a acrylamide group, or a vinyl sulfone group, or an aziridine group, or a disulfide group, or a thiol group, or an electron deficient alkyne.According to a further preferred embodiment of the first aspect of the present disclosure, A is a reactive group having the ability to react with an -SH group of a cysteine in a targeting molecule selected from the group consisting of

[0064]

[0065] wherein the wavy line in A means bond to L of the compound of formula (I) of the first aspect of the present disclosure.

[0066] According to a yet further preferred embodiment of the first aspect of the present

[0067] disclosure,

[0068]

[0069] wherein the wavy line in A means bond to L of the compound of formula (I) of the first aspect of the present disclosure.

[0070] According to another preferred embodiment of the first aspect of the present disclosure,

[0071] A is

[0072]

[0073] , wherein the wavy line in A means bond to L of the compound of formula (I) of the first aspect of the present disclosure. It is noted that the aforementioned reactive group A may react with an -SH group of a cysteine in a targeting molecule thus forming a disulfide bond:

[0074]

[0075] According to another preferred embodiment of the first aspect of the present disclosure,

[0076] A is

[0077]

[0078] , wherein the wavy line in A means bond to L of the compound of formula (I) of the first aspect of the present disclosure. It is noted that the aforementioned reactive group A may react with an -SH group of a cysteine in a targeting molecule thus forming a carbon-sulfide bond:

[0079]

[0080] According to another preferred embodiment of the first aspect of the present disclosure,

[0081] A is

[0082]

[0083] , wherein the wavy line in A means bond to L of the compound of formula (I) of the first aspect of the present disclosure. It is noted that the aforementioned reactive group Amay react with an -SH group of a cysteine in a targeting molecule thus forming a carbon-sulfide bond:

[0084]

[0085] According to a further preferred embodiment of the first aspect of the present disclosure, o

[0086] '•

[0087] A is H wherein the wavy line in A means bond to L of the compound of formula (I) of the first aspect of the present disclosure. It is noted that the aforementioned reactive group A may react with an -SH group of a cysteine in a targeting molecule thus forming a carbon-sulfide bond:

[0088]

[0089] According to a most preferred embodiment of the first aspect of the present disclosure, A

[0090]

[0091] wherein the wavy line in A means bond to L of the compound of formula (I) of the first aspect of the present disclosure. It is noted that the aforementioned reactive group A may react with an -SH group of a cysteine in a targeting molecule thus forming a carbon-sulfide bond:

[0092]

[0093] Alternatively the maleimide group may undergo a ring-opening thus forming a group A’ as disclosed herein with regard to the second aspect of the present disclosure.

[0094] The aforementioned reactive groups A provide for a stable and covalent bond of the compound according the first aspect of the present disclosure with a cysteine in a targeting molecule, such as an antibody or an antibody fragment.

[0095] According to another preferred embodiment of the first aspect of the present disclosure, A is a reactive group having the ability to react with an -NH₂ group of a lysine in a targeting molecule. Such functional groups having the ability to react with an -NH₂ group of a targeting molecule are known to the skilled person.

[0096] According to a preferred embodiment of the first aspect of the present disclosure, A has the structure of V-S-Y, wherein V is a vector capable of interacting with a fragment crystallizable (Fc) region of a targeting molecules, such as an antibody or fragment thereof, S is a spacer, and Y is a reactive group capable of reacting with the side chain of an amino acid, preferably cysteine or lysine, most preferably Y is capable of reacting with the side chain of a lysine. It isunderstood that the reactive group Y is covalently attached to the linker group L of the compound of formula (I) as disclosed herein. It is noted that the aforementioned reactive group A having the structure V-S-Y may react with an -NH₂ group of a lysine in a targeting molecule thus forming a covalent bond, such as a carbamate group:

[0097] ,0..0.. o

[0098] v“sY II 7 - ► At) / XN A O+v-s-OH

[0099] O H

[0100] At the same time, the vector V and the spacer S are cleaved off the compound of formula (I). This technology may be further described in WO 2021 / 110860 A1 and

[0101] WO 2022 / 079031 A1 which are incorporated herein by reference.

[0102] Vector V

[0103] According to a preferred embodiment of the first aspect of the present disclosure, the vector V is a peptide. According to another preferred embodiment of the first aspect of the present disclosure, the vector V is a peptide comprising a sequence of 11 to 17 amino acids, preferably 13 to 17 amino acids. According to another preferred embodiment of the first aspect of the present disclosure, the vector V is selected from the group consisting of:

[0104]

[0105] Z2— Asp-Cys— Ala — Trp— His— Leu— Gly-Orn-Leu— Vai — Trp-Cys— Thr — Z1(10h; SEQ ID NO.: 8),S - S

[0106] Z22— Asp-Cys-Dap — Trp— His-Leu— Gly— Glu— Leu— Val— Trp-Cys— Thr — Z1

[0107]

[0108] Z2— Asp-Cys— Ala — Trp— His-Dap-Gly— Glu— Leu— Val— Trp-Cys— Thr — Z1

[0109] (10j; SEQ ID NO.: 10),

[0110] S - S Z22— Asp-Cys— Ala — Trp— His-Dap-Gly— Gln— Leu— Val— Trp-Cys— Thr — Z1

[0111] (10k; SEQ ID NO.: 11),

[0112] S - S Z22— Asp-Cys— Ala — Trp— His-Leu— Gly-Dap-Leu— Val— Trp-Cys— Thr — Z1

[0113]

[0114] Z2— Asp-Cys — hLys— Trp— His-Leu— Gly— Glu— Leu— Val— Trp-Cys— Thr — Z1

[0115]

[0116] Z2— Asp-Cys— Ala — Trp— His-hLys-Gly— Glu— Leu— Val— Trp-Cys— Thr — Z1

[0117] (10n; SEQ ID NO.: 14),

[0118] s - s Z2— Asp-Cys— Ala — Trp— His— Leu— Gly-hLys-Leu— Val— Trp-Cys— Thr — Z1

[0119] (10o; SEQ ID NO.: 15),

[0120] S - S Z22— Asp-Cys-Dab — Trp— His-Leu— Gly— Glu— Leu— Val— Trp-Cys— Thr — Z1

[0121] (10p; SEQ ID NO.: 16),

[0122] S - S Z22— Asp-Cys— Ala — Trp— His-Dab— Gly— Glu— Leu— Val— Trp-Cys— Thr — Z1

[0123] (10q; SEQ ID NO.: 17),

[0124] S - S Z2— Asp-Cys— Ala — Trp— His-Leu— Gly-Dab-Leu— Val— Trp-Cys— Thr — Z1

[0125] (10r; SEQ ID NO.: 18),

[0126]

[0127] Z2— Asp-Cys— Ala — Trp— His— Tyr— Gly— Gln— Leu— Val— Trp-Cys— Thr — Z1

[0128] (10u; SEQ ID NO.: 21),Z2— Asp-Cys— Ala — Trp— His— Leu— Gly— Tyr— Leu— Val — Trp-Cys— Thr — Z1

[0129]

[0130] wherein Z2represents a group covalently attached to the N-terminus of Asp and is selected from a hydrogen atom or a carbonyl containing group, preferably Z2is an acetyl group, and Z1represents a group covalently attached to the C-terminus of Thr and is selected from -N(H)(RV) wherein Rvis a hydrogen atom or an organic residue as disclosed herein, preferably wherein Z1is -NH2.

[0131] According to a further preferred embodiment of the first aspect of the present disclosure, the vector V is of formula (1 Of), wherein Z1is NH2and Z2is acetyl.

[0132] According to another preferred embodiment of the first aspect of the present disclosure, the spacer S is covalently attached to a side-group of an Orn or Lys in the vector V. According to a further preferred embodiment of the first aspect of the present disclosure, the spacer S is covalently attached to a side-group of Orn in the vector V.

[0133] Spacer S

[0134] According to a preferred embodiment of the first aspect of the present disclosure, the spacer S is a single bond. In other words, the reactive moiety Y may be covalently attached to the vector V.

[0135] According to another preferred embodiment of the first aspect of the present disclosure, the spacer S is divalent group, preferably comprising one or more atoms selected from carbon, nitrogen, oxygen, phosphorus and sulfur.

[0136] In an embodiment, the spacer comprises a polyalkylene oxide group having from 1 to 24 repeating units and 2 or 3 carbon atoms per repeating unit, preferably 1 to 10 repeating units; and preferably a group represented by the formula

[0137] -NH-(CH2CH2O)ni-CH2CH2-E’-,

[0138] wherein n1 is an integer of 0 to 24, e.g. 1 to 10, and E’ is (C=O) or (C=S).

[0139] Reactive moiety Y

[0140] According to a preferred embodiment of the first aspect of the present disclosure, the reactive group Y is capable of reacting with a side chain of a lysine in a targeting molecule as disclosed herein.

[0141] According to another preferred embodiment of the first aspect of the present disclosure, the reactive group Y is selected from the group consisting of:

[0142]

[0143]

[0144] wherein the symbol „white circle” indicates covalent attachment to the linker group L, and the symbol “black circle” indicates covalent attachment to the vector V or the spacer S, if present.

[0145] The above groups are capable of reacting with a functional group in the side chain of a targeting molecule as disclosed herein, such as an -NH2 group of a lysine. Thus, a carbamate group or an amide group or the like may be formed.

[0146] Preferred groups A of structure V-S-Y

[0147] According to a further preferred embodiment of the first aspect of the present disclosure, groups V-S-Y together form a structure of formula:

[0148]

[0149] O

[0150] (SEQ ID NO.: 7)

[0151] wherein the wavy line indicates a covalent attachment to the group L of the compound of formula (I) as disclosed herein.

[0152] The divalent linker group L

[0153] According to the first aspect of the present disclosure, the compound of formula (I) as disclosed herein comprises a divalent linker group L. It is understood that the divalent linkergroup L connects the reactive group A having ability to react with a functional group in a targeting molecule to the branching group B.

[0154] According to the second aspect of the present disclosure, the compound of formula (V) as disclosed herein comprises a divalent linker group L. It is understood that the divalent linker group L connects the group A’ to the branching group B.

[0155] As used herein, the terms “L is a divalent linker group”, “linker group L”, “divalent linker group L”, “group L”, and “L” are used interchangeably.

[0156] As used herein, the divalent linker group L is not particularly limited as long as the linker group has two valences, one of which connects the divalent linker group L covalently to the reactive group A having ability to react with a functional group in a targeting molecule, and the other connects the divalent linker group L covalently to the branching group B.

[0157] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has a structure of G^L1L2^<

[0158] z, wherein z is 0 or 1; symbol “black circle” in said divalent linker group L means bond to branching group B; and symbol “white circle” in said divalent linker group L means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure. In other words, the divalent linker L may comprise two parts: a first linker component L1and a second linker component L2.

[0159] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, z is 0. In other words, L2may be absent. In case z is 0, then L1is directly connected to branching group B.

[0160] In other words, when z is 0, then the divalent linker group L has the structure of,

[0161]

[0162] , wherein symbol “black circle” in said divalent linker group L means bond to branching group B; and symbol “white circle” in said divalent linker group L means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0163] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, z is 1. In other words, L2may be present. In case z is 1, then L1is directly connected to L2via a covalent bond and L2is connected to branching group B via a covalent bond.

[0164] The first linker component L1

[0165] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the first linker component L1is a divalent linear or branched Ci-Ce carbonylene, wherein linear or branched C1-C6alkylene group is attached to a carbonyl group. It is understood that the -(C=O)- of said divalent linear or branched Ci-Ce binds to L2. According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the first linker component L1is -(C=O)-, -CH2-(C=O)-, -CH2-CH2-(C=O)-, -CH2-CH2-CH2-(C=O)-,

[0166] or -CH2-CH2-CH2-CH2-CH2-(C=O)-, wherein the -(C=O)-binds to L2. According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the first linker component L1is -CH2-(C=O)-, -CH2-CH2-(C=O)-,

[0167] or -CH2-CH2-CH2-(C=O)-, wherein the -(C=O)-binds to L2.

[0168] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the structure

[0169]

[0170] wherein z is 0 or 1, x is an integer in the range of from 0 to 6, symbol “black circle” in said divalent linker group L means bond to branching group B; and symbol “white circle” in said divalent linker group L means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0171] It is understood that when x is 1, the -(CH2)- group directly binds to A. In other words, if x is 1, the divalent linker group L has the structure

[0172]

[0173] wherein z is 0 or 1, symbol “black circle” in said divalent linker group L means bond to branching group B; and symbol “white circle” in said divalent linker group L means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure. Preferably, when A is a reactive group that has ability to react with an -SH group of a cysteine in a targeting molecule, x is 1. The inventors have surprisingly found that compounds with such divalent linker group L have better plasma stability. Without wishing to be bound by theory, it is postulated that close vicinity (i.e. a single -(CH2)- group) between the carbonyl-group and reactive group A, such as a maleimide group, introduces an electron deficiency on the carbonyl-group of the maleimide, facilitating a stabilizing, ring-opening at pH = 8. Furthermore, the carbonyl-group of L can act as a hydrogen-bond acceptor, thereby coordinating a water molecule from the aqueous medium and holding it in the exact geometric position needed for the ring-opening reaction of the succinimide carbonyl of reactive group A after conjugation.

[0174] It is understood that when x is 0, the -(C=O)- group directly binds to A. In other words, if x is 0, the divalent linker group L has the structure

[0175]

[0176] wherein z is 0 or 1, symbol “black circle” in said divalent linker group L means bond to branching group B; and symbol “white circle” in said divalent linker group L means a) bond to Ain the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0177] In yet other words, if x is 0, then the first linker component L1is -(C=O)-.

[0178] According to a further preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, x is 0 or 1 or 2, preferably 1 or 2.

[0179] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the first linker component L1is a linear or branched C1-C6alkylene. According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the first linker component L1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-(CH-CH3)-CH2-, -CH2-CH2-CH2-CH2-,

[0180] -CH2-CH2-CH2-CH2-CH2-, or -CH2-CH2-CH2-CH2-CH2-CH2-. According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the first linker component L1is -CH2- (methylene), -CH2-CH2- (ethylene),

[0181] or -CH2-CH2-CH2- (propylene).

[0182] In other words, according to a further preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the structure

[0183]

[0184] wherein z is 0 or 1, symbol “black circle” in said divalent linker group L means bond to branching group B; and symbol “white circle” in said divalent linker group L means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0185] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the first linker component is a bond.

[0186] The second linker component L2

[0187] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the second linker component L2is present. In other words, z is 1.

[0188] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the second linker component L2is connected to L1via an amide group or via an ester group. In other words, the carbonyl group of L1and a nitrogen or oxygen atom in the second linker component L2are bound together via a covalent bond. Preferably, the second linker component L2is connected to the first linker component L1via an amide group.

[0189] In yet other words, according to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the second linker component L2comprises a connecting group Z, wherein Z is -O- or-NRN-, wherein RNis H, -CH3, -CH2-CH3,or -CH(CH3)2. Preferably, RNis H. According to a further preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the connecting group Z is -NH-.

[0190] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the second linker component L2comprises at least one -CH2-CH2-O- group. In other words, the second linker component L2may comprise one or more ethylene oxide groups. According to a further preferred embodiment of the present disclosure, the second linker component L2may contain of from 1 to 5 ethylene oxide groups.

[0191] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the second linker component L2comprises a linear or branched C2-C6 carbonylene. According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the second linker component L2is -CH2-(C=O)-, -CH2-CH2-(C=O)-, -CH2-CH2-CH2-(C=O)-,

[0192] or -CH2-CH2-CH2-CH2-CH2-(C=O)-, wherein the -(C=O)-binds to branching group B. According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the second linker component L2is

[0193] -CH2-(C=O)-, -CH2-CH2-(C=O)-, or -CH2-CH2-CH2-(C=O)-, wherein the -(C=O)-binds to branching group B.

[0194] According to another preferred embodiment of the present disclosure, the second linker component L2has a structure of

[0195]

[0196] wherein Z is a connecting group as disclosed herein, p is an integer in the range of from 1 to 5, a is an integer in the range of from 0 to 4, symbol “black circle” in said second linker component L2means bond to branching group B; and symbol “white circle” in said second linker component L2means a) bond to L1, or b) bond to A in the first aspect of the present disclosure, or c) bond to A’ in the second aspect of the present disclosure.

[0197] It is understood that when a is 0, the -(C=O)- group directly binds to the -CH2- group in the structure of L2. In other words, if a is 0, the second linker component L2has a structure of

[0198]

[0199] wherein Z is a connecting group as disclosed herein, p is an integer in the range of from 1 to 5, the symbol “white circle” in said second linker component L2means a) bond to L1or b) bond to A in the first aspect of the present disclosure or c) bond to A’ in the second aspect of the present disclosure, and the symbol “black circle” in said second linker component L2means bond to branching group B.As p is at least 1, the structure of the second linker component L2may alternatively be

[0200]

[0201] wherein Z is a connecting group as disclosed herein, y is an integer in the range of from 0 to 4, a is an integer in the range of from 0 to 4, the symbol “white circle” in said second linker component L2means a) bond to L1, or b) bond to A in the first aspect of the present disclosure or c) bond to A’ in the second aspect of the present disclosure, and symbol “black circle” in said second linker component L2means bond to branching group B.

[0202] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, a is an integer in the range of from 0 to 2. According to a further referred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, a is 0 or 1. According to a most preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, a is 0.

[0203] According to another preferred embodiment of the present disclosure, the second linker component L2has the structure

[0204]

[0205] wherein Z is a connecting group as disclosed herein, y is an integer in the range of from 0 to 4, the symbol “white circle” in said second linker component L2means a) bond to L1, or b) bond to A in the first aspect of the present disclosure, or c) bond to A’ in the second aspect of the present, and the symbol “black circle” in said second linker component L2means bond to branching group B.

[0206] Particularly preferred divalent linker groups L

[0207] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the structure of formula (IV)

[0208]

[0209] wherein x is an integer in the range of from 0 to 5, preferably x is 0 or 1; y is an integer in the range of from 0 to 4; a is an integer in the range of from 0 to 4, preferably a is 0 or 1; z is 0 or 1, symbol “white circle” in said divalent linker group L of formula (IV) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure, and symbol “black circle” in said divalent linker group L of formula (IV) means bond to branching group B.According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVa)

[0210]

[0211] wherein x is an integer in the range of from 0 to 5, preferably x is 0 or 1; y is an integer in the range of from 0 to 4; z is 0 or 1; symbol “white circle” in said divalent linker group L of formula (IVa) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVa) means bond to branching group B.

[0212] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L has the structure of formula (IVa-1)

[0213]

[0214] wherein x is an integer in the range of from 0 to 5, preferably x is an integer in the range of from 2 to 5, most preferably x is 4 or 5, and symbol “white circle” in said divalent linker group L means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L means bond to B.

[0215] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L has the structure of formula (IVa-2)

[0216]

[0217] wherein symbol “white circle” in said divalent linker group L means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L means bond to B.

[0218] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L has the structure of formula (IVa-3)

[0219]

[0220] wherein symbol “white circle” in said divalent linker group L means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L means bond to B.

[0221] As is shown in the examples of the present disclosure, compounds with such linker L of formula (IV), in particular (IVa-1), (IVa-2), or (IVa-3) can be advantageously prepared in high yield. Furthermore, the linkers of formulae (IV), (IVa-1), or (IVa-3) are highly stable. Therefore, the compound of formula (I) containing such divalent linker group L can be used in antibody conjugation reactions without degradation. Thus, the yield of the conjugation reaction is increased. In particular, it is understood that said divalent linker groups L do not contain carbonate or carbamate groups which render them more stable during manufacture of a compound of formula (I) as disclosed herein and more stable during antibody conjugation according to a method of the fourth aspect of the present disclosure. Thus, it is understood that also the targeting molecule-drug conjugate of formula (V) according to the second aspect of the present disclosure is highly stable. In vivo, the linker group L is highly stable and not cleaved. On the other hand, linker groups containing carbamates or carbonates may be subject to hydrolysis or other degradation which reduces the efficiency of payload delivery to the target site. On the other hand, the linkers of formulae (IV), (IVa-1), or (IVa-3) are highly stable in vivo and enable a highly efficient delivery of the payload to the target site as is shown in examples 10-13 and 18 of the present disclosure.

[0222] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVb)

[0223]

[0224] wherein y is an integer in the range of from 0 to 4; a is an integer in the range of from 0 to 4, preferably a is 0 or 1; z is 0 or 1; symbol “white circle” in said divalent linker group L of formula (IVb) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVb) means bond to branching group B.

[0225] In other words, according to a preferred embodiment of the first aspect of the present disclosure, the reactive group having ability to react with a functional group in a targeting molecule Ab and the divalent linker group L together have the formula (IVb-2)

[0226]

[0227] wherein y is an integer in the range of from 0 to 4; a is an integer in the range of from 0 to 4, preferably a is 0 or 1; z is 0 or 1; and symbol “black circle” in said divalent linker group L of formula (IVb-2) means bond to branching group B.

[0228] In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVb-3)

[0229]

[0230] wherein y is an integer in the range of from 0 to 4; a is an integer in the range of from 0 to 4, preferably a is 0 or 1; z is 0 or 1; and symbol “black circle” in said divalent linker group L of formula (IVb-3) means bond to branching group B.

[0231] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVc)

[0232]

[0233] wherein y is an integer in the range of from 0 to 4; z is 0 or 1; symbol “white circle” in said divalent linker group L of formula (IVc) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVc) means bond to branching group B.

[0234] In other words, according to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule Ab and the divalent linker group L together have the formula (IVc-2)

[0235]

[0236] wherein y is an integer in the range of from 0 to 4; z is 0 or 1; and symbol “black circle” in said divalent linker group L of formula (IVc-2) means bond to branching group B.In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVc-3)

[0237]

[0238] wherein y is an integer in the range of from 0 to 4; z is 0 or 1; and symbol “black circle” in said divalent linker group L of formula (IVc-3) means bond to branching group B.

[0239] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVd)

[0240]

[0241] wherein y is an integer in the range of from 0 to 4; symbol “white circle” in said divalent linker group L of formula (IVd) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVd) means bond to branching group B.

[0242] According to a most preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVd-1)

[0243]

[0244] wherein symbol “white circle” in said formula (IVd-1) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said formula (IVd-1) means bond to B.

[0245] In other words, according to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule Ab and the divalent linker group L together have the formula (IVd-2)

[0246]

[0247] wherein y is an integer in the range of from 0 to 4; and symbol “black circle” in said divalent linker group L of formula (IVd-2) means bond to branching group B.In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVd-3)

[0248]

[0249] wherein y is an integer in the range of from 0 to 4; and symbol “black circle” in said divalent linker group L of formula (IVd-3) means bond to branching group B.

[0250] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L has the structure of formula (IVd-4)

[0251]

[0252] wherein symbol “black circle” in said formula (IVd-4) means bond to B.

[0253] In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVd-5)

[0254]

[0255] wherein symbol “black circle” in said formula (IVd-5) means bond to B.

[0256] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the structure of formula (IVe)

[0257]

[0258] wherein x is an integer in the range of from 0 to 5, preferably x is 0 or 1; y is an integer in the range of from 0 to 4; a is an integer in the range of from 0 to 4, preferably a is 0 or 1; z is 0 or 1, symbol “white circle” in said divalent linker group L of formula (IVe) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVe) means bond to branching group B.According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVf)

[0259]

[0260] wherein x is an integer in the range of from 0 to 5, preferably x is 0 or 1; y is an integer in the range of from 0 to 4; z is 0 or 1; symbol “white circle” in said divalent linker group L of formula (IVf) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVf) means bond to branching group B.

[0261] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVg)

[0262]

[0263] wherein y is an integer in the range of from 0 to 4; a is an integer in the range of from 0 to 4, preferably a is 0 or 1; z is 0 or 1; symbol “white circle” in said divalent linker group L of formula (IVg) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVg) means bond to branching group B.

[0264] In other words, according to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule Ab and the divalent linker group L together have the formula (IVg-2)

[0265]

[0266] wherein y is an integer in the range of from 0 to 4; a is an integer in the range of from 0 to 4, preferably a is 0 or 1; z is 0 or 1; and symbol “black circle” in said divalent linker group L of formula (IVg-2) means bond to branching group B.

[0267] In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVg-3)

[0268]

[0269] wherein y is an integer in the range of from 0 to 4; a is an integer in the range of from 0 to 4, preferably a is 0 or 1; z is 0 or 1; and symbol “black circle” in said divalent linker group L of formula (IVg-3) means bond to branching group B.

[0270] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVh)

[0271]

[0272] wherein y is an integer in the range of from 0 to 4; z is 0 or 1; symbol “white circle” in said divalent linker group L of formula (IVh) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVh) means bond to branching group B.

[0273] In other words, according to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule Ab and the divalent linker group L together have the formula (IVh-2)

[0274]

[0275] wherein y is an integer in the range of from 0 to 4; z is 0 or 1; and symbol “black circle” in said divalent linker group L of formula (IVh-2) means bond to branching group B.

[0276] In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVh-3)

[0277]

[0278] wherein y is an integer in the range of from 0 to 4; z is 0 or 1; and symbol “black circle” in said divalent linker group L of formula (IVh-3) means bond to branching group B.

[0279] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVi)

[0280]

[0281] wherein y is an integer in the range of from 0 to 4; symbol “white circle” in said divalent linker group L of formula (IVi) means a) bond to A in the first aspect of the present disclosure, or b)bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVi) means bond to branching group B.

[0282] In other words, according to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule Ab and the divalent linker group L together have the formula (IVi-2)

[0283]

[0284] wherein y is an integer in the range of from 0 to 4; and symbol “black circle” in said divalent linker group L of formula (IVi-2) means bond to branching group B.

[0285] In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVi-3)

[0286]

[0287] wherein y is an integer in the range of from 0 to 4; and symbol “black circle” in said divalent linker group L of formula (IVi-3) means bond to branching group B.

[0288] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVj)

[0289]

[0290] wherein symbol “white circle” in said divalent linker group L of formula (IVj) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVj) means bond to branching group B.

[0291] In other words, according to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule Ab and the divalent linker group L together have the formula (IVj-2)

[0292]

[0293] wherein symbol “black circle” in said divalent linker group L of formula (IVj-2) means bond to branching group B.In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVj-3)

[0294]

[0295] wherein symbol “black circle” in said divalent linker group L of formula (IVj-3) means bond to branching group B.

[0296] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker group L has the formula (IVk)

[0297]

[0298] wherein symbol “white circle” in said divalent linker group L of formula (IVk) means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and symbol “black circle” in said divalent linker group L of formula (IVk) means bond to branching group B.

[0299] In other words, according to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule Ab and the divalent linker group L together have the formula (IVk-2)

[0300]

[0301] wherein y is an integer in the range of from 0 to 4; and symbol “black circle” in said divalent linker group L of formula (IVk-2) means bond to branching group B.

[0302] In other words, according to a preferred embodiment of the second aspect of the present disclosure, the group A’ formed by a reaction between A and a functional group in Ab and the divalent linker group L together have the formula (IVk-3)

[0303]

[0304] wherein y is an integer in the range of from 0 to 4; and symbol “black circle” in said divalent linker group L of formula (IVk-3) means bond to branching group B.

[0305] The branching group B

[0306] According to the first aspect of the present disclosure, the compound of formula (I) as disclosed herein comprises a branching group B. It is understood that the branching group connects the divalent linker L with each of the 2 or more groups E.According to the second aspect of the present disclosure, the compound of formula (V) as disclosed herein comprises branching group B. It is understood that the branching group connects the divalent linker L with each of the 2 or more groups E.

[0307] As used herein, the terms “B is a branching group”, and “branching group B”, and “B” are used interchangeably.

[0308] As used herein, the branching group is not particularly limited as long it comprises 3 or more valences. In other words, the branching group is at least trivalent. At one of said valences, the branching group is connected to the divalent linker L via a covalent bond. At the second, third, and any further valences, a group E as disclosed herein is bound to the branching group B via a covalent bond.

[0309] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group comprises a number of e -(C=O)- groups. As used herein, e is 2 or more.

[0310] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0311]

[0312] wherein b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; symbol “white circle” in said branching group B means bond to divalent linker group L, and each of symbols “black circle” in said branching group B means bond to a group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.

[0313] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0314]

[0315] wherein symbol “white circle” in said branching group B means bond to divalent linker group L, and each of symbols “black circle” in said branching group B means bond to a group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.

[0316] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0317]

[0318] wherein symbol "white circle" in said branching group B means bond to divalent linker group L, and each of symbols “black circle” means bond to a group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.

[0319] According to a further preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0320]

[0321] wherein symbol “white circle” in said branching group B means bond to divalent linker L, and each of symbols “black circle” in said branching group B means bond to group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.

[0322] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0323]

[0324] wherein symbol “white circle” in said branching group B means bond to divalent linker group L, and each of symbols “black circle” in said branching group B means bond to a group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.

[0325] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0326]

[0327] wherein symbol “white circle” in said branching group B means bond to divalent linker group L, and each of symbols “black circle” means bond to a group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.

[0328] According to a further preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0329]

[0330] wherein symbol “white circle” in said branching group B means bond to divalent linker L, and each of symbols “black circle” in said branching group B means bond to group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0331]

[0332] wherein b is an integer in the range of from 1 to 5, preferably b is 1 or 2; symbol “white circle” in said branching group B means bond to divalent linker group L, and each of symbols “black circle” in said branching group B means bond to a group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2. It is understood that - if the branching group B is of the diamino-acid type, one on Lehas a -(C=O)- group binding to said amino group of the branching group B.

[0333] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0334]

[0335] wherein symbol “white circle” in said branching group B means bond to divalent linker group L, and each of symbols “black circle” in said branching group B means bond to a group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.

[0336] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0337]

[0338] wherein symbol “white circle” in said branching group B means bond to divalent linker group L, and each of symbols “black circle” means bond to a group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.

[0339] According to a further preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0340]

[0341] wherein symbol “white circle” in said branching group B means bond to divalent linker L, and each of symbols “black circle” in said branching group B means bond to group E as disclosed herein, wherein both E are the same or the two groups E are different from each other. In other words, e is 2.According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the branching group B has the formula

[0342]

[0343] wherein b2 is 1 or 2; symbol “white circle” in said branching group B means bond to divalent linker L, and each of symbols “black circle” in said branching group B means bond to a group E as disclosed herein, wherein all E are the same or the three groups E are different from each other. In other words, e is 3.

[0344] The inventors of the present disclosure have found that by using a branching group B, the drug-targeting molecule ratio, in particular the drug-antibody ratio, can be considerably increased. Thus, the therapeutic effect of the payload(s) and a targeting molecule are significantly increased in a synergistic manner as shown in examples 10 to 13. For instance, the antitumor activity of a compound according to the second aspect of the present disclosure is considerably improved over a respective compound without a branching group B.

[0345] The group E

[0346] According to the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE)

[0347]

[0348] wherein the wavy line in formula (IE) means bond to B; each Leis independently a divalent linker group as disclosed herein; each f is independently 0 or 1; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each CL is independently a cleavable linker group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or an organic residue.

[0349] According to the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e, preferably 2 or 3, groups E of formula (IE) which are preferably independently selected from the group consisting of formulae (IE), (IE-A), (IE-B), (IE-C), (IE-D), and (IE-E).

[0350] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-A)

[0351]

[0352] wherein the wavy line in formula (IE-A) means bond to B; each Leis independently a divalent linker group as disclosed herein; each f is independently 0 or 1; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or an organic residue.

[0353] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-A1)

[0354]

[0355] wherein the wavy line in formula (IE-A1) means bond to B; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or C1-C6alkyl.

[0356] According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-Exa)

[0357]

[0358] wherein the wavy line in formula (IE-Exa) means bond to B; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or C1-C6alkyl.According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-Prexa)

[0359]

[0360] (IE-Prexa),

[0361] wherein the wavy line in formula (IE-Prexa) means bond to B; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or C1-C6alkyl.

[0362] According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-MMAE)

[0363]

[0364] wherein the wavy line in formula (IE-Prexa) means bond to B; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or C1-C6alkyl.

[0365] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-B)

[0366]

[0367] wherein the wavy line in formula (IE-B) means bond to B; each Leis independently a divalent linker group as disclosed herein; each f is independently 0 or 1; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or an organic residue.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-B1)

[0368]

[0369] wherein the wavy line in formula (IE-B1) means bond to B; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or C1-C6alkyl.

[0370] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-B)

[0371]

[0372] wherein the wavy line in formula (IE-EtACPT) means bond to B; each Leis independently a divalent linker group as disclosed herein; each f is independently 0 or 1; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or an organic residue.

[0373] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-C)

[0374]

[0375] wherein the wavy line in formula (IE-C) means bond to B; each Leis independently a divalent linker group as disclosed herein; each f is independently 0 or 1; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or an organic residue.

[0376] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-C1)

[0377]

[0378] wherein the wavy line in formula (IE-C1) means bond to B; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or C1-C6alkyl.

[0379] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-D)

[0380]

[0381] wherein the wavy line in formula (IE-D) means bond to B; each Leis independently a divalent linker group as disclosed herein; each f is independently 0 or 1; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or an organic residue.

[0382] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-D1)

[0383]

[0384] wherein the wavy line in formula (IE-D1) means bond to B; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein R1is hydrogen or C1-C6alkyl.

[0385] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-E)

[0386]

[0387] wherein the wavy line in formula (IE-E) means bond to B; each Leis independently a divalent linker group as disclosed herein; each f is independently 0 or 1; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein RCLis hydrogen or an organic residue.

[0388] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure comprises a number of e of groups E of formula (IE-E1)

[0389]

[0390] wherein the wavy line in formula (IE-E1) means bond to B; each Pep comprises 1 to 6 amino acid groups; each T is independently a solubilizing group as disclosed herein; each P-X1is independently a payload as disclosed herein; each X1is O, S, or NR1, wherein RCLis hydrogen or C1-C6alkyl.

[0391] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, all groups E are identical. According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the groups E are different from each other.

[0392] According to the first aspect of the present disclosure, the compound of formula (I) comprises a number of e groups E of formula (IE), wherein e is an integer of two or more. According to the second aspect of the present disclosure, the compound of formula (V) comprises a number of e groups E of formula (IE), wherein e is an integer of two or more.

[0393] Thus, it is understood that the compounds of formula (I) enables preparing targeting molecule-drug conjugates with particularly high targeting molecule / drug ratio, such as high drug / antibody ratio (DAR). The inventors of the present disclosure have surprisingly found that a higher drug / targeting molecule ratio, in particular higher drug / antibody ratio (ADR), of 16 and more may be achieved.

[0394] In other words, it is understood that the compounds of formula (V) according to the second aspect of the present disclosure have a particularly high targeting molecule / drug ratio, such as high drug / antibody ratio (ADR). The inventors of the present disclosure havesurprisingly found that a higher drug / targeting molecule ratio, in particular higher drug / antibody ratio (ADR), of 16 and more may be achieved.

[0395] According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the integer e is 5 or less. According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the integer e is 4 or less. According to a further preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the integer e is 2 or 3. According to a most preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the integer e is 2.

[0396] Particularly preferred groups E1of formula (IE-1) are disclosed in Table 1, wherein X1-P is as disclosed herein:

[0397] Table 1 Particularly preferred groups E1of formula (IE-1)

[0398]

[0399]

[0400]

[0401]

[0402] According to a further preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) comprises at least one group E of formula lE-ha, wherein X1-P is of formula (P1) and at least one group E of formula lE-ha, wherein X1-P is of formula (P2).

[0403] According to a most preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) comprises one group E of formula lE-ha, wherein X1-P is of formula (P1), and one group E of formula lE-ha, wherein X1-P is of formula (P2). The inventors of the present disclosure have surprisingly found that a compound of formula (I) with the aforementioned combinations of groups E may be advantageously used to prepare a compound with improved anticancer activity (see examples 10 and 12, Fig. 1).

[0404] According to a further preferred embodiment of the second aspect of the present disclosure, the compound of formula (V) comprises at least one group E of formula lE-ha, wherein X1-P is of formula (P1) and at least one group E of formula lE-ha, wherein X1-P is of formula (P2). According to a most preferred embodiment of the second aspect of the present disclosure, the compound of formula (V) comprises one group E of formula lE-ha, wherein X1-P is of formula (P1), and one group E of formula lE-ha, wherein X1-P is of formula (P2). The inventors of the present disclosure have surprisingly found that a compound of formula (V) with the aforementioned combinations of groups E exhibits considerably improved anticancer activity (see examples 10 and 12, Fig. 1).

[0405] According to a further preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) comprises at least one group E of formula lE-ha, wherein X1-P is of formula (P1) and at least one group E of formula lE-ha, wherein X1-P is of formula (P1).

[0406] According to a most preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) comprises one group E of formula lE-ha, wherein X1-P is of formula (P1), and one group E of formula lE-ha, wherein X1-P is of formula (P1). The inventors of the present disclosure have surprisingly found that a compound of formula (I) with theaforementioned combinations of groups E may be advantageously used to prepare a compound with improved anticancer activity (see examples 11 and 13, Fig. 2).

[0407] According to a further preferred embodiment of the second aspect of the present disclosure, the compound of formula (V) comprises at least two groups E of formula lE-ha, wherein X1-P is of formula (P1). According to a most preferred embodiment of the second aspect of the present disclosure, the compound of formula (V) comprises two groups E of formula lE-ha, wherein X1-P is of formula (P1). The inventors of the present disclosure have surprisingly found that a compound of formula (V) with the aforementioned combinations of groups E exhibits considerably improved anticancer activity (see examples 11 and 13, Fig. 2).

[0408] The linker Le

[0409] According to the first aspect of the present disclosure or the second aspect of the present disclosure, the group E of formula (IE) as disclosed herein comprises a divalent linker group Le. It is understood that the divalent linker group Leconnects the branching group B to Pep.

[0410] As used herein, the terms “Leis a divalent linker group”, “divalent linker group Le”, “linker Le”, and “Le” are used interchangeably.

[0411] As used herein, the divalent linker group Leis not particularly limited as long as the linker group has two valences, one of which connects the branching group B covalently divalent linker group Le, and the other connects the divalent linker group Lecovalently to Pep.

[0412] According to the first aspect of the present disclosure or the second aspect of the present disclosure, f is an integer of 0 or 1.

[0413] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, f is 0. In other words, Lemay be absent. In yet other words, if f is 0, Pep is bound to the branching group via a covalent group.

[0414] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, f is 1. In other words, Lemay be present.

[0415] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker Leis connected to the branching group B via an amide group or via an ester group. In other words, the carbonyl group of B and a nitrogen or oxygen atom in the divalent linker Leare bound together via a covalent bond. Preferably, the divalent linker Leis connected to the branching group B via an amide group.

[0416] In yet other words, according to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker Lecomprises a connecting group Ze, wherein Zeis -O- or -NRN-, wherein RNis H, -CH3, -CH2-CH3,

[0417] or -CH(CH3)2. Preferably, RNis H. According to a further preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the connecting group Zeis -NH-.According to a preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker Lecomprises at least

[0418] one -CH2-CH2-O- group. In other words, the divalent linker Lemay comprise one or more ethylene oxide groups. According to a further preferred embodiment of the present disclosure, the divalent linker Lemay contain of from 1 to 6 ethylene oxide groups.

[0419] According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker Lecomprises a linear or branched C2-C6 carbonylene. According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker Leis -CH2-(C=O)-, -CH2-CH2-(C=O)-, -CH2-CH2-CH2-(C=O)-, or -CH2-CH2-CH2-CH2-CH2-(C=O)-, wherein the -(C=O)-binds to Pep. According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, the divalent linker Leis -CH2-(C=O)-, -CH2-CH2-(C=O)-, or -CH2-CH2-CH2-(C=O)-, wherein the -(C=O)-binds to Pep.

[0420] According to another preferred embodiment of the present disclosure, the divalent linker group Lehas a structure

[0421]

[0422] wherein Zeis a connecting group as disclosed herein, peis an integer in the range of from 1 to 5, aeis an integer in the range of from 0 to 4; symbol “black circle” in said divalent linker group Lemeans bond to Pep; and symbol “white circle” in said divalent linker group Lemeans bond to branching group B.

[0423] It is understood that when aeis 0, the -(C=O)- group directly binds to the -CH2- group in the structure of Le. In other words, if aeis 0, the divalent linker group Lehas a structure of

[0424]

[0425] wherein Zeis a connecting group as disclosed herein; peis an integer in the range of from 1 to 5; symbol “black circle” in said divalent linker group Lemeans bond to Pep; and symbol “white circle” in said divalent linker group Lemeans bond to branching group B.

[0426] As peis at least 1, the structure of the divalent linker group Lemay alternatively be of formula (Le1)

[0427]

[0428] wherein Zeis a connecting group as disclosed herein; u is an integer in the range of from 0 to 4; aeis an integer in the range of from 0 to 4; symbol “black circle” in said divalent linker group Lemeans bond to Pep; and symbol “white circle” in said divalent linker group Lemeans bond to branching group B.According to another preferred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, aeis an integer in the range of from 0 to 2. According to a further referred embodiment of the first aspect of the present disclosure or of the second aspect of the present disclosure, aeis 0 or 1. According to a most preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, aeis 0.

[0429] According to another preferred embodiment of the present disclosure, the divalent linker group Lehas the structure of formula (Le2)

[0430]

[0431] (Le2),

[0432] wherein Zeis a connecting group as disclosed herein; u is an integer in the range of from 0 to 4; symbol “black circle” in said divalent linker group Lemeans bond to Pep; and symbol “white circle” in said divalent linker group Lemeans bond to branching group B.

[0433] According to another preferred embodiment of the present disclosure, the divalent linker group Lehas the structure of formula (Le3)

[0434]

[0435] symbol “black circle” in said divalent linker group Lemeans bond to Pep; and symbol “white circle” in said divalent linker group Lemeans bond to branching group B.

[0436] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker Leis a bond. In other words, the branching group B and the group Pep are directly connected via a covalent bond.

[0437] According to another preferred embodiment of the present disclosure, the divalent linker group Lehas the structure of formula

[0438]

[0439] wherein o is an integer in the range of from 1 to 4, and symbol “black circle” in said divalent linker group Lemeans bond to Pep; and symbol “white circle” in said divalent linker group Lemeans bond to branching group B.

[0440] According to a further preferred embodiment of the present disclosure, the divalent linker group Lehas the structure of formula (Le5)

[0441]

[0442] symbol “black circle” in said divalent linker group Lemeans bond to Pep; and symbol “white circle” in said divalent linker group Lemeans bond to branching group B.

[0443] As is shown in the examples of the present disclosure, compounds of formula (I) with such linkers Le, in particular of formulae (Le3), (Le4), or (Le5) can be advantageously prepared in high yield. Furthermore, the linkers of formulae (Le3), (Le4), and (Le5) are highly stable.

[0444] Therefore, the compound of formula (I) containing such divalent linker group Lecan be used in antibody conjugation reactions without degradation. Thus, the yield of the conjugation reaction is increased. In particular, it is understood that said divalent linker groups Ledo not contain carbonate or carbamate groups which render them more stable during manufacture of a compound of formula (I) as disclosed herein and more stable during antibody conjugation according to a method of the fourth aspect of the present disclosure. Thus, it is understood that also the targeting molecule-drug conjugate of formula (V) according to the second aspect of the present disclosure is highly stable. In vivo, the linker group Leis highly stable and not cleaved. On the other hand, linker groups Lecontaining carbamates or carbonates may be subject to hydrolysis or other degradation which reduces the efficiency of payload delivery to the target site. However, the linkers Leof formulae (Le3), (Le4), and (Le5) are highly stable in vitro and in vivo and enable a highly efficient delivery of the payload to the target site as is shown in examples 33-37 of the present disclosure.

[0445]

[0446] According to the first aspect of the present disclosure or the second aspect of the present disclosure, each group E of formula (IE) as disclosed herein comprises a group “Pep” comprising 1 to 6 amino acid groups. It is understood that Pep connects the divalent linker group Leto the PAB group.

[0447] According to the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep comprises 1 to 6 amino acids. In other words, the group Pep is a peptide comprising 1 to 6 amino acids. In yet other words, the group Pep is an amino acid, or a dipeptide (comprising 2 amino acids), or a tripeptide (comprising 3 amino acids), or a tetrapeptide (comprising 4 amino acids), or a pentapeptide (comprising 5 amino acids), or a hexapeptide (comprising 6 amino acids).

[0448] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep consists of 1 to 6 amino acid groups.

[0449] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep comprises, preferably consists of, 1 to 4 amino acid groups. According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep comprises, preferably consists of, 1 or 3 amino acid groups. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep comprises, preferably consists of, 2 or 3 amino acid groups.According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the amino acid group(s) are independently selected from the group consisting of L-glycine (Gly), L-valine (Vai), L-citrulline (Cit), L-cysteic acid (sulfoAla), L-lysine (Lys), L-isoleucine (He), L-phenylalanine (Phe), L-methionine (Met), L-asparagine (Asn), L-proline (Pro), L-alanine (Ala), L-leucine (Leu), L-tryptophan (Trp), and L-tyrosine (Tyr). According to a further preferred embodiment, the amino acid group(s) are independently selected from the group consisting of L-glycine (Gly), L-valine (val), L-alanine (Ala), L-phenylalanine (Phe), L-lysine (Lys), and L-citrulline (Cit).

[0450] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (II)

[0451]

[0452] wherein R3is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R3is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2; R4is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R4is H, or-CHs, or-CH2-CH3, or -CH(-CH3)2,

[0453] or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; symbol “white circle” in formula (II) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (II) means bond to NH of the PAB group.

[0454] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (Ila)

[0455]

[0456] (Ha),

[0457] wherein R3is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R3is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2; R4is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R4is H, or-CHs, or-CH2-CH3, or -CH(-CH3)2,

[0458] or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; symbol “white circle” in formula (Ila) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (Ila) means bond to NH of the PAB group.

[0459] In other words, Pep is preferably a dipeptide of formula (II), more preferably a dipeptide a dipeptide of formula (Ila).

[0460] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (II) and R3is -CH3, or -CH(CH3)2, or -CH2-C6H5 (benzyl).According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (II) and R4is -CH3,

[0461] or -CH2-CH2-CH2-CH2-NH2, or -CH2-CH2-CH2-NH-(C=O)-NH2.

[0462] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (II) and R3is -CH3, or-CH(CH3)2, or-CH2-C6H5(benzyl) and R4is -CH3, or -CH2-CH2-CH2-CH2-NH2,

[0463] or -CH2-CH2-CH2-NH-(C=O)-NH2.

[0464] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (lib)

[0465]

[0466] symbol “white circle” in formula (lib) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (lib) means bond to NH of the PAB group. In other words, Pep may preferably be Ala-Ala.

[0467] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (He)

[0468]

[0469] symbol “white circle” in formula (lie) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (lie) means bond to NH of the PAB group. In other words, Pep may preferably be Ala-Lys.

[0470] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (lid)

[0471]

[0472] (lid),

[0473] symbol “white circle” in formula (lid) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (lid) means bond to NH of the PAB group. In other words, Pep may preferably be Ala-Arg.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (He)

[0474]

[0475] symbol “white circle” in formula (lie) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (lie) means bond to NH of the PAB group. In other words, Pep may preferably be Phe-Ala.

[0476] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (Ilf)

[0477]

[0478] symbol “white circle” in formula (Ilf) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (Ilf) means bond to NH of the PAB group. In other words, Pep may preferably be Phe-Lys.

[0479] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (llg)

[0480]

[0481] symbol “white circle” in formula (llg) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (llg) means bond to NH of the PAB group. In other words, Pep may preferably be Phe-Arg.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (llh)

[0482]

[0483] (llh),

[0484] symbol “white circle” in formula (llh) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (llh) means bond to NH of the PAB group. In other words, Pep may preferably be Val-Ala.

[0485] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (Hi)

[0486]

[0487] symbol “white circle” in formula (Hi) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (Hi) means bond to NH of the PAB group. In other words, Pep may preferably be Val-Lys.

[0488] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (llj)

[0489]

[0490] (llj),

[0491] symbol “white circle” in formula (llj) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (llj) means bond to NH of the PAB group. In other words, Pep may preferably be Val-Arg.

[0492] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (Ilk)

[0493]

[0494] symbol “white circle” in formula (Ilk) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (Ilk) means bond to NH of the PAB group. In other words, Pep may preferably be Gly-Gly.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (llm)

[0495]

[0496] (llm),

[0497] symbol “white circle” in formula (I I m) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (I I m) means bond to NH of the PAB group. In other words, Pep may preferably be Phe-Gly.

[0498] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep has the formula (I In)

[0499]

[0500] (lln),

[0501] symbol “white circle” in formula (lln) means bond to the divalent linker group Le(if f is 1) or bond to the branching group B (if f is 0); and symbol “black circle” in formula (lln) means bond to NH of the PAB group. In other words, Pep may preferably be Gly-Pro.

[0502] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep may be cleavable. In other words, Pep may be cleaved thus releasing the PAB group with its substituents at the target site.

[0503] Additionally, Pep may be cleavable by a tumor-expressive enzyme. The tumor-expressive enzyme can be a peptidase or a protease.

[0504] The Pep group may be capable of specifically releasing the payload upon internalization in a target cell or in the target cell micro-environment. It may utilize an inherent property of the target cell, e.g. a tumor cell, for selectively releasing the payload from a targeting molecule, for example Pep may be sensitive to proteases (enzyme-triggered release). According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep is cleavable by a tumor-expressed protease, such as FAP and / or Cat B. According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep is a substrate of Fibroblast Activation Protein (FAP) or proteases in its tumor microenvironment. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, Pep is a substrate of Cathepsin B (Cat B). According to a further preferred embodiment, Pep is cleavable by intracellular Cathepsin B.

[0505] It is understood that Cathepsin B belongs to a family of lysosomal cysteine proteases known as the cysteine cathepsins and plays an important role in intracellular proteolysis.Cathepsin B is upregulated in certain cancers, in pre-malignant lesions, and in various other pathological conditions.

[0506] It is understood that the Pep groups as disclosed herein, such as the Pep groups of formulae (lib) to (I Im) are cleavable by Cathepsin B. Furthermore, it is understood that the Pep group of formula (lln) is cleavable by Fibroblast Activation Protein (FAP).

[0507] In other words, the group Pep as disclosed herein, is cleaved at the target site, such as by a tumor-expressed enzyme in or close to a tumor. Thus, the payload group P-X1is delivered to the tumor tissue in its “native” state. It is understood that upon cleavage of the Pep group, the properties of the adjacent PAB-group are changed in that the reactivity of the O-(C=O)-X1is increased and the group can be cleaved, e.g. hydrolyzed, thus releasing P-X1-H.

[0508] In other words, the group Pep as disclosed herein, is cleaved at the target site, such as by a tumor-expressed enzyme in or close to a tumor. Thus, the payload group P-X1is delivered to the tumor tissue in its “native” state. As shown in examples 10 to 13 and Figs. 1 and 2, the payload group P-X1is efficiently delivered to a tumor so that the anti-tumor activity is considerably improved. As can be concluded from Fig. 1, when administering a compound according to the second aspect of the present disclosure, there is substantially no tumor growth within the first 28 days after subcutaneous inoculation with cancer cells, while the absence of mortality and body weight loss indicate that the treatment was well tolerated. The in vivo antitumor activity of the representative examples (compounds 42 and 49) according to the second aspect of the present disclosure significantly exceeds the activity of the clinical comparator trastuzumab deruxtecan. At the same time, the group Pep is not cleaved in serum, i.e. is highly stable in non-tumor environments (see example 9).

[0509] The PAB group

[0510] According to the first aspect of the present disclosure or the second aspect of the present disclosure, the compound of formula (I) as disclosed herein comprises a PAB group.

[0511] As used herein, “PAB group” refers to a group of the following formula

[0512]

[0513] wherein the wavy line in said PAB group means bond to T as disclosed herein, symbol “white circle” in said PAB group means bond to Pep, and symbol “black circle” in said PAB group means bond to CL as disclosed herein.

[0514] The inventors of the present disclosure surprisingly found that providing a PAB group having an oxygen in the meta-position to the amino group as shown above, improves the cleavage of the bond between CL, such as the -CH2-O-(C=O)- group of CL, and X1thus providing for a fast and efficient release of P-X1-H at the target site as shown in examples 10 to 13. On the other hand, the bond is sufficiently stable at non-target sites, such as serum, as shown in example 9.The solubilizing group T

[0515] According to the first aspect of the present disclosure or the second aspect of the present disclosure, the group E of formula (IE) as disclosed herein comprises a solubilizing group T. It is understood that the solubilizing group T is connected to the PAB group via an O in the meta-position to the amino group of the PAB group.

[0516] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T comprises an amide.

[0517] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T comprises an optionally substituted (5 to 6 membered) heteroaryl. According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T comprises an optionally substituted aryl.

[0518] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, T comprises a triazole group. According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, T comprises a triazole group as a bridging group.

[0519] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T comprises at least one ethyleneoxide group (-CH₂-CH₂-O-).

[0520] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T comprises n ethyleneoxide groups (-CH₂-CH₂-O-). In other words, the solubilizing group T comprises a group (-CH2-CH2-O-)n.

[0521] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, n is an integer in the range of from 1 to 35. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, n is an integer in the range of from 7 to 23. According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, n is an integer in the range of from 10 to 20. According to an even further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, n is an integer in the range of from 13 to 18. According to a most preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, n is an integer in the range of from 15 to 17.

[0522] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T has the formula (VI)

[0523]

[0524] wherein t is an integer in the range of from 1 to 6, Ar is a (5 to 6 membered) heteroaryl or an aryl as disclosed herein, n is an integer in the range of from 1 to 35, V is a H or a linear or branched (Ci-Ce) alkyl as disclosed herein, preferably V is -CH3, and the wavy line in formula (VI) means bond to O.

[0525] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T has the formula (VI), wherein n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17.

[0526] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T has the formula (VI), wherein n is an integer in the range of from 4 to 24, more preferably n is an integer in the range of from 6 to 20, even more preferably n is an integer in the range of from 7 to 18, most preferably n is an integer in the range of from 8 to 16.

[0527] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T has the formula (VI), and wherein t is 1 or 2, preferably 1. In other words, O and Ar may be connected via a methylene group. In yet other words, O is in “benzylic” position of Ar.

[0528] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T has the formula (VI), and wherein Ar is selected from the group consisting of

[0529]

[0530] wherein symbol “white circle” in said Ar means bond to -(CH2)t-, and symbol “black circle” in said Ar means bond to -(CH2-CH2-O)n-E.

[0531] It was surprisingly found that the presence of an optionally substituted aryl or heteroaryl in the solubilizing group T as disclosed herein offers several practical advantages tied to stability, release efficiency, and molecular interactions:After cleavage of the Pep group, e.g. by hydrolases / peptidases, the PAB-group undergoes an elimination reaction to release the X1-P group. An aromatic system adjacent tot he PAB group as disclosed may stabilize transition states and intermediates during this elimination. This makes payload release faster and more reliable, especially under physiological conditions as is shown in examples 32 and 33 of the present disclosure. Furthermore, the presence of aromatic rings in the solubilizing group T surprisingly improves the rate of cleavage of the PAB-breakdown and payload release. Besides, aromatics provide controlled hydrophobicity which leads to improved membrane permeability after internalization, reduced aggregation of the targeting molecule-drug conjugate of formula (V) of the second aspect as disclosed herein (when balanced with the polar ethylene glycol groups) and help maintain overall pharmacokinetics.

[0532] Independently, aromatic groups can undergo TT-TT stacking thus improving conformational stability. This surprisingly improves linker orientation and shielding thus reducing off-target degradation as shown in example 32 of the present disclosure.

[0533] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T has the formula (VI), and wherein Ar is

[0534]

[0535] wherein symbol wavy line in said formula (VI) means bond to -(CH2)t-.

[0536] According to another preferred embodiment of the first aspect of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T has the formula (VI), and wherein V is -CH3, or -CH2-CH3, or -CH2-CH2-CH3, or -CH(CH3)2.

[0537] According to a further preferred embodiment of the first aspect of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T has the formula (VI) and V is -CH3. Without wishing to be bound by theory, the presence of a -CH3, or -CH2-CH3, or -CH2-CH2-CH3, or -CH(CH3)2 functional group at the end of ethyleneoxide group (-CH2-CH2-O-) provides for the avoidance of an acidic microenvironment of the compound. Therefore, the targeting molecule-drug conjugate of formula (V) of the second aspect as disclosed herein may have lower clearance after administration.

[0538] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T the formula (Illa) or formula (I I lb)

[0539]

[0540] wherein the wavy line in formula (Illa) and formula (111 b) means bond to O; and n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, most preferably from 8 to 16.

[0541] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T the formula (Illa)

[0542]

[0543] wherein the wavy line in formula (Illa) means bond to O of PAB group as disclosed herein; and n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, most preferably from 8 to 16.

[0544] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the solubilizing group T the formula (lllb)

[0545]

[0546] wherein the wavy line in formula (lllb) means bond to O of PAB group as disclosed herein; and n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, most preferably from 8 to 16.

[0547] As is shown in the examples of the present disclosure, the solubilizing groups of formulae (Illa) and (lllb) may be prepared in high yields at a late stage of synthesis in a sitespecific manner via “click chemistry”. Further, triazoles have a high metabolic stability and are resistant to oxidation, hydrolysis and enzymatic cleavage thus reducing off-target hydrolysis and payload release as shown in example 32 of the present disclosure. On the other hand, the payload release at the target site is fast and efficient as shown in examples 32 - 37 of the present disclosure. In other words, it was surprisingly found that compounds of formula (I) and (V) as disclosed herein can be prepared in high yield and purity if the solubilizing group is of formula (Illa) or (lllb). Said compounds have an advantageous balance of hydrophilic and hydrophobic properties with excellent aqueous solubility, and improved payload-release properties.

[0548] The oxygen connecting T and PAB

[0549] According to the first aspect of the present disclosure or the second aspect of the present disclosure, the compound of formula (I) as disclosed herein comprises

[0550] an -O- connecting the solubilizing group T to the PAB group.

[0551] According to the second aspect of the present disclosure or the second aspect of the present disclosure, the compound of formula (V) as disclosed herein comprises

[0552] an -O- connecting the solubilizing group T to the PAB group.The inventors of the present disclosure have surprisingly found that binding oxygen directly to the PAB group, makes CL and P-X1a better leaving group. Without wishing to be bound by theory, the oxygen as disclosed herein has an electron donating effect via mesomeric effect (or resonance effect) thus pushing electrons into the orf / io-position of the oxygen in the PAB group. Thus, the bond CL-X1may be cleaved more easily during the self-immolation process thus releasing the payload P-X1-H from a targeting molecule-drug conjugate. Thus, for example, the therapeutic effect of the payload is increased. Surprisingly, the serum stability of such compounds of formula (I) and / or formula (V) is not affected. To the contrary, the compounds according to the present disclosure are highly stable in serum but allow quick and efficient release of the payload in the target tissue. Electron donating effect of the meta-located oxygen is expected to stabilize the amide bound between Pep and NH in formula (I). When the ADC is in blood circulation away from the tumor site, the amide bound between Pep and NH is comprised between sterically hindered groups. The addition and possible synergy between these two effects may explain the high stability of the compounds of the present invention as demonstrated in example 9. When the compounds according to the second aspect of the present disclosure reach the cells / target site, lysosomal degradation of the targeting molecule Ab. such as an antibody, is expected to release the steric hindrance of the antibody resulting in good cleavability by tumor expressed enzymes such as Cathepsin B.

[0553] The cleavable linker group CL

[0554] According to the first aspect of the present disclosure or the second aspect of the present disclosure, the compound of formula (I) or formula (V) as disclosed herein comprise two or more groups E of formula (IE) with a cleavable linker group CL. It is understood that the cleavable linker group CL is adapted to be cleaved at the target site upon enzymatic cleavage of the Pep group as disclosed herein. Therefore, the payload group P-X1is released from the compound of formula (I) or formula (V) as disclosed herein.

[0555] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the cleavable linker CL has a structure selected from the group consisting of

[0556]

[0557] wherein RCLis H or CH3, and wherein symbol “white circle” means bond to the benzene ring in the group E of formula (IE), and symbol “black circle” means bond to X1.According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group CL-X1-P in a group E of formula (IE) as disclosed herein together form a structure selected from the group consisting of:

[0558]

[0559] wherein RCLis H or CH3. In the afore structures of CL-X1-P, the wavy line means bond to the benzene ring in the group of formula (IE).

[0560] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group CL-X1-P in a group E of formula (IE) as

[0561]

[0562] disclosed herein together form the structure O, wherein the wavy line indicates a bond to the benzene ring in the group E of formula (IE). In other words, it is a preferred embodiment of the first aspect of the present disclosure that the group E of formula (IE) has the structure of formula (IE-A) as disclosed herein. The same applies to the compound of formula (V) according to the second aspect of the present disclosure. It is understood that the aforementioned CL-X1-P group and group of formula (1-1) are particularly useful for payloads comprising a primary or secondary amine group, such as exatecan, prexasertib and monomethyl auristatin E (MMAE).

[0563] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group CL-X1-P in a group E of formula (IE)

[0564] RCI.

[0565]

[0566] as disclosed herein together form the structure O, wherein RCLis H or CH3, and wherein the wavy line indicates a bond to the benzene ring in the group E of formula (IE). In other words, it is a preferred embodiment of the first aspect of the present disclosure that the group E of formula (IE) has the structure of formula (IE-C) as disclosed herein. The same applies to the compound of formula (V) according to the second aspect of the present disclosure. It is understood that the aforementioned CL group and group E of formula (IE-B) are particularly useful for payloads comprising a -OH group and an amide group, such as paclitaxel and talazoparib.

[0567] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group CL-X1-P in a group E of formula (IE) as disclosed herein or formula (V) as disclosed herein together form the structure

[0568]

[0569] , wherein the wavy line indicates a bond to the benzene ring in the group E of formula (IE). In other words, it is a preferred embodiment of the first aspect of the present disclosure that the group E of formula (IE) has the structure of formula (IE-C) as disclosed herein. The sameapplies to the compound of formula (V) according to the second aspect of the present disclosure. It is understood that the aforementioned CL group and group E of formula (IE-C) are particularly useful for payloads comprising a tertiary amine group, an aniline group or pyrazoles, such as navitoclax, auristatin E, 7-ethyl-10-aminocamptothecin, vincristine, and camonsertib.

[0570] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group CL-X1-P in a group E of formula (IE)

[0571] as disclosed herein or formula (V) as disclosed herein together form the structure

[0572]

[0573] , wherein the wavy line indicates a bond to the benzene ring in the group E of formula (IE). In other words, it is a preferred embodiment of the first aspect of the present disclosure that the group E of formula (IE) has the structure of formula (IE-D) as disclosed herein. The same applies to the compound of formula (V) according to the second aspect of the present disclosure. It is understood that the aforementioned CL group and group of formula (I-4) are particularly useful for payloads comprising a -OH group, such as auristatin E.

[0574] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group CL-X1-P in a group E of formula (IE)

[0575] as disclosed herein together form the structure

[0576]

[0577] , wherein RCLis H or CH3, and wherein the wavy line indicates a bond to the benzene ring in the group E of formula (IE). In other words, it is a preferred embodiment of the first aspect of the present disclosure that the group E of formula (IE) has the structure of formula (IE-E) as disclosed herein. The same applies to the compound of formula (V) according to the second aspect of the present disclosure. It is understood that the aforementioned CL group and group of formula (1-4) are particularly useful for payloads comprising a -OH group, such as gemcitabine.

[0578] The group X1

[0579] According to the first aspect of the present disclosure, the compound of formula (I) as disclosed herein comprises a group X1being O, S, NR1, or N+R1R11, wherein R1and R11are each independently a hydrogen or an organic residue as defined herein.

[0580] In other words, if X1is NR1and R1is hydrogen, the group P-NH- forms a secondary amine with the rest of the compound of formula (I) or formula (V), respectively. After hydrolysis or cleavage of CL and X1(such as the bond between -(C=O)- and X1) at the target site, the group P-X1then forms P-NH2, i.e. a primary amine.

[0581] If X1is NR1and R1is an organic residue as defined, the group P-NH- forms a tertiary amine with the rest of the compound of formula (I) or formula (V), respectively. After hydrolysisor cleavage of CL and X1(such as the bond between -(C=O)- and X1) at the target site, the group P-X1then forms P-NHR1, i.e. a secondary amine.

[0582] In yet other words, R1is a substituent selected such that P-NR1H forms a primary or secondary amine, preferably wherein R1is hydrogen or C1-C6alkyl. According to the second aspect of the present disclosure, the compound of formula (V) as disclosed herein comprises a group X1being O, S, or NR1, wherein R1is hydrogen or C1-C6alkyl. It is understood that X1connects the group P to the PAB group and together with the neighboring CL group forms a leaving group.

[0583] If X1is N+R1R11and both R1and R11are an organic residue as defined, the group X1forms an ammonium ion with the rest of the group E of formula (IE). After hydrolysis or cleavage of the bond between CL and X1at the target site, the group P-X1then forms P-NR1R11, i.e. a tertiary amine. If X1is N+R1R11it is preferable that both R1and R11are -CH3 or R1and R11together form a cyclic group, preferably a 5- or 6-membered ring. In other words, X1may preferably be N+(-CH3)2. According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, X1is N+R1R11and N+R1R11together from a pyrrolidinyl-ion, a morpholinyl-ion, a piperidinyl-ion, or a piperazinyl-ion. On other words, X1may be selected from the group consisting of

[0584]

[0585] wherein symbol „white circle" means bond to CL and symbol “black circle" means bond to P.

[0586] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, X1is O. For example, the group X1together with the neighboring -O-(C=O)- group of CL forms a carbonate group.

[0587] According to the most preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, X1is NR1, wherein R1is a hydrogen or an organic residue as defined herein. For example, the group X1together with the

[0588] neighboring -O-(C=O)- group of CL forms a carbamate group.

[0589] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, X1is NH. According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, X1is NR1.

[0590] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, R1is a linear or branched (Ci-Ce)alkyl as defined herein. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, X1is NR1and R1is -CH3.According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, X1is S. For example, the group X1together with the neighboring -O-(C=O)- group of CL forms a thiocarbonate group.

[0591] The payload group P-X1

[0592] According to the first aspect of the present disclosure, the compound of formula (I) as disclosed herein comprises a payload P-X1. According to the second aspect of the present disclosure, the compound of formula (V) as disclosed herein comprises a payload P-X1.

[0593] Herein, the terms “P-X1is a payload” and “payload group P-X1”, “payload P-X1”, “group P-X1” and “P-X1” are used interchangeably.

[0594] The payload P-X1is not particularly limited. The term “payload” as used herein characterizes a substance (e.g. a naturally occurring or synthetic substance) which can confer a novel functionality when it is attached (conjugated) to a targeting molecules, such as an antibody or antibody fragment.

[0595] It is understood that the group P-X1forms a functional substance, such as a drug, upon cleavage of the bond between CL and X1(such as the decarboxylation of the -O-(C=O)-X1group). In other words, the group P-X1-H may be a therapeutic agent selected from the group consisting of a cytotoxic agent, a cellular checkpoint inhibitor, an immune-onco agent, an anti-angiogenic agent, an antibiotic, and an antiviral drug as disclosed herein.

[0596] In other words, the group P-X1as disclosed herein is a therapeutic agent selected from the group consisting of a cytotoxic agent, a cellular checkpoint inhibitor, an immune-onco agent, an anti-angiogenic agent, an antibiotic, and an antiviral drug as disclosed herein, wherein a hydrogen bound to X1is replaced with the CL group of the PAB group as disclosed herein.

[0597] In other words, the term “group P-X1” as used herein refers to a derivative of a compound as disclosed herein, such as a therapeutic agent, a labeling agent, a diagnostic agent, or a binding agent, wherein one -OH group, or one -NH2 group, or one -NHR1group, or on -NHR1R11group as defined herein, or one -SH group is modified in that a proton is replaced by a bond to the -O-(C=O)- group of the PAB group as disclosed herein.

[0598] According to a preferred embodiment of first aspect of the present disclosure or the second aspect of the present disclosure, P-X1is exatecan, preferably P-X1has the structure of formula (P1)

[0599]

[0600] wherein the wavy line in said formula (P1) means bond to CL, preferably wherein CL is -CH2-O-(C=O)-, of the benzene of the PAB group. In other words, the group CL-X1-P most preferably has the structure of formula (C-P1)

[0601]

[0602] wherein the wavy line in said formula (C-P1) means bond to benzene of the PAB group.

[0603] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, P-X1is prexasertib, preferably P-X1has the structure of formula (P2)

[0604]

[0605] wherein the wavy line in said formula (P1) means bond to CL, preferably to -CH2-O-(C=O)-, of the PAB group. In other words, the group CL-X1-P most preferably has the structure of formula (C-P2)

[0606]

[0607] wherein the wavy line in said formula (C-P2) means bond to benzene of the PAB group.

[0608] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is navitoclax, preferably P-X1has the structure of formula (P3)

[0609]

[0610] wherein the wavy line in said group P-X1means bond to CL, preferably wherein CL is -CH2-. In other words, the group CL-X1-P further preferably has the structure of formula (C-P3)

[0611]

[0612] wherein the wavy line in said formula (C-P3) means bond to benzene of the PAB group.

[0613] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is paclitaxel, preferably P-X1has the structure of formula (P4)

[0614]

[0615] wherein the wavy line in said group P-X1means bond to CL, preferably wherein CL is -CH2-NH-(C=O)-O-CH2- as disclosed herein. In other words, the group CL-X1-P further preferably has the structure of formula (C-P4)

[0616]

[0617] wherein the wavy line in said formula (C-P4) means bond to benzene of the PAB group.

[0618] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is talazoparib, preferably P-X1has the structure of formula (P5)

[0619]

[0620] wherein the wavy line in said group P-X1means bond to CL, preferably bond

[0621] to -CH2-NH-(C=O)-O-CH2- as disclosed herein. In other words, the group CL-X1-P further preferably has the structure of formula (C-P5)

[0622]

[0623] wherein the wavy line in said formula (C-P5) means bond to benzene of the PAB group.

[0624] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is gemcitabine, preferably P-X1has the structure of formula (P6)

[0625]

[0626] wherein the wavy line in said group P-X1means bond to CL, preferably wherein CL is CH2-O-(C=O)- or 2-tetrahydropyranyl as disclosed herein. In other words, the group CL-X1-P further preferably h

[0627]

[0628] wherein the wavy line in said formula (C-P6A) and (CP-6B) means bond to benzene of the PAB group.

[0629] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is auristatine E, preferably P-X1has the structure of formula (P7)

[0630]

[0631] wherein the wavy line in said group P-X1means bond to CL, preferably wherein CL

[0632] is -CH2-O-(C=O)- or 2-tetrahydropyranyl as disclosed herein. In other words, the group CL-X1-P further preferably has the structure of formula (C-7PA) or C-(P7B)

[0633]

[0634] wherein the wavy line in said formula (C-P6A) and (CP-6B) means bond to benzene of the PAB group.

[0635] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is monomethyl auristatin E (MMAE), preferably P-X1has the structure of formula (P8)

[0636]

[0637] wherein the wavy line in said group P-X1means bond to CL, preferably wherein CL

[0638] is -CH2-O-(C=O)- or 2-tetrahydropyranyl as disclosed herein. In other words, the group CL-X1-P most preferably has the structure of formula (C-P8)

[0639]

[0640] wherein the wavy line in said formula (C-P8) means bond to benzene of the PAB group.

[0641] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is 7-ethyl-10-hydroxycamptothecin, preferably P-X1has the structure of formula (P9)

[0642]

[0643] wherein the wavy line in said group P-X1means bond to CL, preferably wherein CL is -CH2- as disclosed herein. In other words, the group CL-X1-P most preferably has the structure of formula (C-P9)

[0644]

[0645] wherein the wavy line in said formula (C-P9) means bond to benzene of the PAB group.

[0646] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is vincristine, preferably P-X1has the structure of formula (P10)

[0647]

[0648] wherein the wavy line in said group P-X1means bond to CL, preferably wherein CL is -CH2- as disclosed herein. In other words, the group CL-X1-P most preferably has the structure of formula (C-P10)

[0649]

[0650] wherein the wavy line in said formula (C-P10) means bond to benzene of the PAB group.

[0651] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, P-X1is camonsertib, preferably P-X1has the structure of formula (P11)

[0652]

[0653] wherein the wavy line in said group P-X1means bond to CL, preferably wherein CL is -CH2- as disclosed herein. In other words, the group CL-X1-P most preferably has the structure of formula (C-P11)

[0654]

[0655] wherein the wavy line in said formula (C-P11) means bond to benzene of the PAB group.

[0656] In other words, the group P-X1as disclosed herein is a therapeutic agent selected from the group consisting of a cytotoxic agent, a cellular checkpoint inhibitor, an immune-onco agent, an anti-angiogenic agent, an antibiotic, and an antiviral drug as disclosed herein. Example payloads of interest may include Ataxia Telangiectasia and Rad3-related kinase (ATR) inhibitors, Ataxia Telangiectasia Mutated (ATM) kinase inhibitors, Checkpoint Kinase (CHK) inhibitors, Topoisomerase I (Topol) inhibitors, Topoisomerase II (Topo2) inhibitors, Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors, Poly(ADP-ribose) Polymerase (PARP1 / 2) inhibitors, Phosphoinositide 3-kinase (PI3K) inhibitors, Mechanistic Target of Rapamycin (mTOR) inhibitors, Cyclin-Dependent Kinase (CDK) inhibitors, B-cell Lymphoma 2 (Bcl-2) inhibitors, Myeloid cell leukemia-1 (Mcl-1) inhibitors, Aurora Kinase B (AURKB) inhibitors, Polo-like Kinase 1 (PLK1) inhibitors, Microtubule Associated Serine / Threonine Kinase- Like (MASTL) inhibitors, KRAS mutation Glycine-to-Aspartate at position 12 (KRAS G12D) inhibitors, MAPK / ERK Kinase (Mitogen-Activated Protein Kinase / Extracellular Signal-Regulated Kinase Kinase) inhibitors, Src / Abl Tyrosine Kinase (Scr / Abl TK) inhibitors, Histone Deacetylase (HDAC) inhibitor, N-Myristoyltransferase (NMT) inhibitor and G1-to-S Phase Transition 1 protein (GSPT1) inhibitors.

[0657] In some embodiments, the term “payload” as used herein is to be understood as a labeling moiety (e.g. chromophore, fluorophore, radiolabeled moiety) that enables and / or facilitates the detection and / or visualization of a complementary moiety (e.g. an antibody) to which it is attached. For instance, the labeling moiety can be detected and / or visualized by functional (physiological) imaging techniques known in the art such as computed tomography (CT), positron emission tomography (PET), etc.In some embodiments, the term “payload” as used herein is to be understood as a pharmacologically active substance or prodrug thereof which can inhibit or prevent the function of cells and / or kill cells.

[0658] In some embodiments, the term “payload” is to be understood as being synonymous with other terms commonly used in the art such as “cytotoxic agent”, “toxin” or “drug” used in the field of cancer therapy. In some embodiments, the term “payload” is a prodrug of a “cytotoxic agent”, “toxin” or “drug” used in the field of cancer therapy.

[0659] Alternatively, the payload may be a conjugation group. The payload may include a group derivable from a functional group that allows covalent attachment of the payload to the remainder of the compound, such as a primary amine, a secondary amine, a hydroxyl group, a thiol group, or the like.

[0660] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a therapeutic agent, or a labelling agent, or a diagnostic agent, or a binding agent.

[0661] The payload P-X1is a therapeutic agent

[0662] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a therapeutic agent or a prodrug of such agent.

[0663] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a therapeutic agent selected from the group consisting of an anticancer agent, an immunomodulatory agent, an antibiotic, an antiviral drug

[0664] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an anticancer drug.

[0665] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a DNA-alkylating agent, preferably duocarmycin, cyclophosphamide, chorambucil, melphalan, busulfan, mechliretamine, or the like.

[0666] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a topoisomerase inhibitor, preferably doxorubicin, etoposide, irinotecan, topotecan, mitoxantrone, exatecan, or the like. According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload PX1is exatecan or a derivative thereof.

[0667] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a RNA-polymerase II inhibitor, preferably alpha-amanitin, triptolide, actinomycin D, flavopiridol, THZ1, or the like.

[0668] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a DNA cleaving agent, preferably calicheamicin, bleomycin, esperamicin, dynemicin A, neocarzinostatin, or the like.According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1an anti-metabolite, preferably gemcitabine, methotrexate, 5-fluorouracil, cytrabine, 6-mercaptopurine, or the like.

[0669] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a kinesin spindle protein inhibitor, preferably filanesib, ispisenib (SB-715992), filanesib (ARRY-520), MK-0731, BIIB-104, litrosenib (CK-174), or the like.

[0670] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a kinase inhibitor, preferably ipatasertib, gefitinib, imatinib, sorafenib, erlotinib, palbociclib, prexasertib, or the like. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a checkpoint kinase inhibitor. According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is prexasertib (also known as LY2606368) or a derivative thereof.

[0671] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a nicotinamide phosphoribosyl transferase inhibitor, preferably 2241014-82-2, FK866 (also known as APO866), CHS-828, GMX1778, OT-82, STF-118804, or the like.

[0672] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a matrix metallopeptidase 9 inhibitor, preferably CGS27023A, marimastat, batimastat, prinomastat, SB-3CT, TAPI-2, or the like.

[0673] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a phosphatase inhibitor, preferably mycrocystin-LR, okadaic acid, calyculin A, sanguinarine, cantharidin, a peroxocanadium compound, or the like.

[0674] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a DNA-alkylating agent. Preferred DNA-alkylating agents include duocarmycin (including synthetic analogues thereof: adozelesin, carzelesin, bizelesin, KW-2189 and CBI-TMI), nitrogen mustard analogues (e.g. cyclophosphamide chlorambucil, melphalan, chlormethine, ifosfamide, trofosfamide, prednimustine.bendamustine, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, mannomustine, mitolactol, novembichin, phenesterine, uracil mustard), alkyl sulphonates (e.g. busulfan, treosulfan, mannosulfan, improsulfan and piposulfan), ethylene imines (e.g. thiotepa, triaziquone, carboquone), nitrosoureas (e.g. carmustine, lomustine, semustine, streptozocin, chlorozotocin, fotemustine, nimustine,ranimustine), epoxides (e.g. etoglucid), other alkylating agents (e.g. mitobronitol, pipobroman, temozolomide, dacarbazine).

[0675] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a topoisomerase inhibitor. Preferred topoisomerase inhibitors include doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino- doxorubicin, deoxydoxorubicin, etoposide, etoposide phosphate, irinotecan and metabolites thereof such as SN-38, teniposide, topotecan, resveratrol, epipodophyllins (e.g. 9-aminocamptothecin, camptothecin, crisnatol, daunomycin, mitoxantrone, novantrone, retinoic acids (retinols), 9-nitrocamptothecin (RFS 2000)).

[0676] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a RNA-polymerase II inhibitor. Preferred RNA-polymerase II inhibitors include alpha-amanitin, and other amatoxins.

[0677] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a DNA-cleaving agent. A preferred DNA-cleaving agent is calicheamicin.

[0678] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an anti-metabolite.

[0679] Preferred anti-metabolites include DHFR inhibitors (e.g. methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid) or other folic acid analogues such as raltitrexed, pemetrexed, pralatrexate), IMP dehydrogenase inhibitors (e.g. mycophenolic acid, tiazofurin, ribavirin, EICAR), ribonucleotide reductase inhibitors (e.g. hydroxyurea, deferoxamine), pyrimidine analogs (e.g. cytarabine, fluorouracil, 5-fluorouracil and metabolites thereof, tegafur, carmofur, gemcitabine, capecitabine, azacitidine, decitabine, fluorouracil combinations, tegafur combinations, trifluridine combinations, cytosine arabinoside, ancitabine, floxuridine, doxifluridine), uracil analogs (e.g. 6-azauridine, deoxyuridine), cytosine analogs (e.g. enocitabine), purine analogs (e.g. azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine, cladribine, clofarabine, nelarabine), or folic acid replenisher such as folinic acid.

[0680] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a kinesin spindle protein inhibitor. A preferred kinesin spindle protein inhibitor is filanesib.

[0681] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a kinase inhibitor. Preferred kinase inhibitors include patasertib, BIBW2992 (anti-EGFR / Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib, vandetanib, afatinib, vemurafenib, crizotinib, regorafenib, masitinib, dabrafenib, trametinib, ibrutinib, ceritinib, lenvatinib, nintedanib, cediranib, palbocidib, osimertinib, alectinib, alectinib, rociletinib, cobimetinib, midostaurin, olmutinib, E7080 (anti-VEGFR2), mubritinib, ponatinib(AP24534), bafetinib (INNO-406), bosutinib (SKI-606), cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, tivozanib, ispinesib, temsirolimus, everolimus, or ridaforolimus.

[0682] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a nicotinamide phosphoribosyl transfer inhibitor. A preferred nicotinamide phosphoribosyl transfer inhibitors includes CAS No. 2241014-82-2.

[0683] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a matrix metallopeptidase 9 inhibitor. A preferred matrix metallopeptidase 9 inhibitor is CGS27023A or a derivative thereof.

[0684] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a phosphatase inhibitor. A preferred phosphatase inhibitor is mycrocystin-LR.

[0685] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an immunomodulatory agent. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is selected from the group consisting of a TLR7 / 8 agonist (preferably resiquimod), a STING agonist (preferably ADU-S100, or MK-1454), an immune checkpoint inhibitor, an IL-2 agonist (preferably NKTR-214), granzyme B, an indoleamine 2, 3, -dioxygenase inhibitor (preferably epacadostat), a CD40 agonist (preferably selicrelumab), a proteasome inhibitor (preferably bortezomib), an IMiD (preferably lenalidomide or pomalidomide), a glucocorticoid (preferably fluticasione), and an 4-1 BB agonist. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a glucocorticoid, preferably fluticasone.

[0686] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an immunomodulatory agent, such as an immunostimulant or an immunosuppressant.

[0687] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an immunomodulatory agent is selected from the group consisting of cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, and cyclophosphamide.

[0688] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a corticosteroid, preferably amcinonide, betamethasone, budesonide, hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, prednisone, triamcinolone acetonide, or beclometasone dipropionate).

[0689] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an immunomodulatory agentis selected from the group consisting of DHEA, hydroxychloroquine, meloxicam, methotrexate, mofetil, mycophenylate, sirolimus, tacrolimus, everolimus, fingolimod, ibrutinib, imiquimod, resiquimod, cytokines, and peptidic immunomodulators such as TLR agonists (e.g. CpG oligonucleotides).

[0690] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an antibiotic. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is selected from the group consisting of an anthracyclin (preferably doxorubicin or aclarubicin), a beta-lactam (preferably penicillin G or amoxicillin), a fluoroquinolone (preferably ciprofloxacin), a macrolide (preferably erythromycin), an amphenicol (preferably chloramphenicol), a tetracycline (preferably chlortetracycline or eravacycline, or sarecycline, or doxycycline), a lincosamide (preferably clindamycin), a gylcopeptide (preferably vancomycin), an aminoglycoside (preferably gentamicin), a rifamycin (preferably rifampicin or rifabutin), a pleutimutilin (preferably retapamulin), and a lipopeptide (preferably daptomycin).

[0691] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a rifamycin, clindamycin or reptamulin.

[0692] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an antiviral drug. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is selected from the group consisting of a guanosine analog (preferably acyclovir or entecavir), a nucleoside reverse transcriptase inhibitor (preferably zidovudine or lamivudine ortenofovir), a neuraminidase inhibitor (preferably oseltamivir), an adenosine nucleotide analog (preferably remdesivir), a protease inhibitor (preferably ritonavir), a DNA polymerase inhibitor (preferably foscarnet), and a CCR5 receptor antagonist (preferably maraviroc).

[0693] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a remdesivir, foscarnet or tenofovir.

[0694] According to a particularly preferred embodiment of the first aspect of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a moiety derived from exatecan, PNU-159682, amanitin, duocarmycin, tubulysin, calicheamicin, SN-38, taxol, daunomycin, vinblastine, doxorubicine, methotrexate, pyrrolobenzodiazepine, pyrrole-based kinesin spindle protein (KSP) inhibitors, indolino-benzodiazepine dimers, or radioisotopes and / or pharmaceutically acceptable salts thereof.

[0695] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a cytotoxic agent, preferablya cytotoxic agent selected from the group consisting of monomethyl auristatin E (MMAE), Monomethyl auristatin F (MMAF), maytansinoid DM1, maytansinoid DM4, calicheamicin, duocarmycin, pyrrolobenzodiazepine (PBD) dimers, SN-387, camptothecin derivatives, and auristatin F-HPA.

[0696] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a cellular checkpoint inhibitor, preferably a cellular checkpoint inhibitor selected from the group consisting of PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 blocking agents, LAG-3 inhibitors, TIM-3 inhibitors, IDO1 inhibitors, TGF-p trap peptides, CD47-SIRPa inhibitors, 0X40 agonists, and CD137 (4-1 BB) agonists.

[0697] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a cellular checkpoint inhibitor, preferably a cellular checkpoint inhibitor selected from the group consisting of indoximod, edacadostat, navoximod, linrodostat, MK-1454, ADU-S100, BO-112, N-803, and CV8102.

[0698] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an immune-onco agent, preferably an immune-onco agent selected from the group consisting of indoximod, edacadostat, BMS-986205, ADU-S100, MK-1454, NKTR-214, ALT-803, BO-112, bintrafusp alfa, and CV8102.

[0699] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is an anti-angiogenic agent, preferably an anti-angiogenic agent selected from the group consisting of sunitinib, axitinib, sorafenib, pazopanib, lanvatinib, cadozantinib, tivozanib, cediranib, brivanib, and lucitanib.

[0700] According to a more preferred embodiment of the first aspect of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is exatecan or prexasertib. According to a most preferred embodiment of the first aspect of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is exatecan or prexasertib, or a derivative thereof.

[0701] The skilled person is aware of suitable methods for binding the above compounds via a group X1in each group P-X1to the -O-(C=O)- group of PAB to form a compound of formula (I) of the present disclosure. For example, an -OH group, an -NH₂ group, an -NR1H group, or an -SH group of the above-mentioned drugs may form the group X1of the compound of formula (I) of the present disclosure. In other words, the compound of formula (I) as disclosed herein may be prepared by activating an -OH, -NH₂, -NR1H, or -SH group in the above compound and binding it to the PAB group thus forming X1. This is further illustrated in the examples of the present disclosure.According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group P-X1is of formula (P1)

[0702]

[0703] wherein the wavy line in said group P-X1means bond to -CH2-O-(C=O)- of the PAB group.

[0704] According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group P-X1is of formula (P2)

[0705]

[0706] wherein the wavy line in said group P-X1means bond to -CH2-O-(C=O)- of the PAB group.

[0707] According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group P-X1is of formula (P8)

[0708]

[0709] wherein the wavy line in said group P-X1means bond -O-(C=O)- of the PAB group.

[0710] The payload P-X1is a labelling agent

[0711] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a labelling agent. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a metal chelator.

[0712] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the labelling agent includes a radionuclide, preferably wherein said labelling agent is a moiety containing, or capable of containing a radionuclide.

[0713] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the labelling agent contains, or is capable ofcontaining a non-metallic radionuclide, such as125l,123l,131l,11C,15O, or18F. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the labelling agent is derived from 4-hydroxyphenylpropionate containing a radionuclide such as125l,123l or1311,

[0714] As used herein, the terms “metal chelator” and “chelating agent” are used interchangeably.

[0715] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the labelling agent is a chelating agent comprising a chelated radionuclide selected from the group consisting of diethylenetriamine pentaacetic acid (DTPA), cyclohexyl diethylenetriamine pentaacetic acid (CH-X-DTPA), desferrioxamine (DFO),

[0716] N 1 -(27-amino-11,22-dihydroxy-7, 10,18,21 -tetraoxo-6, 11, 17,22-tetraazaheptacosyl)-N 1 -hydroxy-N4-(5-(N-hydroxyacetamido)pentyl)succinimide (DFO’),

[0717] N1-(5-(3-(4-aminobutyl)-1-hydroxy-2-oxopiperidine-3-carboxamido)pentyl)-N1-hydroxy-N4-(5-(N -15 hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinimide (DFO-cyclo’), 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-tetraacetic acid (NODAGA), 1.4.7.10-tetraazacyclododecane-1 -glutaric acid-4,7, 10-triacetic acid

[0718] (DOTAGA),2,2'-(1,4,7-triazacyclononane-1,4-diyl)diacetate (NO2A), 1,4,7,10-20 tetraatacyclododecane-1,4,7,10-tetraacetic acid (DOTA), mercaptoacetyl-glycyl-glycyl-glycine (maGGG), mercaptoacetyl-serine-serine-serine (maSSS),

[0719] 1.4.7.10-tetraatacyclododecane-1,4,7, 10-tetraacetic acid-methonine (DOTA-Met),

[0720] 1.4.7-triazacyclononane-1,4,7-triacetic acid (NOTA), ethylenediaminetetraacetic acid (EDTA), ethylenediaminediacetic acid, triethylenetetraminehexaacetic acid(TTHA),

[0721] 1.4.8.11-tetraazacyclotetradecane (CYCLAM),

[0722] 1.4.8.11-tetraazacyclotetradecane- 1,4,8,11 -tetraacetic acid (TETA),

[0723] 1.4.8.11-tetraazabicyclo[6.6.2]hexadecane-4, 11 -diaceticacid (CB-TE2A),

[0724] 2,2’,2”-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetamide (DO3AM),30

[0725] 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid (DO2A), 1,5, 9- triazacyclododecane (TACD), (3a1s,5a1s)-dodecahydro-3a,5a,8a,10a-tetraazapyrene (cis-glyoxal-cyclam),

[0726] 1.4.7-triazacyclononane (TACN), 1,4,7, 10-tetraazacyclododecane (cyclen), tri(hydroxypyridinone) (THP),3-(((4,7-bis((hydroxy(hydroxymethyl)phosphoryl)methyl)-1,4,7-35 triazonan-1-yl)methyl)(hydroxy)phosphoryl)propanoic acid (NOPO),

[0727] 3,6,9, 15-T etraazabicyclo[9.3.1 ]pentadeca-1 (15), 11, 13-triene-3, 6, 9- triacetic acid (PCTA), 2,2',2”,2”’-(1,4,7,10-tetraazacyclotridecane-1,4,7,10-tetrayl)tetraacetic acid (TRITA), 2,2',2”,2”’-(1,4,7,10-tetraazacyclotridecane-1,4,7,10-tetrayl)tetraacetamide (TRITAM), 2,2',2”-(1,4,7,10-tetraazacyclotridecane-1,4,7-triyl)triacetamide (TRITRAM),

[0728] trans-N-dimethyl-cyclam, 2,2',2”-(1,4,7-triazacyclononane-1,4,7-triyl)triacetamide (NOTAM), oxocyclam, dioxocyclam, 1,7-dioxa-4,10-diazacyclododecane, cross-bridged-cyclam(CB-cyclam), triazacyclononane phosphinate (TRAP), dipyridoxyl diphosphate (DPDP), meso-tetra-(4-sulfanotophenyl)porphine (TPPS4), ethylenebishydroxyphenylglycine (EHPG), hexamethylenediaminetetraacetic acid, dimethylphosphinomethane (DM PE), methylenediphosphoric acid, dimercaptosuccinic acid (DMPA), and derivatives thereof.

[0729] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a chelating agent comprising a chelated radionuclide selected from the group consisting of DTPA, DOTA, DFO, NOTA, PCTA, CH-X-DTPA, NODAGA, DOTAGA, maSSS, maGGG, and DOTA-Methionine, and derivatives thereof. According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a chelating agent comprising a chelated radionuclide selected from the group consisting of DOTA, DTPA, CH-X-DTPA, PCTA, NOTA, DFO, and derivatives thereof.

[0730] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the chelated radionuclide is selected from the group consisting of124l,131l,86Y,90Y,177Lu,111ln,188Re,55Co,64Cu,67Cu,68Ga,89Zr,203Pb,212Pb,212Bi,213Bi,72As,211At,225Ac,223Ra,97Ru,149Tb,152Tb,161Tb,99mTc,226Th,227Th,201TI,89Sr,44 / 43Sc,47Sc,153Sm,133Xe, and AI18F. According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the chelated radionuclide is selected from the group consisting of89Zr,111In,64Cu,177Lu,68Ga,99mTc,203Pb,72As,55Co,97Ru,201TI,152Tb,133Xe,86Y, and AI18F. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the chelated radionuclide is selected from the group consisting of89Zr,111In,64Cu,177Lu,68Ga, and99mTc. According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the chelated radionuclide is selected from the group consisting of68Ga,64Cu,99mTc, and111ln.

[0731] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a chelating agent comprising a chelated radionuclide, wherein the chelating agent is DOTA, PCTA, DTPA, CH-X-DTPA, or a derivative thereof, and the chelated radionuclide is111In. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a chelating agent comprising a chelated radionuclide, wherein the chelating agent is CH-X-DTPA or a derivative thereof, and the chelated radionuclide is111ln.

[0732] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a chelating agent comprising a chelated radionuclide, wherein the chelating agent is NOTA, NODAGA, PCTA, or a derivative thereof, and the chelated radionuclide is64Cu. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, thepayload P-X1is a chelating agent comprising a chelated radionuclide, wherein the chelating agent is NOTA or a derivative thereof, and the chelated radionuclide is64Cu.

[0733] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a chelating agent comprising a chelated radionuclide, wherein the chelating agent is DOTA, DFO, DFO’, DFO-cyclo’, ora derivative thereof, and the chelated radionuclide is89Zr. According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a chelating agent comprising a chelated radionuclide, wherein the chelating agent is DFO or a derivative thereof, and the chelated radionuclide is89Zr.

[0734] The skilled person is aware of suitable methods for binding the above compounds to X1of the compound of formula (I) of the present disclosure. For example, an -OH group, an -NH₂ group, an -NR1H group, or an -SH group of the above-mentioned labelling agents may form the group X1of the compound of formula (I) of the present disclosure. In other words, the compound of formula (I) as disclosed herein may be prepared by activating

[0735] an -OH, -NH₂, -NR1H, or -SH group in the above compound and binding it to the PAB group. The payload P-X1is a diagnostic agent

[0736] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a diagnostic agent.

[0737] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the diagnostic agent is selected from the group consisting of a fluorescent substance, a luminescent substance, a phosphorescent substance, and.

[0738] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the diagnostic agent comprises a chromophore.

[0739] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a phosphorophore or a fluorophore, preferably fluorescein or rhodamine.

[0740] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a fluorescent substance. Preferred fluorescent substances include Cy5, Cy7, Alexa Fluor 488, Alexa Fluor 647, IRDye 800CW, FITC (fluorescein isothiocyanate), rhodamine (e.g. TAMRA), quantum dots, BODIPY dyes, or zwitterionic NIR fluorophores (e.g. ZW800-1).

[0741] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a phosphorescent substance. Preferred phosphorescent substances include iridium(lll) complexes, ruthenium(ll) polypyridyl complexes, europium(lll) chelates, terbium(lll) chelates, zinc(ii) porphyrins, palladium^ I) porphyrins, platinum(ll) complexes, cyclometalated platinum(ll) complexes, benzoporphyrin derivatives (e.g. BPD-MA), or iridium(lll) phenylpyridine derivatives.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a luminescent substance. Preferred luminescent substances include luciferin, Cy7, renilla luciferase substrate (coelenterazine), or luminol.

[0742] The skilled person is aware of suitable methods for binding the above compounds to X1of the compound of formula (I) of the present disclosure. For example, an -OH group, an -NH₂ group, an -NR1H group, or an -SH group of the above-mentioned diagnostic agents may form the group X1of the compound of formula (I) of the present disclosure. In other words, the compound of formula (I) as disclosed herein may be prepared by activating

[0743] an --OH, -NH₂, -NR1H, or -SH group in the above compound and binding it to the PAB group. The payload P-X1is a binding agent

[0744] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a binding agent. It is understood that a binding agent may be used for late-stage functionalization.

[0745] In other words, the binding agent may preferably be a bioorthogonal group. As used herein, the terms “bioorthogonal group” and “conjugation group” are used interchangeably.

[0746] According to another preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the payload P-X1is a binding agent comprises a functional group selected from the group consisting of an optionally substituted conjugated diene, an optionally substituted tetrazine (TZ), an optionally substituted alkyne or azide, an optionally substituted dibenzocyclooctyne (DBCO), an optionally substituted trans-cyclooctene (TCO), an optionally substituted bicyclo[6.1.0]nonyne (BCN), an optionally substituted aldehyde, an optionally substituted ketone, an optionally substituted halogenoacetamide, an optionally substituted maleimide, and an optionally substituted or protected thiol, said thiol being preferably protected with a monomethoxytrityl group.

[0747] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the binding agent comprises an alkyne or an azide.

[0748] Particularly preferred compounds and combinations

[0749] According to a particularly preferred embodiment of the first aspect of the present disclosure or according to the second aspect of the present disclosure, the compound according to formula (I) or formula (V), respectively, comprises one or more of the following moieties.The group A-L

[0750] According to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule and the divalent linker group L together form

[0751]

[0752] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and wherein the wavy line in said group A-L means bond to branching group B.

[0753] According to another preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule and the divalent linker group L together form

[0754]

[0755] wherein y is an integer in the range of from 0 to 4, preferably y is 1, and wherein the wavy line in said group A-L means bond to branching group B.

[0756] According to another preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule and the divalent linker group L together form

[0757]

[0758] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and wherein the wavy line in said group A-L means bond to branching group B.

[0759] According to a further preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule and the divalent linker group L together form

[0760]

[0761] wherein the wavy line in said group A-L means bond to B.

[0762] According to a further preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule and the divalent linker group L together form

[0763]

[0764] wherein the wavy line in said group A-L means bond to B.According to a further preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule and the divalent linker group L together form

[0765]

[0766] wherein the wavy line in said group A-L means bond to Pep.

[0767] According to a further preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule and the divalent linker group L together form

[0768]

[0769] wherein the wavy line in said group A-L means bond to Pep.

[0770] The group A-L-B

[0771] According to a preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule, the divalent linker group L, and the branching group B together form

[0772]

[0773] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and wherein

[0774] b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and each of symbols “black circle” in said group A-L-B means bond to a group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.According to another preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule, the divalent linker group L, and the branching group B together form

[0775]

[0776] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and wherein

[0777] b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and each of symbols “black circle” in said group A-L-B means bond to a group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[0778] According to another preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule, the divalent linker group L, and the branching group B together form

[0779]

[0780] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and wherein

[0781] b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and each of symbols “black circle” in said group A-L-B means bond to a group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[0782] According to a further preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule, the divalent linker group L, and the branching group B together form

[0783]

[0784] wherein b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein each of symbols “black circle” in said group A-L-B means bond to a group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.According to a further preferred embodiment of the first aspect of the present disclosure, the reactive group A having ability to react with a functional group in a targeting molecule and the divalent linker group L together form

[0785]

[0786] wherein b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein each of symbols “black circle” in said group A-L-B means bond to a group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[0787] The group B-Le

[0788] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups Leand B together form a structure of formula

[0789]

[0790] wherein each of symbols “black circle” in said group B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group B-Lemeans bond to L as disclosed herein.

[0791] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups Leand B together form a structure of formula

[0792]

[0793] wherein each of symbols “black circle” in said group B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group B-Lemeans bond to L as disclosed herein.

[0794] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups Leand B together form a structure of formula

[0795]

[0796] wherein each of symbols “black circle” in said group B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group B-Lemeans bond to L as disclosed herein.

[0797] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups Leand B together form a structure of formula

[0798]

[0799] wherein each of symbols “black circle” in said group B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group B-Lemeans bond to L as disclosed herein.

[0800] The group L-B-Le

[0801] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0802]

[0803] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0804] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0805]

[0806] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0807]

[0808] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0809] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0810]

[0811] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0812] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0813]

[0814] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0815] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0816]

[0817] wherein each of symbols black circle in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0818] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0819]

[0820] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0821] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0822]

[0823] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0824] According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0825]

[0826] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.According to a preferred embodiment of the first aspect or the second aspect of the present disclosure, the groups L, B, and Letogether form a structure of formula

[0827]

[0828] wherein each of symbols “black circle” in said group L-B-Lemeans bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B-Lemeans a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure. The group L-B

[0829] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, Leis absent and the groups L-B together form a structure of formula

[0830]

[0831] wherein each of symbols “black circle” in said group L-B means bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0832] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, Leis absent and the groups L-B together form a structure of formula

[0833]

[0834] wherein each of symbols “black circle” in said group L-B means bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0835] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, Leis absent and the groups L-B together form a structure of formula

[0836]

[0837] wherein each of symbols “black circle” in said group L-B means bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, Leis absent and the groups L-B together form a structure of formula

[0838]

[0839] wherein each of symbols “black circle” in said group L-B means bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0840] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, Leis absent and the groups L-B together form a structure of formula

[0841]

[0842] wherein each of symbols “black circle” in said group L-B means bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0843] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, Leis absent and the groups L-B together form a structure of formula

[0844]

[0845] wherein each of symbols “black circle” in said group L-B means bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure.

[0846] According to another preferred embodiment of the first aspect or the second aspect of the present disclosure, Leis absent and the groups L-B together form a structure of formula

[0847]

[0848] wherein each of symbols “black circle” in said group L-B means bond to a group Pep as disclosed herein, and symbol “white circle” in said group L-B means a) bond to A in the first aspect of the present disclosure or b) bond to A’ in the second aspect of the present disclosure. The group PAB and X1

[0849] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the PAB group, and X1together form

[0850]

[0851] wherein symbol “white circle” in said group PAB-X1means bond to Pep, and symbol “black circle” in said group PAB-X1means bond to P, and the wavy line in said group PAB-X1means bond to the solubilizing group T as disclosed herein.

[0852] The group PAB-T

[0853] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the PAB group and T together form

[0854]

[0855] wherein n is an integer in the range of from 1 to 35, symbol “white circle” in said group PAB-T means bond to Pep, and symbol “black circle” in said group PAB-T means bond to CL as disclosed herein. Preferably, n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17.

[0856] 77?e group Pep-PAB-T

[0857] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep, the PAB group, and T together form a compound of the structure

[0858]

[0859] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0860] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0861] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein

[0862] symbol “white circle” in said group Pep-PAB-T means a) bond to the branching group B (if f is 0) or b) bond to Le(if f is 1); and symbol “black circle” in said group Pep-PAB-T means bond to CL as disclosed herein.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep, the PAB group, CL, and T together form a compound of the structure

[0863]

[0864] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0865] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0866] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein

[0867] symbol “white circle” in said group Pep-PAB-T means a) bond to the branching group B (if f is 0) or b) bond to Le(if f is 1); and symbol “black circle” in said group Pep-PAB-T means bond to X1-P as disclosed herein.

[0868] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep, the PAB group, and T together form a compound of the structure

[0869]

[0870] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and whereinsymbol “white circle” in said group Pep-PAB-T means a) bond to the branching group B (if f is 0) or b) bond to Le(if f is 1); and symbol “black circle” in said group Pep-PAB-T means bond to CL as disclosed herein.

[0871] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep, the PAB group, CL, and T together form a compound of the structure

[0872]

[0873] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0874] symbol “white circle” in said group Pep-PAB-T means a) bond to the branching group B (if f is 0) or b) bond to Le(if f is 1); and symbol “black circle” in said group Pep-PAB-T means bond to X1-P as disclosed herein.

[0875] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep, the PAB group, and T together form a compound of the structure

[0876]

[0877] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0878] symbol “white circle” in said group Pep-PAB-T means a) bond to the branching group B (if f is 0) or b) bond to Le (if f is 1); and symbol “black circle” in said group Pep-PAB-T means bond to CL as disclosed herein.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep, the PAB group, CL, and T together form a compound of the structure

[0879]

[0880] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0881] symbol “white circle” in said group Pep-PAB-T means a) bond to the branching group B (if f is 0) or b) bond to Le(if f is 1); and symbol “black circle” in said group Pep-PAB-T means bond to X1-P as disclosed herein.

[0882] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep, the PAB group, and T together form a compound of the structure

[0883]

[0884] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0885] symbol “white circle” in said group Pep-PAB-T means a) bond to the branching group B (if f is 0) or b) bond to Le(if f is 1); and symbol “black circle” in said group Pep-PAB-T means bond to CL as disclosed herein.

[0886] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the group Pep, the PAB group, CL, and T together form a compound of the structure

[0887]

[0888] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is aninteger in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0889] symbol “white circle” in said group Pep-PAB-T means a) bond to the branching group B (if f is 0) or b) bond to Le(if f is 1); and symbol “black circle” in said group Pep-PAB-T means bond to X1-P as disclosed herein.

[0890] The group Le-Pep-PAB-T

[0891] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, and T together form a compound of the structure of formula (Via)

[0892]

[0893] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0894] u is an integer in the range of from 0 to 4; and wherein

[0895] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0896] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein f is 0 or 1; and wherein

[0897] symbol “white circle” in formula (Via) means bond to the branching group B; and symbol “black circle” in formula (Via) means bond to CL as disclosed herein.

[0898] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, CL, and T together form a compound of the structure of formula (Via)

[0899]

[0900] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0901] u is an integer in the range of from 0 to 4; and wherein

[0902] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and whereinR4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein f is 0 or 1; and wherein

[0903] symbol “white circle” in formula (Vla-1) means bond to the branching group B; and symbol “black circle” in formula (Vla-1) means bond to X1-P as disclosed herein.

[0904] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, and T together form a compound of the structure of formula (Vlb)

[0905]

[0906] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0907] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0908] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein f is 0 or 1; and wherein

[0909] u is an integer in the range of from 0 to 4; and wherein f is 0 or 1; and wherein

[0910] symbol “white circle” in formula (Vlb) means bond to the branching group B; and symbol “black circle” in formula (Vlb) means bond to CL as disclosed herein.

[0911] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, CL, and T together form a compound of the structure of formula (Vlb-1)

[0912]

[0913] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0914] u is an integer in the range of from 0 to 4; and wherein f is 0 or 1; and wherein

[0915] symbol “white circle” in formula (Vlb-1) means bond to the branching group B; and symbol “black circle” in formula (Vlb-1) means bond to X1-P as disclosed herein.According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, and T together form a compound of the structure of formula (Vic)

[0916]

[0917] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0918] R3is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2or benzyl; and wherein

[0919] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein f is 0 or 1; and wherein

[0920] symbol “white circle” in formula (Vic) means bond to the branching group B; and symbol “black circle” in formula (Vic) means bond to CL as disclosed herein.

[0921] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, and T together form a compound of the structure of formula (Vlc-1)

[0922]

[0923] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0924] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0925] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein f is 0 or 1; and wherein

[0926] symbol “white circle” in formula (Vlc-1) means bond to the branching group B; and symbol “black circle” in formula (Vlc-1) means bond to X1-P as disclosed herein.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, and T together form a compound of the structure of formula (Vid)

[0927]

[0928] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[0929] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0930] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein f is 0 or 1; and wherein

[0931] symbol “white circle” in formula (Vid) means bond to the branching group B; and symbol “black circle” in formula (Vid) means bond to CL as disclosed herein.

[0932] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, CL, and T together form a compound of the structure of formula (Vld-1)

[0933]

[0934] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[0935] symbol “white circle” in formula (Vld-1) means bond to the branching group B; and symbol “black circle” in formula (Vld-1) means bond to X1-P as disclosed herein.

[0936] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, and T together form a compound of the structure of formula (Vie)

[0937]

[0938] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[0939] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0940] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein f is 0 or 1; and wherein

[0941] symbol “white circle” in formula (Vie) means bond to the branching group B; and symbol “black circle” in formula (Vie) means bond to CL as disclosed herein.

[0942] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group Le, Pep, the PAB group, CL, and T together form a compound of the structure of formula (Vle-1)

[0943]

[0944] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[0945] symbol “white circle” in formula (Vle-1) means bond to the branching group B; and symbol “black circle” in formula (Vle-1) means bond to X1-P as disclosed herein.

[0946] The group L-B-Pep-PAB-T

[0947] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, the divalent linker Le, Pep, the PAB group, and T together form a compound of the structure

[0948]

[0949] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferablyn is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0950] x is an integer in the range of from 1 to 3, preferably x is 1 or 2; and wherein

[0951] R3is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2or benzyl; and wherein

[0952] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein

[0953] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and each symbol “black circle” indicates a bond to CL-X1-P independently selected as disclosed herein.

[0954] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, the divalent linker Le, Pep, the PAB group, CL, and T together form a compound of the structure

[0955]

[0956] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0957] x is an integer in the range of from 1 to 3, preferably x is 1 or 2; and wherein

[0958] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0959] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein

[0960] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).

[0961] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branchinggroup B, the divalent linker Le, Pep, the PAB group, CL, and T together form a compound of the structure

[0962]

[0963] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0964] x is an integer in the range of from 1 to 3, preferably x is 1 or 2; and wherein

[0965] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0966] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein

[0967] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P8), or (P-X1)1is of formula (P8) and (P-X1)2is of formula (P1).

[0968] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, the divalent linker Le, Pep, the PAB group, and T together form a compound of the structure

[0969]

[0970] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and whereinx is an integer in the range of from 1 to 3, preferably x is 1 or 2; and wherein

[0971] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and each symbol “black circle” indicates a bond to CL-X1-P independently selected as disclosed herein.

[0972] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, the divalent linker Le, Pep, the PAB group, CL, and T together form a compound of the structure

[0973]

[0974] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0975] x is an integer in the range of from 1 to 3, preferably x is 1 or 2; and wherein

[0976] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).

[0977] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branchinggroup B, the divalent linker Le, Pep, the PAB group, CL and T together form a compound of the structure

[0978]

[0979] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0980] x is an integer in the range of from 1 to 3, preferably x is 1 or 2; and wherein

[0981] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1is of formula (P1) and (P-X1)2is of formula (P8), or (P-X1)1is of formula (P8) and (P-X1)2is of formula (P1).

[0982] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of the structure

[0983]

[0984] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0985] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0986] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and whereinsymbol “white circle” in said group B-Le-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and each symbol “black circle” independently means covalent bond to a group CL-X1-P independently selected as disclosed herein.

[0987] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, CL, and T together form a compound of the structure

[0988]

[0989] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0990] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0991] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein

[0992] symbol “white circle” in said group B-Le-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, CL, and T together form a compound of the structure

[0993]

[0994] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[0995] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[0996] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein

[0997] symbol “white circle” in said group B-Le-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1is of formula (P1) and (P-X1)2is of formula (P8), or (P-X1)1is of formula (P8) and (P-X1)2is of formula (P1).

[0998] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of the structure

[0999]

[1000] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and whereinsymbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and each symbol “black circle” independently means covalent bond to a group CL-X1-P independently selected as disclosed herein.

[1001] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, CL, and T together form a compound of the structure

[1002]

[1003] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[1004] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).

[1005] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, CL, and T together form a compound of the structure

[1006]

[1007] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[1008] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1is of formula (P1) and (P-X1)2is of formula (P8), or (P-X1)1is of formula (P8) and (P-X1)2is of formula (P1).

[1009] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of the structure

[1010]

[1011] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[1012] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and each symbol “black circle” independently means covalent bond to a group CL-X1-P independently selected as disclosed herein.According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, CL, and T together form a compound of the structure

[1013]

[1014] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[1015] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).

[1016] According to a further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, CL, and T together form a compound of the structure

[1017]

[1018] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and whereinsymbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and (P-X1)1is of formula (P1) and (P-X1)2is of formula (P8), or (P-X1)1is of formula (P8) and (P-X1)2is of formula (P1).

[1019] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of the structure

[1020]

[1021] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[1022] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and each symbol “black circle” independently means covalent bond to a group CL-X1-P independently selected as disclosed herein.

[1023] According to a preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of the structure

[1024]

[1025] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein f is 0 or 1; and wherein

[1026] symbol “white circle” in said group B-Pep-PAB-T means a) bond to A in the first aspect of the present disclosure, or b) bond to A’ in the second aspect of the present disclosure; and eachsymbol “black circle” independently means covalent bond to a group CL-X1-P independently selected as disclosed herein.

[1027] The group A-L-B-(Pep-PAB-T)2

[1028] According to a preferred embodiment of the first aspect of the present disclosure, the reactive group A, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of formula (Ic)

[1029]

[1030] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[1031] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[1032] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).

[1033] According to a preferred embodiment of the first aspect of the present disclosure, the reactive group A, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of formula (Id)

[1034]

[1035] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).

[1036] According to a preferred embodiment of the first aspect of the present disclosure, the reactive group A, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of formula (le)

[1037]

[1038] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[1039] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[1040] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2and wherein (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).According to a preferred embodiment of the first aspect of the present disclosure, the reactive group A, the divalent linker group L, the branching group B, Pep, the PAB group, and T together form a compound of formula (If)

[1041]

[1042] wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein (P-X1)1and (P-X1)2are each independently as disclosed herein, preferably (P-X1)1is of formula (P1) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P1) and (P-X1)2is of formula (P2), (P-X1)1is of formula (P2) and (P-X1)2is of formula (P1), or (P-X1)1is of formula (P2) and (P-X1)2is of formula (P2).

[1043] Particularly preferred compounds of formula (IE)

[1044] According to a yet further preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, each group E of formula (I E) is independently selected from Table 2.Table 2 Particularly preferred groups E

[1045]

[1046] According to a most preferred embodiment of the first aspect of the present disclosure or the second aspect of the present disclosure, each group E of formula (IE) is independently selected from Table 3.Table 3 Most preferred groups E

[1047]

[1048] Particularly preferred compounds of formula (I)

[1049] According to a yet further preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) is a compound selected from Table 4.Table 4 Particularly preferred compounds of formula (I)

[1050]

[1051]

[1052] Further particularly preferred compounds

[1053] According to a yet further preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) has a structure of formula:

[1054]

[1055] wherein:

[1056]

[1057]

[1058]

[1059]

[1060]

[1061] and wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17.

[1062] According to a further preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) has a structure of formula:

[1063]

[1064] wherein:

[1065]

[1066]

[1067]

[1068]

[1069] and wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17.

[1070] The targeting molecule-drug conjugate

[1071] In a second aspect, the present disclosure relates to a targeting molecule-drug conjugate of formula (V)

[1072] Ab[-A’-L-B(-E)e]d (V)

[1073] wherein Ab is a targeting molecule; d is at least 1; A’ is a group formed by a reaction between A and a fuinctional group in Ab; and wherein L, B, E, and e are as defined herein with regard to the first aspect of the present disclosure or the second aspect of the present disclosure.

[1074] The targeting molecule Ab

[1075] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is an antibody. In other words, the second aspect of the present disclosure may relate to an antibody-drug conjugate (ADC).

[1076] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is a chimeric antibody or a humanized antibody or a human antibody. Chimeric antibodies

[1077] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is a chimeric antibody.

[1078] According to a further preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is rituximab, basiliximab, infliximab, cetuximab, siltuximab, dinutuximab, or altertoxaximab.

[1079] Humanized antibodies

[1080] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is a humanized antibody.

[1081] According to a further preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is daclizumab, palivizumab, trastuzumab (Tmab), naratuximab (Nmab) alemtuzumab, omalizumab, efalizumab, bevacizumab, natalizumab (lgG-4), tocilizumab, eculizumab (lgG2), mogamulizumab, pertuzumab, obinutuzumab, vedolizumab, pembrolizumab (lgG4), mepolizumab, elotuzumab, daratumumab, ixekizumab (lgG-4), reslizumab (lgG4), or atezolizumab.

[1082] According to a most preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is Trastuzumab (Tmab). According to a most preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is naratuximab (Nmab).

[1083] Cases not referring to the IgG subtype indicate that they are IgG1.Human antibodies

[1084] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is a human antibody.

[1085] According to a further preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab is adalimumab, panitumumab, golimumab, ustekinumab, canakinumab, ofatumumab, denosumab (lgG2), ipilimumab, belimumab, raxibacumab, ramucirumab, nivolumab (lgG4), secukinumab, evolocumab (lgG2), alirocumab, necitumumab, brodalumab (lgG2), olaratumab, or dupilumab (lgG4).

[1086] Cases not referring to the IgG subtype indicate that they are IgG1.

[1087] The group A’ formed by a reaction between A and a functional group in Ab According to the second aspect of the present disclosure, the compound of formula (V) as disclosed herein comprises a group A’ formed by a reaction between A and a functional group in the targeting molecule Ab.

[1088] Said group A’ is formed when a compound of formula (I) as disclosed herein reacts with a targeting molecule during formation of a targeting molecule-drug conjugate, such as an antibody-drug conjugate. During the reaction of the group A with a functional group of an amino acid in a targeting molecule, a covalent bond is formed between said functional group of an amino acid and the group A thus forming a group A’.

[1089] Herein, the terms “A’ is a group formed by a reaction between A and a functional group in Ab”, “group A’ formed by a reaction between A and a functional group in Ab”, “group A’ ”, and “A’ ” are used interchangeably.

[1090] As used herein, the group A’ is determined by the reactive group A and its reaction partner in the targeting molecule, such as an -SH group in the side chain of a cysteine in the targeting molecule.

[1091] According to a preferred embodiment of the second aspect of the present disclosure, A’ is a group formed by a reaction between A having ability to react with a -SH group of a cysteine as disclosed herein and a cysteine in Ab.

[1092] According to a further preferred embodiment of the second aspect of the present disclosure, the group A’ is formed by a reaction between A and a cysteine (-SH group) in Ab.According to a further preferred embodiment of the second aspect of the present disclosure, group A’ is group formed by a reaction between A and an -SH group of a cysteine in a targeting molecule Ab selected from the group consisting of

[1093]

[1094] wherein the symbol “white circle” in group A’ means bond to Ab (specifically to -S in the side chain of a cysteine), and the symbol “black circle” in group A’ means bond to the divalent linker group L.

[1095] According to a yet further preferred embodiment of the second aspect of the present

[1096] disclosure, group

[1097]

[1098] wherein the symbol “white circle” in group A’ means bond to Ab (specifically to -S in the side chain of a cysteine), and the symbol “black circle" in group A’ means bond to the divalent linker group L.

[1099] According to another preferred embodiment of the second aspect of the present

[1100]

[1101] , wherein the symbol “white circle” in group A’ means bond to Ab (specifically to -S in the side chain of a cysteine), and the symbol “black circle“in group A’ means bond to the divalent linker group L.

[1102] According to another preferred embodiment of the second aspect of the present

[1103] H

[1104] disclosure, A’ is

[1105]

[1106] , wherein the symbol “white circle” in group A’ means bond to Ab (specifically to -S in the side chain of a cysteine), and the symbol “black circle" in group A’ means bond to the divalent linker group L.

[1107] According to a further preferred embodiment of the second aspect of the present

[1108] disclosure, A’ is

[1109]

[1110] , wherein the symbol “white circle” in group A’ means bond to Ab(specifically to -S in the side chain of a cysteine), and the symbol “black circle" in group A’ means bond to the divalent linker group L.

[1111] According to a further preferred embodiment of the second aspect of the present disclosure, A’ is

[1112]

[1113] wherein the symbol “white circle” in group A’ means bond to Ab (specifically to -S in the side chain of a cysteine), and the symbol “black circle” in group A’ means bond to the divalent linker group L. It is understood that said groups A’ have a chiral center, i.e., the group A’ may further preferably be

[1114]

[1115] According to a most preferred embodiment of the second aspect of the present

[1116] disclosure,

[1117]

[1118] , wherein the symbol “white circle” in group A’ means bond to Ab (specifically to -S in the side chain of a cysteine), and the symbol “black circle" in group A’ means bond to the divalent linker group L.

[1119] According to another preferred embodiment of the second aspect of the present disclosure, A’ is a group formed by a reaction between A having ability to react with a -NH2group of a lysine as disclosed herein and a lysine in Ab.

[1120] According to a further preferred embodiment of the second aspect of the present disclosure, the group A’ is formed by a reaction between A and a lysine (-NH2group) in Ab.

[1121] According to a further preferred embodiment of the second aspect of the present disclosure, group A’ is a group formed by a reaction between A and an -NH2group of a lysine in a targeting molecule Ab that is

[1122]

[1123] wherein the symbol “white circle” in said group A’ means bond to Ab (specifically to -NH in the side chain of a cysteine), and the symbol “black circle” in said group A’ means bond to the divalent linker group L.

[1124] The aforementioned groups A’ provide for a stable and covalent bond of the compound according the first aspect of the present disclosure with a cysteine in a targeting molecule, such as an antibody or an antibody fragment.The number of conjugation sites d

[1125] According to the second aspect of the present disclosure, the targeting molecule is conjugated with a number d of compounds as disclosed herein, wherein d is at least 1.

[1126] According to another preferred embodiment of the second aspect of the present disclosure, d is an integer in the rage of from 1 to 12. According to another preferred embodiment of the second aspect of the present disclosure, d is an integer in the range of from 4 to 9. According to another preferred embodiment of the second aspect of the present disclosure, d is an integer in the range of from 6 to 9. According to another preferred embodiment of the second aspect of the present disclosure, d is an integer in the range of from 7 to 9. According to another preferred embodiment of the second aspect of the present disclosure, d is 8.

[1127] It is understood that when d is 8 and e is 2, then the drug-targeting molecule ratio is 16.

[1128] Particularly preferred compounds and combinations

[1129] According to a particularly preferred embodiment of the second aspect of the present disclosure, the compound according to formula (V) comprises one or more of the following moieties.

[1130] The group Ab-A ’-L-B

[1131] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B together form

[1132]

[1133] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and wherein

[1134] b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein

[1135] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1136] each of symbols “black circle” in said group Ab-A’-L-B means bond to group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[1137] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with afunctional group in a targeting molecule Ab, the divalent linker group L, and the branching group B together form

[1138]

[1139] wherein b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein

[1140] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1141] each of symbols “black circle” in said group Ab-A’-L-B means bond to group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[1142] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B together form

[1143]

[1144] wherein b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein

[1145] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1146] each of symbols “black circle” in said group Ab-A’-L-B means bond to group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[1147] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B together form

[1148]

[1149] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and whereinb is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein

[1150] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1151] each of symbols “black circle” in said group Ab-A’-L-B means bond to group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[1152] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B together form

[1153]

[1154] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and wherein

[1155] b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein

[1156] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1157] each of symbols “black circle” in said group Ab-A’-L-B means bond to group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[1158] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B together form

[1159]

[1160] wherein y is an integer in the range of from 0 to 4, preferably y is 1; and wherein

[1161] b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein

[1162] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and whereineach of symbols “black circle” in said group Ab-A’-L-B means bond to group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[1163] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B together form

[1164]

[1165] wherein b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein

[1166] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1167] each of symbols “black circle” in said group Ab-A’-L-B means bond to group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[1168] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B together form

[1169]

[1170] wherein b is an integer in the range of from 1 to 5, preferably b is an integer in the range of from 1 to 3; and wherein

[1171] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1172] each of symbols “black circle” in said group Ab-A’-L-B means bond to group E as disclosed herein. Preferably, the groups E are different from each other. Alternatively, the groups E are identical.

[1173] The group Ab-A’-L-B-(Pep-PAB-T)2

[1174] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with afunctional group in a targeting molecule Ab, the divalent linker group L, and the branching group B, Pep, the PAB group, and T together form a compound of formula (Va)

[1175]

[1176] a compound of formula (Va-2)

[1177]

[1178] a compound of formula (Va-3)

[1179]

[1180] wherein Ab is a targeting molecule as disclosed herein, and wherein

[1181] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[1182] R3is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2; and wherein

[1183] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and whereind is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1184] (CL-X1-P)1and (CL-X1-P)2are a group CL-X1-P as disclosed herein and are identical or different from each other.

[1185] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B, Pep, the PAB group, and T together form a compound of formula (Vb)

[1186]

[1187] a compound of formula (Vb-3)

[1188]

[1189] wherein Ab is a targeting molecule as disclosed herein; and wherein

[1190] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[1191] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1192] (CL-X1-P)1and (CL-X1-P)2are a group CL-X1-P as disclosed herein and are identical or different from each other.

[1193] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B, Pep, the PAB group, and T together form a compound of formula (Vc)

[1194]

[1195] a compound of formula (Vc-2)

[1196]

[1197] a compound of formula (Vc-3)

[1198]

[1199] wherein Ab is a targeting molecule as disclosed herein; and wherein

[1200] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17; and wherein

[1201] R3is H, or -CH3, or -CH2-CH3, or –CH(-CH3)2or benzyl; and wherein

[1202] R4is H, or -CH3, or -CH2-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2; and wherein

[1203] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1204] (CL-X1-P)1and (CL-X1-P)2are a group CL-X1-P as disclosed herein and are identical or different from each other.

[1205] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with a functional group in a targeting molecule Ab, the divalent linker group L, and the branching group B, Pep, the PAB group, and T together form a compound of formula (Vd)

[1206]

[1207] d

[1208] (Vd), ora compound of formula (Vd-2)

[1209]

[1210] (Vd-2), or

[1211] a compound of formula (Vd-3)

[1212]

[1213] d

[1214] (Vd-3);

[1215] wherein Ab is a targeting molecule as disclosed herein; and wherein

[1216] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17;

[1217] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1218] (CL-X1-P)1and (CL-X1-P)2are a group CL-X1-P as disclosed herein and are identical or different from each other.

[1219] According to a preferred embodiment of the second aspect of the present disclosure, the targeting molecule Ab, group A’ formed by a reaction between A as disclosed herein with afunctional group in a targeting molecule Ab, the divalent linker group L, and the branching group B, Pep, the PAB group, and T together form a compound of formula (Ve)

[1220]

[1221] (Ve),

[1222] wherein Ab is a targeting molecule as disclosed herein; and wherein

[1223] n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17;

[1224] d is an integer in the range of from 1 to 12, preferably in the range of from 4 to 9, more preferably in the range of from 6 to 9, even more preferably in the range of from 7 to 9, most preferable d is 8; and wherein

[1225] (CL-X1-P)1and (CL-X1-P)2are a group CL-X1-P as disclosed herein and are identical or different from each other.

[1226] Particularly preferred compounds of formula (V)

[1227] According to a yet further preferred embodiment of the first aspect of the present disclosure, the compound of formula (V) comprises a group A-L-B-(Pep-PAB-T)2, (X1-P)1and (X1-P)2as disclosed in Table 5.Table 5 Particularly preferred compounds of formula (V)

[1228]

[1229] According to a yet further preferred embodiment of the first aspect of the present disclosure, the compound of formula (V) has a structure of formula:

[1230]

[1231] wherein:

[1232]

[1233]

[1234]

[1235]

[1236]

[1237] wherein A’ is

[1238]

[1239] wherein symbol “white circle” means covalent bond to Ab, and symbol “black circle” means covalent bond to L,

[1240] and wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17.

[1241] According to a further preferred embodiment of the first aspect of the present disclosure, the compound of formula (I) has a structure of formula:

[1242]

[1243] wherein:

[1244]

[1245]

[1246]

[1247]

[1248]

[1249] wherein A’ is

[1250]

[1251] wherein symbol “white circle” means covalent bond to Ab, and symbol “black circle” means covalent bond to L, and wherein n is an integer in the range of from 1 to 35, preferably n is an integer in the range of from 7 to 23, more preferably n is an integer in the range of from 10 to 20, even more preferably n is an integer in the range of from 13 to 18, most preferably n is an integer in the range of from 15 to 17.

[1252] The method of manufacturing a targeting molecule-drug conjugate

[1253] In a third aspect, the present disclosure relates to method of manufacturing a targeting molecule-drug conjugate of formula (V) according to the second aspect of the present disclosure, the method comprising the steps of providing a compound of formula (I) according to the first aspect of the present disclosure, providing a targeting molecule Ab, and reacting said compound of formula (I) according to the first aspect of the present disclosure with the targeting molecule Ab to provide the targeting molecule-drug conjugate according to the second aspect of the present disclosure.

[1254] The targeting molecule-drug conjugate prepared by a method of the present disclosure According to a fourth aspect, the present disclosure relates to a targeting molecule-drug conjugate prepared by the method according to the third aspect of the present disclosure.

[1255] It is understood that the targeting molecule-drug conjugate according to the fourth aspect of the present disclosure is characterized by essentially the same features as the targeting molecule-drug conjugate according to the second aspect of the present disclosure. The medical use

[1256] According to a fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in medicine.

[1257] According to a preferred embodiment of the fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in a method of treating an autoimmune disease.According to a preferred embodiment of the fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in a method of treating a bacterial infection.

[1258] According to a preferred embodiment of the fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in a method of treating a viral infection.

[1259] According to a further preferred embodiment of the fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in a method of treating cancer.

[1260] According to a preferred embodiment of the fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in a method of diagnosing an autoimmune disease.

[1261] According to a preferred embodiment of the fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in a method of diagnosing a bacterial infection.

[1262] According to a preferred embodiment of the fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in a method of diagnosing a viral infection.

[1263] According to a further preferred embodiment of the fifth aspect, the present disclosure relates to a targeting molecule-drug conjugate according to the second aspect of the present disclosure or according to the fourth aspect of the present disclosure for use in a method of diagnosing cancer.

[1264] Definitions

[1265] As used herein, the term “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated member, integer or step but not the exclusion of any other non-stated member, integer or step, unless the context requires otherwise. The term “consist of” is a particular or preferred embodiment of the term “comprise”, wherein any other non-stated member, integer or step is excluded. In the context of the present invention, the term “comprise” encompasses the term “consist of”. The term “comprising” thus encompasses “including” as well as “consisting of’ e.g, a composition “comprising” X may consist exclusively of X or may include something additional e.g., X + Y.The terms “a” and “an” and “the” and similar reference used in the context of describing the invention (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[1266] The word “substantially” does not exclude “completely” e.g., a composition which is “substantially free” from Y may be completely free from Y. Where necessary, the word “substantially” may be omitted from the definition of the invention.

[1267] The term “about” in relation to a numerical value x means x ± 20 %, preferably x ± 10 %, more preferably x ± 5 %, even more preferably x ± 2 %, and still more preferably x ± 1 %.

[1268] As used herein, the terms “biological target”, “target structure”, “target cell”, and “target area” are used interchangeably.

[1269] As used herein, the term “pharmaceutically acceptable salt” refers to an ionic assembly of cations and anions, which is composed of related numbers of cations and anions, so that the product (the pharmaceutically acceptable salt) is electrically neutral (without net charge). In that, it is understood that the skilled person may balance the charge of a component, such as an ascorbate ion, with a respective pharmaceutically acceptable cation or a pharmaceutically acceptable anion as needed.

[1270] As used herein, the term “pharmaceutically acceptable cation” refers to a cation that is not toxic to mammals. Preferred pharmaceutically acceptable cations are lithium, sodium, potassium, aluminium, and zinc, cations made from organic bases such as choline, diethanolamine, morpholine, ammonium salts, quaternary salts such as tetramethylammonium salt; amino acid addition salts such as salts with glycine and arginine.

[1271] As used herein, the term “pharmaceutically acceptable anion" refers to an anion that is not toxic to mammals. Said pharmaceutically acceptable anion may have one, two, three, or more negative charges. Preferred pharmaceutically acceptable anions are F; Cl; Br, I; OH; tosylate, mesylate, triflate, trifluoroacetate, sulfate, acetate, tartrate, benzoate, oxylate, salicylate, or camphorsulfonate. Further preferred pharmaceutically acceptable anions are F; Cl; Br; I; or OH'. A particularly preferred pharmaceutically acceptable anion is Cl'.

[1272] As used herein, the term “room temperature” refers to a temperature of 25 °C. All reactions were performed at room temperature, unless explicitly stated otherwise.

[1273] As used herein, the term “linear or branched C2-C6 carbonylene” refers to a group comprising one to six carbon atoms, wherein one terminal carbon is a carbonyl group. Nonlimiting examples of linear or branched C2-C6 carbonylenes are: -CH2-(C=O)-,

[1274] -CH2-CH2-(C=O)-, -CH2-CH2-CH2-(C=O)-, and -CH2-CH2-CH2-CH2-CH2-(C=O)-. Preferred linearor branched C2-C6 carbonylenes are: -CH2-(C=O)-,-CH2-CH2-(C=O)-,

[1275] and -CH2-CH2-CH2-(C=O)-.

[1276] As used herein, the term “organic residue” refers to any substituent derived from an organic compound, which may include, but is not limited to, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocyclic groups, and may optionally be substituted with one or more functional groups such as halogen, hydroxyl, amino, nitro, cyano, carboxyl, ester, ether, or thioether groups. Particularly preferred embodiments of an “organic residue” include linear or branched (Ci-Ce)alkyl as defined herein.

[1277] As used herein, the term “(5 to 6 membered)heteroaryl” either refers to groups containing an aromatic ring containing 5 to 6 ringatoms, wherein one or two or three, preferably three, of said ringatoms are a heteroatom selected from nitrogen, oxygen and sulphur; the remainder of the ringatoms being carbon atoms. Preferred (5 to 6 membered)heteroarylelene are thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, isoindolizine, xantholene, phenoxatine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, cinnoline, carbazole, phenanthridine, acridine, phenazine, thiazole, isothiazole, triazole, phenothiazine, oxazole, isooxazole, furazane, phenoxazine, 2-, 3- or 4 -pyridyl, 2-, 3-, 4-, 5-, or 8- quinolyl, 1-, 3-, 4-, or 5-isoquinolinyl 1 -, 2-, or 3-indolyl, and 2-, or 3-thienyl. The group may be a terminal group or a bridging group. A particularly preferred (5 to 6 membered)heteroaryl is triazole.

[1278] The term “linear or branched (Ci-C6)alkyl” as used herein refers to an aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain, preferably 1 to 4 carbons. Preferred linear or branched (Ci-Ce)alkyl is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl. The letter is also referred to as tBu. The group may be a terminal group ora bridging group.

[1279] The term “substituted” as used throughout the specification denotes that the group contains one or more substituent groups. Preferably the substituent groups are one or more groups independently selected from the group consisting of halogen, =0, =S, -CN, -NO2, -CF3, -OCF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl; alkoxy, alkoxyalkyl, alkoxycycloalkyl, alkoxyheterocycloalkyl, alkoxyaryl, alkoxyheteroaryl, alkoxycarbonyl, alkylaminocarbonyl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, phenoxy, benzyloxy, heteroaryloxy, arylalkyloxy, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyloxy, amino, alkylamino,acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, alkylsulfinyl, arylsulfinyl, aminosulfinylaminoalkyl, one or more ethyleneoxide groups, and -COOH. A particularly preferred substituent group is ethyleneoxide(s). Said ethyleneoxides consist of -CH2-CH2-O- repeating units.

[1280] As used herein, the term “unsubstituted” means that there is no substituent or that the only substituents are hydrogen.

[1281] For the purpose of the present disclosure, the term “aryl” as used by itself or as part of another group refers to a mono-, bi-, or tricyclic aromatic ring system having from six to fourteen, i.e. 6, 7, 8, 9, 10, 11, 12, 13 or 14, carbon atoms ( / .e., Ce-Cuaryl). Non-limiting exemplary aryl groups include phenyl (abbreviated as “Ph”), naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In one embodiment, the aryl group is chosen from phenyl or naphthyl.

[1282] For the purpose of the present disclosure, the term “substituted aryl” as used herein by itself or as part of another group means that the aryl as defined above is substituted with one to ten, preferably one to eight, more preferably one to five substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (cycloalkylamino)alkyl, (C1-C4 haloalkoxy)alkyl, or (heteroaryl)alkyl. In one embodiment, the substituted aryl is a substituted phenyl. In one embodiment, the substituted phenyl has four substituents. In another embodiment, the substituted phenyl has three substituents. In another embodiment, the substituted phenyl has two substituents. In another embodiment, the substituted phenyl has one substituent. Nonlimiting exemplary substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl, 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, and 3-chloro-4-fluorophenyl. The term substituted aryl is meant to include groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclo rings. Examples include

[1283]

[1284] As used herein, the term “(4 to 8 membered)heterocyclyl” refers to a saturated or partially saturated monocyclic or bicyclic ring containing of from 4 to 8 atoms, wherein at least one of said 4 to 8 atoms is a heteroatom selected from nitrogen, sulfur, or oxygen, preferablysaid “(4 to 8 membered)heterocyclyl exhibits from 1 to 3 heteroatoms. Preferred (4 to 8 membered)heterocyclyl groups are selected from pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, and 1,4-oxathiapane. The group may be a terminal group or a bridging group. Further (4 to 8 membered)heterocyclyl groups include:

[1285]

[1286] As used herein reference to the normal chain when used in the context of a bridging group refers to the direct chain of atoms linking the two terminal positions of the bridging group.

[1287] For the purpose of the present disclosure, the term “(4 to 8 membered) cyclyl” as used by itself or as part of another group refers to saturated and partially unsaturated (e.g. containing one or two double bonds) cyclic aliphatic hydrocarbons containing one or two rings having from four to eight carbon atoms ( / .e., C4-C8 cycloalkyl) or the number of carbons designated. In one embodiment, the (4 to 8 membered) cyclyl group has two rings. In one embodiment, the (4 to 8 membered) cyclyl group has one ring. In one embodiment, the (4 to 8 membered) cyclyl group is a saturated cyclic aliphatic hydrocarbon containing one or two rings, preferably one ring, and having 4, 5, 6, 7, or 8 carbon atoms. In another embodiment, the (4 to 8 membered) cyclyl group is selected as a C4-C6 cycloalkyl group. Non-limiting exemplary (4 to 8 membered) cyclyl groups include cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. The group may be a terminal group or a bridging group.For the purpose of the present disclosure, the term “(hydroxy)haloalkyl” as used by itself or as part of another group refers to an alkyl group substituted by one or more halogen atoms and one hydroxy group. A non-limiting exemplary (hydroxy)haloalkyl group is -CH(OH)CF3.

[1288] For the purpose of the present disclosure, the term “hydroxyalkyl” as used by itself or as part of another group refers to an alkyl group substituted with one or more, e.g., one, two, or three, hydroxy groups. In one embodiment, the hydroxyalkyl group is a monohydroxyalkyl group, i.e., substituted with one hydroxy group. In another embodiment, the hydroxyalkyl group is a dihydroxyalkyl group, i.e., substituted with two hydroxy groups. In another embodiment, the hydroxyalkyl group is chosen from a C1.4 hydroxyalkyl group. Non-limiting exemplary hydroxyalkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, such as 1 -hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-1-methylpropyl, and 1,3-dihydroxyprop-2-yl.

[1289] For the purpose of the present disclosure, the term “cycloalkyl” as used by itself or as part of another group refers to saturated and partially unsaturated (containing one or two double bonds) cyclic aliphatic hydrocarbons containing one to three rings having from three to twelve carbon atoms (i.e., C3-12 cycloalkyl) or the number of carbons designated. In one embodiment, the cycloalkyl group has two rings. In one embodiment, the cycloalkyl group has one ring. In one embodiment, the cycloalkyl group is a saturated cyclic aliphatic hydrocarbon containing one or two rings, preferably one ring, and having 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. In another embodiment, the cycloalkyl group is chosen from a C3-8 cycloalkyl group. In another embodiment, the cycloalkyl group is chosen from a C3-6 cycloalkyl group. Non-limiting exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, and the like.

[1290] For the purpose of the present disclosure, the term “alkoxy” as used by itself or as part of another group refers to an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl attached to a terminal oxygen atom. In one embodiment, the alkoxy group is chosen from a C1.4 alkoxy group. In another embodiment, the alkoxy group is chosen from a C1.4 alkyl attached to a terminal oxygen atom, e.g., methoxy, ethoxy, and tert-butoxy.

[1291] For the purpose of the present disclosure, the term “alkylthio” as used by itself or as part of another group refers to a sulfur atom substituted by an optionally substituted alkyl group. In one embodiment, the alkylthio group is chosen from a C1.4 alkylthio group. Non-limiting exemplary alkylthio groups include -SCH3, and -SCH2CH3.

[1292] For the purpose of the present disclosure, the term “alkoxyalkyl” as used by itself or as part of another group refers to an alkyl group substituted with an alkoxy group. Non-limiting exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxy propyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, and pentyloxymethyl.

[1293] For the purpose of the present disclosure, the term “haloalkoxy” as used by itself or as part of another group refers to a haloalkyl attached to a terminal oxygen atom. Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.

[1294] The term “linear or branched (Ci-C6)alkyl” as used herein refers to an aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain, preferably 1 to 4 carbons. Preferred linear or branched (Ci-Ce)alkyl is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl. The letter is also referred to as tBu. The group may be a terminal group ora bridging group.

[1295] As used herein, the term “absent” means that a group is not present in a compound. Instead, the absent group is a single bond.

[1296] “Heteroalkyl” refers to a straight- or branched-chain alkyl group preferably having from 2 to 14 carbons, more preferably 2 to 10 carbons in the chain, one or more of which has been replaced by a heteroatom selected from S, O, and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, amides, alkyl sulfides, and the like. The group may be a terminal group or a bridging group. As used herein reference to the normal chain when used in the context of a bridging group refers to the direct chain of atoms linking the two terminal positions of the bridging group. Non-limiting exemplary heteroalkyl groups include: -CH2N(H)CH2CH2N(CH3)2; -CH2N(CH3)CH2CH2N(CH3)2; -CH2N(H)CH2CH2CH2N(CH3)2; -CH2N(H)CH2CH2OH; -CH2N(CH3)CH2CH2OH; -CH2OCH2CH2OCH3, -OCH2CH2OCH2CH2OCH3; -CH2NHCH2CH2OCH2; -OCH2CH2NH2; and -NHCH2CH2N(H)CH3.

[1297] As used herein, the term “targeting molecule” is understood to be a biochemical entity, such as an antibody, an antibody fragment, a small molecule, or a peptide, that selectively binds to specific cellular markers or receptors, facilitating the directed delivery of therapeutic or diagnostic agents to particular cells or tissues. These molecules confer specificity to drug conjugates by recognizing and engaging molecular targets that are differentially expressed, often on diseased cells, thereby enhancing efficacy and minimizing off-target effects.

[1298] Further aspects

[1299] The present disclosure is further described in the following numbered Aspects.

[1300] 1. A compound of formula (I)

[1301] A-L-B-(E)e(I)

[1302] wherein

[1303] A is a reactive group having ability to react with a functional group in a targeting molecule; L is a divalent linker group;

[1304] B is a branching group;

[1305] e is an integer of 2 or more; andeach E is independently a group of formula (IE-A)

[1306]

[1307] wherein

[1308] the wavy line in formula (IE-A) means bond to B;

[1309] each Leis independently a divalent linker group;

[1310] each f is independently 0 or 1;

[1311] each Pep independently comprises 1 to 6 amino acid groups;

[1312] each T is independently a solubilizing group; and

[1313] each group P-X1is independently a payload, wherein each X1is independently O, S, or NR1, wherein R1is hydrogen or an organic residue.

[1314] The compound of formula (I) according to Aspect 1, wherein each X1of formula (IE-A) is NR1, wherein R1is hydrogen or C1-C6alky, preferably each X1is NH.

[1315] The compound of formula (I) according to Aspect 1 or 2, wherein e is an integer in the range of from 2 to 6, preferably e is an integer in the range of from 2 to 4, more preferably e is 2 or 3, most preferably e is 2.

[1316] The compound of formula (I) according to any one of Aspects 1 to 3, wherein the compound has the formula (laa)

[1317]

[1318] (laa),

[1319] wherein A, L, B, Le, f, Pep, T, and P-X1are as defined in any one of Aspects 1 to 3, preferably wherein the compound has the formula (Iba)

[1320]

[1321] wherein A, L, B, Pep, T, and P-X1are as defined in any one of Aspects 1 to 3, preferably wherein the compound has the formula (Iba).

[1322] The compound of formula (I) according to any one of Aspects 1 to 4, wherein each Pep independently of each other has the formula (II)

[1323]

[1324] wherein

[1325] R3is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R3is H, or-CH3, or-CH(-CH3)2;

[1326] R4is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R4is H, or-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2;

[1327] symbol “white circle” in formula (II) means bond to Leor bond to B; and

[1328] symbol “black circle” in formula (II) means bond to NH.

[1329] The compound of formula (I) according to any one of Aspects 1 to 5, wherein A is a reactive group having the ability to react with an -SH group of a cysteine group in a targeting molecule, preferably A is a reactive group having the ability to react with an -SH group of a cysteine in a targeting molecule selected from the group consisting of

[1330]

[1331] the wavy line in A means bond to L; most preferably wherein

[1332]

[1333] The compound of formula (I) according to any one of Aspects 1 to 6, wherein group P-X1is a) a therapeutic agent, preferably a therapeutic agent selected from the group consisting of a cytotoxic agent, a cellular checkpoint inhibitor, an immune-onco agent, an anti- angiogenic agent, an antibiotic, and an antiviral drug; or

[1334] b) a labelling agent, preferably a metal chelator; or

[1335] c) a diagnostic agent, preferably a diagnostic agent selected from the group consisting of a fluorescent substance, a luminescent substance, and a phosphorescent substance. The compound of formula (I) according to any one of Aspects 1 to 7, wherein each T independently of each other has the formula (Illa) or formula (111 b)

[1336]

[1337] wherein

[1338] the wavy line in formula (Illa) and formula (lllb) means bond to O; and

[1339] n is an integer in the range of from 1 to 35.

[1340] The compound of formula (I) according to any one of Aspects 1 to 8, wherein each Lehas the formula (Le1)

[1341]

[1342] wherein Zeis O or NRN, wherein RNis H, -CH3, -CH2-CH3, or -CH(CH3)2, preferably wherein Zeis NH;

[1343] u is an integer in the range of from 0 to 4;

[1344] aeis an integer in the range of from 0 to 4;

[1345] symbol “black circle” in formula (Le1) means bond to Pep; and symbol “white circle” in formula (Le1) means bond to branching group B.

[1346] The compound of formula (I) according to any one of Aspects 1 to 9, wherein B has a structure of

[1347]

[1348] wherein

[1349] symbol “white circle” in B means bond to L; and

[1350] symbol “black circle” in B means bond to Leor bond to Pep.

[1351] The compound of formula (I) according to any one of Aspects 1 to 10, wherein L has the formula (IV)

[1352]

[1353] wherein

[1354] x is an integer in the range of from 0 to 5;

[1355] y is an integer in the range of from 0 to 4;

[1356] a is an integer in the range of from 0 to 4;

[1357] z is 0 or 1;

[1358] symbol “white circle” in L means bond to A; and

[1359] symbol “black circle” in L means bond to branching group B.

[1360] 12. A targeting molecule-drug conjugate of formula (V)

[1361] Ab[-A’-L-B(-E)e]d (V)

[1362] wherein

[1363] Ab is a targeting molecule;

[1364] d is at least 1;

[1365] A’ is a group formed by a reaction between A and a functional group in Ab; and wherein A, L, B, E, and e are as defined in any one of Aspects 1 to 11.

[1366] 13. The targeting molecule-drug conjugate of formula (V) according to Aspects 12, wherein Ab is

[1367] i) a chimeric antibody, preferably rituximab, basiliximab, infliximab, cetuximab, siltuximab, dinutuximab, or altertoxaximab;

[1368] ii) a humanized antibody, preferably daclizumab, palivizumab, trastuzumab, alemtuzumab, omalizumab, efalizumab, bevacizumab, natalizumab (lgG4), naratuximab, tocilizumab, eculizumab (lgG2), mogamulizumab, pertuzumab, obinutuzumab, vedolizumab, pembrolizumab (lgG4), mepolizumab, elotuzumab, daratumumab, ixekizumab (lgG4), reslizumab (lgG4), or atezolizumab; or

[1369] iii) a human antibody, preferably adalimumab, panitumumab, golimumab, ustekinumab, canakinumab, ofatumumab, denosumab (lgG2), ipilimumab, belimumab, raxibacumab, ramucirumab, nivolumab (lgG4), secukinumab, evolocumab (lgG2), alirocumab, necitumumab, brodalumab (I gG2), olaratumab, or dupilumab (lgG4).

[1370] 14. The targeting molecule-drug-conjugate of formula (V) according to Aspect 12 or 13, wherein each A’ is selected from the group consisting of

[1371]

[1372] symbol “black circle” in A’ means bond to L; preferably wherein

[1373]

[1374] 15. A method of manufacturing a targeting molecule-drug conjugate of formula (V) according to any one of Aspects 12 to 14, the method comprising the steps of

[1375] a) providing a compound of formula (I) according to any one of Aspects 1 to 11, b) providing a targeting molecule Ab, and

[1376] c) reacting said compound of formula (I) according to any one of Aspects 1 to 11 with the targeting molecule Ab to provide the targeting molecule-drug conjugate according to any one of Aspects 12 to 14.

[1377] 16. A targeting molecule-drug-conjugate of formula (V) according to any one of Aspects 12 to 14 or prepared by the method of Aspect 15 for use in medicine.

[1378] 17. The targeting molecule-drug conjugate of formula (V) according to Aspect 16

[1379] a) for use in a method of treating cancer, or an autoimmune disease, or a bacterial infection, or a viral infection; or

[1380] b) for use in a method of diagnosing cancer, or an autoimmune disease, or a bacterial infection, or a viral infection.

[1381] Additional aspects

[1382] The present disclosure is further described in the following additional numbered Aspects.

[1383] 1. A compound of formula (l-Exa-MMAE)

[1384] E1

[1385] A- L- B-(-E)

[1386] E2 e

[1387] (l-Exa-MMAE)

[1388] wherein:

[1389] A is a reactive group having ability to react with a functional group in a targeting molecule; L is a divalent linker group;B is a branching group;

[1390] E1is a group of formula (IE-Exa)

[1391]

[1392] wherein the wavy line in formula (IE-Exa) means bond to B;

[1393] E2is a group of formula (IE-MMAE)

[1394]

[1395] wherein the wavy line in formula (IE-MMAE) means bond to B;

[1396] e is an integer of 0 to 2;

[1397] each E is independently a group of formula (IE-Exa) or (IE-MMAE); and wherein each Lein formulae (lE-Exa) and (IE-MMAE) is independently a divalent linker group; each f in formulae (lE-Exa) and (IE-MMAE) is independently 0 or 1;

[1398] each Pep in formulae (lE-Exa) and (IE-MMAE) independently comprises 1 to 6 amino acid groups; and

[1399] each T in formulae (lE-Exa) and (IE-MMAE) is independently a solubilizing group.

[1400] The compound of formula (l-Exa-MMAE) according to additional item 1, wherein each Pep in formulae (lE-Exa) and (IE-MMAE) independently of each other has the formula (II)

[1401]

[1402] (II),

[1403] wherein

[1404] R3is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R3is H, or-CH3, or-CH(-CH3)2;R4is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R4is H, or-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2;

[1405] symbol “white circle” in formula (II) means bond to Leor bond to B; and

[1406] symbol “black circle” in formula (II) means bond to NH.

[1407] 3. The compound of formula (l-Exa-MMAE) according to additional item 1 or 2, wherein A is a reactive group having the ability to react with an -SH group of a cysteine group in a targeting molecule, preferably A is a reactive group having the ability to react with an -SH group of a cysteine in a targeting molecule selected from the group consisting of

[1408]

[1409] wherein the wavy line in A means bond to L; most preferably wherein

[1410]

[1411] 4. The compound of formula (l-Exa-MMAE) according to any one of additional items 1 to 3, wherein L has the formula (IV)

[1412]

[1413] wherein

[1414] x is an integer in the range of from 0 to 5;

[1415] y is an integer in the range of from 0 to 4;

[1416] a is an integer in the range of from 0 to 4;

[1417] z is 0 or 1;

[1418] symbol “white circle” in L means bond to A; and

[1419] symbol “black circle” in L means bond to branching group B.

[1420] 5. The compound of formula (l-Exa-MMAE) according to any one of additional items 1 to 4, wherein B has a structure of

[1421]

[1422] wherein

[1423] symbol “white circle” in B means bond to L; and

[1424] symbol “black circle” in B means bond to Leor bond to Pep.

[1425] The compound of formula (l-Exa-MMAE) according to any one of additional items 1 to 5, wherein each Lein formulae (lE-Exa) and (IE-MMAE) independently of each other has the formula (Le1)

[1426]

[1427] wherein Zeis O or NRN, wherein RNis H, -CH3, -CH2-CH3, or -CH(CH3)2, preferably wherein Zeis NH;

[1428] u is an integer in the range of from 0 to 4;

[1429] aeis an integer in the range of from 0 to 4;

[1430] symbol “black circle” in formula (Le1) means bond to Pep; and symbol “white circle” in formula (Le1) means bond to branching group B.

[1431] The compound of formula (l-Exa-MMAE) according to any one of additional items 1 to 6, wherein each T in formulae (lE-Exa) and (IE-MMAE) independently of each other has the formula (Illa) or formula (lllb)

[1432]

[1433] wherein

[1434] the wavy line in formula (Illa) and formula (lllb) means bond to O; and

[1435] n is an integer in the range of from 1 to 35.

[1436] The compound of formula (l-Exa-MMAE) according to any one of additional items 1 to 7, wherein the compound has the formula (l-Exa-MMAE-A)

[1437]

[1438] wherein A, L, B, each Le, each f, each Pep, and each T are each independently of each other as defined in any one of additional items 1 to 7.

[1439] 9. The compound of formula (l-Exa-MMAE) according to any one of additional items 1 to 8, wherein the compound has the formula (l-Exa-MMAE-B)

[1440]

[1441] wherein A, L, B, each Pep, each Le, and each T are each independently of each other as defined in any one of additional items 1 to 8.

[1442] 10. A targeting molecule-drug conjugate of formula (V-Exa-MMAE)

[1443]

[1444] wherein

[1445] Ab is a targeting molecule;

[1446] d is at least 1;

[1447] A’ is a group formed by a reaction between A and a functional group in Ab; and wherein A, L, B, E1, E2, E, and e are each independently of each other as defined in any one of additional items 1 to 9.The targeting molecule-drug conjugate of formula (V-Exa-MMAE) according to additional item 10, wherein compound has the formula (V-Exa-MMAE- A)

[1448]

[1449] Ab is a targeting molecule;

[1450] d is at least 1;

[1451] A’ is a group formed by a reaction between A and a functional group in Ab; and wherein A, L, B, each Le, each f, each Pep, and each T are independently of each other as defined in any one of additional items 1 to 9.

[1452] The targeting molecule-drug conjugate of formula (V-Exa-MMAE) according to additional item 10, wherein compound has the formula (V-Exa-MMAE-B)

[1453]

[1454] Ab is a targeting molecule;

[1455] d is at least 1;

[1456] A’ is a group formed by a reaction between A and a functional group in Ab; and wherein A, L, B, each f, each Pep, and each T are independently of each other as defined in any one of additional items 1 to 9.

[1457] The targeting molecule-drug conjugate of formula (V-Exa-MMAE) according to any one of additional items 10 to 12, wherein Ab isi) a chimeric antibody, preferably rituximab, basiliximab, infliximab, cetuximab, siltuximab, dinutuximab, or altertoxaximab;

[1458] ii) a humanized antibody, preferably daclizumab, palivizumab, trastuzumab, alemtuzumab, omalizumab, efalizumab, bevacizumab, natalizumab (lgG4), naratuximab, tocilizumab, eculizumab (lgG2), mogamulizumab, pertuzumab, obinutuzumab, vedolizumab, pembrolizumab (lgG4), mepolizumab, elotuzumab, daratumumab, ixekizumab (lgG4), reslizumab (lgG4), or atezolizumab; or

[1459] iii) a human antibody, preferably adalimumab, panitumumab, golimumab, ustekinumab, canakinumab, ofatumumab, denosumab (lgG2), ipilimumab, belimumab, raxibacumab, ramucirumab, nivolumab (lgG4), secukinumab, evolocumab (lgG2), alirocumab, necitumumab, brodalumab (lgG2), olaratumab, or dupilumab (lgG4).

[1460] 14. The targeting molecule-drug-conjugate of formula (V-Exa-MMAE) according to any one of additional items 10 to 13, wherein each A’ is selected from the group consisting of

[1461]

[1462] symbol “black circle” in A’ means bond to L; preferably wherein

[1463]

[1464] 15. A method of manufacturing a targeting molecule-drug conjugate of formula (V-Exa-MMAE) according to any one of additional items 10 to 14, the method comprising the steps of a) providing a compound of formula (I) according to any one of additional items 1 to 9, b) providing a targeting molecule Ab, and

[1465] c) reacting said compound of formula (l-Exa-MMAE) according to any one of additional items 1 to 9 with the targeting molecule Ab to provide the targeting molecule-drug conjugate according to any one of additional items 10 to 14.

[1466] 16. A compound of formula (V-Exa-MMAE) according to any one of additional items 10 to 14 for use in medicine, preferably for use in a method of treating cancer.In the following section, the abbreviations are used:

[1467] • Ac: Acetyl

[1468] • ADC: Antibody-Drug Conjugate

[1469] • ACN: acetonitrile

[1470] • AMAS: N-a-maleimidoacet-oxysuccinimide ester

[1471] • Da: Dalton

[1472] • DCC: N, N'-Dicyclohexylcarbodiimide

[1473] • DCM: dichloromethane

[1474] • DIBAL-H: Diisobutylaluminium hydride

[1475] • DIEA: diisopropylethylamine

[1476] • DMA: dimethylacetamide

[1477] • DMF: dimethyl formamide

[1478] • DMSO: dimethyl sulfoxide

[1479] • DPBS: Dulbecco’s phosphate-buffered saline

[1480] • EDCI: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

[1481] • EEDQ: N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline

[1482] • EndoS: Endoglycosidase S

[1483] • Et: ethyl

[1484] • EtOAc: ethyl acetate

[1485] • eq.: equivalent

[1486] • ESI: electronspray ionization

[1487] • FA: formic acid

[1488] • FLD: Fluorescence detection

[1489] • Fmoc: 9-fluorenylmethoxycarbonyl

[1490] • HATU: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide • HOBT: hydroxybenzotriazole

[1491] • HPLC: high-performance liquid chromatography

[1492] • HRMS: high resolution mass spectrometry

[1493] • IdeS: Immunoglobulin-degrading Enzyme (IdeS)

[1494] • LC-MS: Liquid chromatography coupled to mass spectrometry

[1495] • ma: maleimidoacetic acid

[1496] • mAb: monoclonal antibody

[1497] • Me: methyl

[1498] • MS: mass spectroscopy

[1499] • MTBE: Methyl tert-butyl ether

[1500] • Mw: molecular weight

[1501] • m / z: mass over charge ratio• NA: Not analyzed

[1502] • NHS: N-Hydroxysuccinimide

[1503] • PAB: para-aminobenzyl group

[1504] • PBr3: Phosphorus tribromide

[1505] • PFP: 2,3,4,5,6-Pentafluorophenol

[1506] • PE: petroleum ether

[1507] • PEG: polyethylene glycol

[1508] • pH: potential for hydrogen

[1509] • QTOF-MS: Quadrupole Time of Flight Mass Spectrometer

[1510] • RP: reversed phase

[1511] • RPM: rotations per minute

[1512] • rt: room temperature

[1513] • Rt: retention time

[1514] • SEC: size exclusion chromatography

[1515] • SQD: single quadrupole detector

[1516] • t: tertio

[1517] • TCEP: tris(2-carboxyethyl)phosphine

[1518] • TEA: triethylamine

[1519] • TFA: trifluoroacetic acid

[1520] • THF: tetra hydrofuran

[1521] • TsCI: tosyl chloride

[1522] • UPLC: ultra-performance liquid chromatography

[1523] • UV: ultraviolet

[1524] • °C: Celsius degree

[1525] •

[1526] Materials

[1527] All starting materials and solvents were obtained from commercial suppliers, unless indicated otherwise. Solvents for synthesis and deprotection reagents from Merck or Fischer Scientific AG (Switzerland); Exatecan was purchased from Zhejiang Huida Biotech., Ltd (BD); Prexasertib was purchased from Ambeed; MMAE was purchased from Enovation Chemicals; Trastuzumab deruxtecan was purchased from AstraZeneca; Ammonium Acetate (MS-grade), DMSO, TFA, triethylamine, DIEA, N-hydroxysuccinimide, HOSu, DPBS, TCEP. HCI 0.5M solutions at pH7 from Sigma-Aldrich (Switzerland); AMAS from Astatech Inc (USA); Solvents and chemicals for high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography mass spectrometry (UPLC-MS) from Biosolve (France); HATU. HPF6 from Combi-Blocks (USA) HiLoad® 16 / 600 Superdex® 200 pg columns were purchased from Cytiva, Sweden; CentriPure 5 - Z50M, 10 - Z50M, 25 - Z50M and 50 - Z50M were purchased from Bioinnovas; AMICON® Ultra-4 and Ultra-15 (50kDa MW cut off) were purchased from MerckMillipore; Trastuzumab (Herceptin®) was purchased from Roche Pharma (Switzerland) and reconstituted in Water according to manufacturer instructions; Naratuximab antibody huCD37-3 (version 1.0) described in WO2019 / 229677; 96-well plates were purchased from Greiner bio-one; 0.22 pm PES sterile syringe filters were purchased from Cole-Parmer; Water from Millipore system; Endoglycosidase S enzyme and GlycoBuffer were purchased from New England Biolabs, IdeS (FabRICATOR®) was purchased from Genovis.

[1528] Methods

[1529] The purity of the compounds was determined using UPLC-MS systems: LC-MS Waters Acquity UPLC System coupled to a Waters SQD mass spectrometer, BEH C181.7pm 50x2.1mm column heated at 40°C and fitted with 2pm insert filter pre-columns (available from Waters), and solvent systems A1 (water+0.1%FA) and B1 (ACN+0.1%FA) at a flow rate of 0.9 mL / min.

[1530] LC-MS mass spectra were recorded on a SQ detector Acquity Waters (Waters Corporation, Waters Milford, 34 Maple St., Milford, USA) equipped with software Empower 2 pro in a positive ionization mode. Ionization conditions: Capillary 2.25 KV, Cone 160 V, Source 100 °C, Desolvation 150 °C; Gas flow Desolvation 500 L / h, Cone 50 L / h.

[1531] NMR Spectra were acquired on a Bruker Avance III spectrometer at 400 MHz using residual undeuterated solvent as reference.

[1532] Preparative SEC was performed on an AKTA pure 25M chromatography system with a multiwavelength detector (Cytiva, Sweden) using a flow rate of 1-1.5 mL / min and DPBS as eluent.

[1533] The aggregate content of the ADCs was determined using SEC: approximately 50 pg of ADC (5-10 pL) was injected onto a Waters® Xbridge Premier Protein SEC column (250 A, 2.5 pm, 4.6 x 150 mm) with a Waters® MaxPeak™ Premier Protein SEC guard (250 A, 2.5 pm, 4.6 x 30 mm) at Rt using a Waters® ACQUITY Premier UPLC System. The mobile phase contained DPBS and set at a flow rate of 0.3 mL / min for 10 min with an isocratic gradient. The UV spectra was acquired at 280 nm and 220 nm. An alternative strategy for the determination of the aggregate content was by injection of approximately 50 pg of ADC (5-10 pL) onto an Agilent AdvanceBio SEC column (300A, 2.7 pm, 4.6 x 50 mm) guard column with a AdvanceBio SEC (300A, 2.7 pm, 4.6 x 300 mm) analytical column at rt. The mobile phase contained 150 mM Sodium phosphate buffer / 300 mM NaCI (pH 6.5) and 10% ACN. The flow rate was 0.25 mL / min, and an isocratic gradient was applied for 25 min. The UV spectra was acquired at 280 nm.

[1534] Determination of molar extinction coefficients (8)

[1535] The values of 8, necessary to calculate ADC concentrations, are determined for the mAb (trastuzumab or naratuximab, respectively) and for the linker-payload compounds using the following methods.£ of the mAb is measured using a solution of the corresponding antibody in DPBS (pH 7.4) if there is no theoretical £ available based on the protein sequence (preferred option).

[1536] The £ of the linker-payload compound are calculated as the sum of the £’s of experimentally measured absorbing building blocks of the linker-payload in 90 / 10 (v / v) H2O / DMSO. If the linker-payload is available and soluble in 90 / 10 (v / v) H2O / DMSO, calibration curves including at least 5 standard solutions of the linker-payload are prepared at varied known concentrations (preferred option). UV measurements are then performed at 280 and 370 nm at room temperature in a 96-well plate using a TECAN Spark UV spectrophotometer (data acquisition using Gen5 software). An optical path of 0.173 is applied for analysis (corresponding to the sample absorbance measured at 900 and 975 nm in 1 cm cuvette). All UV absorbance values are blank subtracted. From these absorbance values for the linker-payload, the £ can be determined according to the Beer-Lambert law as follows:

[1537] £ = A280 / 370 / C x L, where:

[1538] • ε (L·mol-1·cm-1) = Molar extinction coefficient of mAb, or linker-payload

[1539] • A280 / 370 = Absorbance measured at 280 or 370 nm

[1540] • C (mol / L) = Concentration of mAb, or linker-payload

[1541] • L (cm) = Optical path (normalized at 1 cm)

[1542] Determination of ADC concentration by UV

[1543] The ADC sample is diluted with PBS pH 7.4 to a target concentration covered by the mAb standard curve. UV measurements are made in triplicate at 280 and 370 nm at room temperature in a 96-well plate (similarly to the £ measurements). UV spectra were also acquired from 200 nm to 400 nm. An optical path of 0.173 was also applied and all absorbances were subtracted from the blank. The ADC concentration is then determined via:

[1544] Calculation formula 1:

[1545] mol / 4280 x Epayload 370 — 4370 x Epayload280 \

[1546] c ADC ( - ) = - — - - — - - x I L EmAb280 x Epayload370 — EmAb370 x Epayload280 /

[1547] wherein:

[1548] • A280 / 370 = Absorbance measured at 280 or 370 nm

[1549] • εmAb(L·mol-1·cm-1) = Molar extinction coefficient for the mAb (trastuzumab or naratuximab, respectively)

[1550] • εpayload(L·mol-1·cm-1) = Molar extinction coefficient for the linker-payload

[1551] • L (cm) = Optical path (normalized at 1 cm)

[1552] Calculation formula 2:

[1553] CADC (mol / L)=A28O I ((EmAb + DARxEpayload)xL)

[1554] wherein:

[1555] A280 = Absorbance measured at 280 nm

[1556] εmAb(L·mol-1·cm-1) = Molar extinction coefficient for the mAb at 280 nm• Epayioad (L mol’1cm’1) = Molar extinction coefficients for the linker-payload (compound 41 or 48, respectively) at 280 nm

[1557] • DAR = Drug-to-antibody ratio determined for the ADC

[1558] • L (cm) = Optical path (normalized at 1 cm)

[1559] For both methods the ADC concentration in mg / mL was then calculated as follows:

[1560] CADC (mg / mL) = CmOiADC(mol / L) x Mw ADC*

[1561] *Mw ADC (molar mass in g / mol) = Mw mAb + (Mw linker-payload x DAR).

[1562] DAR determination by Native SEC- MS

[1563] The DAR for each of the ADCs (i.e., compounds 34, 41, 42, 58, 71, 77, 87, 96, 102, 110, 120, 133, 135 and 137) was determined by native size-exclusion chromatography (SEC) coupled to High-Resolution Mass Spectrometry (HRMS) after treatment of the ADC with Endoglycosidase S (EndoS) to cleave the N-glycans.

[1564] Sample preparation by EndoS: approximately 50 pg of ADC is combined with the EndoS enzyme and of GlycoBuffer before being completed with PBS (pH 7.4) and incubation of 1h at 37°C and 500rpm. Prior to analysis the sample is further diluted with H2O.

[1565] Chromatography: approximately 10-20 pg of deglycosylated ADC (10 pL) is injected onto a Waters® Xbridge Premier Protein SEC column (250 A, 2.5 pm, 4.6 x 150 mm) at RT using a Waters ACQUITY Premier UPLC System. The mobile phase contained 50 mM ammonium acetate and set at a flow rate of 0.2 mL / min for 15 min with an isocratic gradient. The UV spectra was acquired at 280 nm.

[1566] Mass spectrometry: the QTOF-MS system (Sciex ZenoTOF 7600) was operated in electron spray ionization positive mode with a spray voltage of 5.5 kV and declustering potential of 280V. The source temperature was set to 400°C and the collision energy to 20V. The ion source gas 1 and 1 were set to 70 psi and the curtain gas to 35 psi. The acquisition mass range was from 3000-12000 m / z with a 1s accumulation time. Data acquisition and instrument control were performed via SCIEX OS (v3.3.1.43) and data treatment was performed in Biologies Explorer (v3.1.1) to assign the DAR based on the attributed peaks in the spectra.

[1567] DAR determination by Denaturing RPLC-MS

[1568] An alternative strategy for DAR determination of the ADCs was the use of denaturing RPLC coupled to HRMS after treatment of the ADC with EndoS (i.e. compounds 96, 110 and 120), to cleave the N-glycans, as described previously, or after the ADC reduction (i.e. compound 133 and 137) to open disulfide bridges and separate light and heavy chains.

[1569] Sample reduction by TCEP: approximately 50 pg of ADC is combined with 5 pL of a 100 mM TCEP solution before being completed with PBS (pH 7.4) and incubation of 1h at 37°C and 500rpm. Prior to analysis the sample is further diluted with H2O to a 50 pL final volume.

[1570] Chromatography: approximately 2 pg of deglycosylated or reduced ADC (2 pL) is injected onto Waters® BEH300 C4 column (1.7 µm, 50 x 2.1 mm) at 80 °C using a Waters ACQUITY Premier UPLC System. The mobile phase contained 0.1% FA in water (mobile phaseA) and 0.1 % FA in ACN (mobile phase B) and set at a flow rate of 0.3 mL / min. A gradient set from 20%B to 40%B for 7min after which the column was cleaned for 2 min at 90%B and returned to 20% for 2.5 min prior to the following injection.

[1571] Mass spectrometry: the QTOF-MS system (Sciex ZenoTOF 7600) was operated in electron spray ionization positive mode with a spray voltage of 5.5 kV and declustering potential of 200V. The source temperature was set to 500 °C and the collision energy to 10 V. The ion source gas 1 and 2 were set to 50 psi and the curtain gas to 37 psi. The acquisition mass range was from 400-4000 m / z with a 0.5s accumulation time. Data acquisition and instrument control were performed via SCIEX OS (v3.3.1.43) and data treatment was performed in Biologies Explorer (v3.1.1) to assign the DAR based on the attributed peaks in the spectra.

[1572] Fc / Fab selectivity by RPLC-HRMS with Ides treatment

[1573] For compounds 102, 110 and 120, values of Fc / Fab selectivity were determined by RPLC coupled to HRMS after treatment of the ADC with IdeS (Genovis A0-FR1-050 FabRICATOR) to cleave Fab from Fc (under the hinge region). Fc / Fab selectivity was calculated based on the DAR values determined for each domain. These DAR values were derived from the deconvoluted HRMS spectrum of the ADC after identification of the different species based on their observed masses.

[1574] The % of selectivity was obtained as follows:

[1575]

[1576] Sample preparation: approximately 50 pg of ADC (~10 mg / mL) was combined with 1 pL of IdeS solution (dissolved in H2O), diluted with DPBS to get a final volume of 50 pL, mixed (vortex) and incubated at 37 °C and 500 rpm for 30 min.

[1577] Chromatography and mass spectrometry methods are described in the DAR determination by Denaturing RPLC-MS section.

[1578] DAR determination by denaturing RPLC-FLD

[1579] DAR determination of compound 102 was performed by denaturing RPLC coupled with fluorescence detection. Prior to the analysis, the intact ADC was diluted to a concentration of 3 mg / mL in PBS (pH 7.4). For the analysis, 3 uL of intact ADC was injected onto a Waters® BioResolve RP mAb Polyphenyl column (450A, 2.7pm, 2.1 x 150mm) at 90°C using a Waters ACQUITY Premier UPLC System. The mobile phase contained 0.1% TFA in water (mobile phase A) and 0.1% TFA in ACN (mobile phase B) at a flow rate of 0.6 mL / min. A gradient was set from 34%B to 42%B in 15 min and held at 42%B for 2 min before further increasing to 90%B for 0.1 min. After returning to 34%B the column was reconditioned for 5 min prior to the following injection. FLD was used to detect the separated DAR species with an excitation wavelength of 280 nm and emission wavelength of 260 nm. The DAR was calculated based on the area under the curve of the attributed peaks in the spectra.Example 1: Synthesis of intermediate 19

[1580] Step 1:

[1581]

[1582] To a stirred solution of methyl 2-hydroxy-4-nitrobenzoate 1 (5.0 g, 25.4 mmol) in DMF (200 mL) was added K2CO3 (7.02 g, 50.8 mmol) and 3-bromoprop-1-yne 2 (3.63 g, 30.5 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 18 h. The reaction was monitored by LCMS. After the reaction was completed, the reaction mixture was poured into water (400 mL) and extracted with EtOAc (100 mL x 3). The combined organic layer was dried over sodium sulfate and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with EtOAc / PE, 0% to 20%) to provide 3 (5.4 g, 95% purity, 86% yield) as a yellow solid.

[1583] 1H NMR (400 MHz, Chloroform-d) 58.00 (d, J= 1.9 Hz, 1H), 7.95 -7.88 (m, 2H), 4.90 (d, J= 2.4 Hz, 2H), 3.94 (s, 3H), 2.61 (t, J= 2.4 Hz, 1H).

[1584] Step 2:

[1585]

[1586] To a solution of 3 (1.0 g, 4.0 mmol, 95% purity) and Iron (1.2 g, 21.5 mmol) in EtOH (15 mL) and H2O (15 mL) was added NH4CI (1.84 g, 34.4 mmol) at 25 °C. The reaction mixture was stirred at 80 °C for 1 h. The reaction was monitored by LCMS. After the reaction was completed, the mixture was filtered through Celite. The filtrate was concentrated under vacuum and purified by silica gel column chromatography (eluting with EtOAc / PE, 0% to 50%) to provide 4 (0.8 g, 95% purity, 91% yield) as a yellow solid.

[1587] LCMS (ESI) calcd for C11H12NO3 [M + H]+m / z 206.08, found 206.00.

[1588] Step 3:

[1589]

[1590] To a stirred solution of 4 (1.4 g, 6.48 mmol, 95% purity) in THF (40 mL) was added DIBAL-H (1 M in hexane, 22.5 mL, 22.5 mmol) dropwise at -50 °C under an atmosphere of N2. The reaction mixture was stirred at -50 °C for 50 minutes. The reaction was monitored by LCMS. After the reaction was completed, H2O (0.9 mL) was added dropwise at 0 °C, followed by 15% NaOH aqueous (0.9 mL) and H2O (2.25 mL). The obtained mixture was stirred at 25 °C for 15mins, then filtered through Celite. The filtrate was dried over Na2SO4and concentrated under vacuum toprovide 5 (1.2 g, 90% purity, 94% yield) as a yellow solid, which was used directly in the next step without further purification.

[1591] LCMS (ESI) calcd for C10H10NO [M + H - H2O]+m / z 160.08, found 160.20.

[1592] Step 4:

[1593]

[1594] To a stirred solution of 5 (1.0 g, 5.08 mmol, 90% purity) and 6 (2.55 g, 6.21 mmol) in DCM (15 mL) and MeOH (5 mL) was added EEDQ (1.84 g, 7.45 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 18 h. The reaction was monitored by LCMS. After the reaction was completed, the mixture was concentrated under vacuum. The residue was triturated in MTBE (100 mL) and dried under vacuum to provide crude 7 (3.1 g, 90% purity, 79% yield) as a yellow solid, which was used directly in the next step without further purification.

[1595] LCMS (ESI) calcd for C33H35N3O8Na [M + Na]+m / z 592.24, found 592.20.

[1596] Step 5:

[1597]

[1598] To a stirred solution 7 (1.79 g, 5.88 mmol) in DMF (50 mL) was added DIEA (1.27 g, 9.83 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 0.5 h. T...

Claims

Claims1. A compound of formula (I)A-L-B-(E)e(I)whereinA is a reactive group having ability to react with a functional group in a targeting molecule; L is a divalent linker group;B is a branching group;e is an integer of 2 or more; andeach E is independently a group of formula (IE)whereinthe wavy line in formula (IE) means bond to B;each Leis independently a divalent linker group;each f is independently 0 or 1;each Pep independently comprises 1 to 6 amino acid groups;each T is independently a solubilizing group;each CL is independently a cleavable linker; andeach group P-X1is independently a payload, wherein each X1is independently O, S, NR1, or N+R1R11, wherein R1and R11are each independently a hydrogen or an organic residue.

2. The compound according to claim 1, wherein CL-X1-P together form a structure selected from the group consisting of:,3.

3. The compound according to claim 1 or 2, each E is independently a group of formula (IE-A)wherein Le, f, Pep, T, X1, and P are as defined in claim 1.

4. The compound of formula (I) according to any one of claims 1 to 3, wherein each X1of formula (IE) is NR1, wherein R1is hydrogen or C1-C6alky, preferably each X1is NH.

5. The compound of formula (I) according to any one of claim 1 to 4, wherein e is an integer in the range of from 2 to 6, preferably e is an integer in the range of from 2 to 4, more preferably e is 2 or 3, most preferably e is 2.

6. The compound of formula (I) according to any one of claims 1 to 5, wherein the compound has the formula (la)wherein A, L, B, Le, f, Pep, T, CL, and P-X1are as defined in any one of claims 1 to 5, preferably wherein the compound has the formula (lb)wherein A, L, B, Pep, T, CL, and P-X1are as defined in any one of claims 1 to 5, preferably wherein the compound has the formula (lb).

7. The compound of formula (I) according to any one of claims 1 to 6, wherein each Pep independently of each other has the formula (II)whereinR3is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R3is H, or-CH3, or-CH(-CH3)2;R4is H, or optionally substituted linear or branched C1-C6alkyl, or benzyl, preferably R4is H, or-CH3, or -CH(-CH3)2, or -(CH2)3-NH-(C=O)-NH2, or -(CH2)4-NH2;symbol “white circle” in formula (II) means bond to Leor bond to B; andsymbol “black circle” in formula (II) means bond to NH.

8. The compound of formula (I) according to any one of claims 1 to 7, wherein A is a reactive group having the ability to react with an -SH group of a cysteine group in a targeting molecule, preferably A is a reactive group having the ability to react with an -SH group of a cysteine in a targeting molecule selected from the group consisting ofwherein the wavy line in A means bond to L; most preferably wherein9. The compound of formula (I) according to any one of claims 1 to 7, wherein A is a reactive group having ability to react with an -NH2group of a lysine in a targeting molecule, preferably wherein A iswherein Z2represents a group covalently attached to the N-terminus of Asp and is selected from a hydrogen atom or a carbonyl containing group, preferably Z2is an acetyl group, and Z1represents a group covalently attached to the C-terminus of Thr and is selected from -N(H)(RV) wherein Rvis a hydrogen atom or an organic residue as disclosed herein, preferably wherein Z1is -NH2.

10. The compound of formula (I) according to any one of claims 1 to 9, wherein group P-X1is a) a therapeutic agent, preferably a therapeutic agent selected from the group consisting of a cytotoxic agent, a cellular checkpoint inhibitor, an immune-onco agent, an anti- angiogenic agent, an antibiotic, and an antiviral drug; orb) a labelling agent, preferably a metal chelator; orc) a diagnostic agent, preferably a diagnostic agent selected from the group consisting of a fluorescent substance, a luminescent substance, and a phosphorescent substance.

11. The compound of formula (I) according to any one of claims 1 to 10, wherein each T independently of each other has the formula (Illa) or formula (111 b)whereinthe wavy line in formula (Illa) and formula (lllb) means bond to O; andn is an integer in the range of from 1 to 35.

12. The compound of formula (I) according to any one of claims 1 to 11, wherein each Lehas the formula (Le1)wherein Zeis O or NRN, wherein RNis H, -CH3, -CH2-CH3, or -CH(CH3)2, preferably wherein Zeis NH;u is an integer in the range of from 0 to 4;aeis an integer in the range of from 0 to 4;symbol “black circle” in formula (Le1) means bond to Pep; and symbol “white circle” in formula (Le1) means bond to branching group B.

13. The compound of formula (I) according to any one of claims 1 to 12, wherein each Lehas a structure of formula (Le3)wherein symbol “black circle” in formula (Le1) means bond to Pep; and symbol “white circle” in formula (Le1) means bond to branching group B.

14. The compound of formula (I) according to any one of claims 1 to 13, wherein B has a structure ofwhereinsymbol “white circle” in B means bond to L; andsymbol “black circle” in B means bond to Leor bond to Pep.

15. The compound of formula (I) according to any one of claims 1 to 14, wherein the group B is selected from the group consisting ofwherein symbol “white circle” means bond to L, and symbol “black circle” means bond to Le.

16. The compound of formula (I) according to any one of claims 1 to 11 or 15, wherein Lehas a structure of formula (Le4)wherein o is an integer in the range of from 1 to 4, and wherein the symbol “white circle” in formula (Le4) means bond to B, and symbol “black circle” in formula (Le4) means bond to Pep.

17. The compound of formula (I) according to any one of claims 1 to 11, 15 or 16, wherein Lehas a structure of formula (Le5)wherein the symbol “white circle” in formula (Le5) means bond to B, and symbol “black circle” in formula (Le4) means bond to Pep.

18. The compound of formula (I) according to any one of claims 1 to 11 or 15 to 17, wherein the groups B and Letogether form a structure selected from the group consisting of formulae:wherein symbol “white circle” means bond to L and each symbol “black circle” means bond to Pep.

19. The compound of formula (I) according to any one of claims 1 to 11 or 14, wherein Leis a single bond.

20. The compound of formula (I) according to any one of claims 1 to 12 or 16, wherein the groups B and Letogether form a structure selected from the group consisting of formulae:wherein symbol “white circle” means bond to L and each symbol “black circle” means bond to Pep.

21. The compound of formula (I) according to any one of claims 1 to 20, wherein L has the formula (IV)whereinx is an integer in the range of from 0 to 5;y is an integer in the range of from 0 to 4;a is an integer in the range of from 0 to 4;z is 0 or 1;symbol “white circle” in L means bond to A; andsymbol “black circle” in L means bond to branching group B.

22. The compound of formula (I) according to any one of claims 1 to 21, wherein L has a structure of a formula selected from the group consisting of:wherein symbol “white circle” in said L means bond to A; and symbol “black circle” in said L means bond to B.

23. The compound of formula (I) according to any one of claims 1 to 22, wherein L has a structure of formula:wherein symbol “white circle” in said L means bond to A; and symbol “black circle” in said L means bond to B.

24. The compound of formula (I) according to any one of claims 1 to 15 or 21 to 23, wherein the groups L, B, and Letogether form a structure selected from the group consisting of formulaesymbol “white circle” means bond to A and each symbol “black circle” means bond to Pep.

25. The compound of formula (I) according to any one of claims 1 to 24, wherein the groups L, B, and Letogether form a structure selected from the group consisting of formulae:wherein symbol “white circle” means bond to A and each symbol “black circle” means bond to Pep, wherein A is preferably26. The compound of formula (I) according to any one of claims 1 to 25, wherein the groups L, B, and Letogether form a structure selected from the group consisting of formulae:wherein symbol “white circle” means bond to A and each symbol “black circle” means bond to Pep.

27. The compound of formula (I) according to any one of claims 1 to 26, wherein the groups L, B, and Letogether form a structure selected from the group consisting of formulaesymbol “white circle” means bond to A and each symbol “black circle” means bond to Pep 28. The compound of formula (I) according to any one of claims 1 to 27, wherein the compound of formula (I) comprises at least one, preferably one, group E of formula (IE-Exa)and at least one, preferably one, group E of formula (IE-Prexa)(IE-Prexa),wherein the symbol “wavy line” indicates bond to B, and each of Le, f, Pep, and T is as defined in any one of claims 1 to 27.

29. The compound of formula (I) according to any one of claims 1 to 27, wherein the compound of formula (I) comprises at least one, preferably one, group E of formula (IE-Prexa)(IE-Prexa),and at least one, preferably one, group E of formula (lE-EtAPCT)wherein the symbol “wavy line” indicates bond to B, and each of Le, f, Pep, and T is as defined in any one of claims 1 to 27.

30. The compound of formula (I) according to any one of claims 1 to 5 or 7 to 27, wherein the compound of formula (I) has a structure of formula (I-MMAE-Exa)wherein E1 is a group of formulawherein the wavy line in formula (IE-Exa) means bond to B;E2is a group of formula (IE-MMAE)wherein the wavy line in formula (IE-MMAE) means bond to B;e is an integer of 0 to 2; andA, L, B, Le, f, Pep, and T are as defined in any one of claims 1 to 5 or 7 to 22.

31. The compound of formula (I) according to claim 30, wherein the compound has the formula (I-MMAE-Exa-A)wherein A, L, B, each Le, each f, each Pep, and each T are each independently of each other as defined in any one of claims 1 to 22.

32. The compound of formula (I) according to claim 30 or 31, wherein the compound has the formula (I-MMAE-Exa-B)wherein A, L, B, each Pep, each Le, and each T are each independently of each other as defined in any one of claims 1 to 29.

33. A targeting molecule-drug conjugate of formula (V)Ab[-A’-L-B(-E)e]d (V)whereinAb is a targeting molecule;d is at least 1;A’ is a group formed by a reaction between A and a functional group in Ab; and wherein A, L, B, E, and e are as defined in any one of claims 1 to 32.

34. The targeting molecule-drug conjugate of formula (V) according to claim 33, wherein Ab is i) a chimeric antibody, preferably rituximab, basiliximab, infliximab, cetuximab, siltuximab, dinutuximab, or altertoxaximab;ii) a humanized antibody, preferably daclizumab, palivizumab, trastuzumab, alemtuzumab, omalizumab, efalizumab, bevacizumab, natalizumab (lgG4), naratuximab, tocilizumab, eculizumab (lgG2), mogamulizumab, pertuzumab, obinutuzumab, vedolizumab, pembrolizumab (lgG4), mepolizumab, elotuzumab, daratumumab, ixekizumab (lgG4), reslizumab (lgG4), or atezolizumab; oriii) a human antibody, preferably adalimumab, panitumumab, golimumab, ustekinumab, canakinumab, ofatumumab, denosumab (lgG2), ipilimumab, belimumab, raxibacumab, ramucirumab, nivolumab (lgG4), secukinumab, evolocumab (lgG2), alirocumab, necitumumab, brodalumab (lgG2), olaratumab, or dupilumab (lgG4).

35. The targeting molecule-drug-conjugate according to claim 33 or 34, wherein each A’ is selected from the group consisting ofsymbol “black circle” in A’ means bond to L; preferably wherein36. The targeting molecule-drug-conjugate of formula (V) according to any one of claims 33 to 35, wherein A’ iswherein the symbol “white circle” in said group A’ means bond to Ab (specifically to -NH in the side chain of a cysteine), and the symbol “black circle” in said group A’ means bond to L.

37. The compound of formula (V) according to any one of claims 33 to 36, wherein L has a structure of a formula selected from the group consisting of:wherein symbol “white circle” in said L means bond to A’; and symbol “black circle” in said L means bond to B.

38. The compound of formula (V) according to any one of claims 33 to 37, wherein L has a structure of formula:wherein symbol “white circle” in said L means bond to A’; and symbol “black circle” in said L means bond to B.

39. The targeting molecule-drug conjugate according to any one of claims 33 to 38, wherein the compound of formula (V) comprises at least one, preferably one, group E of formula (IE-Exa)and at least one, preferably one, group E of formula (IE-Prexa)(IE-Prexa),wherein the symbol “wavy line” indicates bond to B, and each of Le, f, Pep, and T is as defined in any one of claims 1 to 27.

40. The compound of formula (V) according to any one of claims 33 to 38, wherein the compound of formula (I) comprises at least one, preferably one, group E of formula (IE-Prexa)(IE-Prexa),and at least one, preferably one, group E of formula (lE-EtAPCT)41. wherein the symbol “wavy line” indicates bond to B, and each of Le, f, Pep, and T is as defined in any one of claims 1 to 27.

42. The targeting molecule-drug-conjugate according to any one of claims 33 to 38, wherein the targeting molecule-drug conjugate of formula (V) has a structure offormula (V-MMAE-Exa)wherein E1 is a group of formulawherein the wavy line in formula (IE-Exa) means bond to B;E2is a group of formula (IE-MMAE)wherein the wavy line in formula (IE-MMAE) means bond to B; ande is an integer of 0 to 2.

43. The targeting molecule-drug conjugate of formula (V) according to claim 42, wherein compound has the formula (V-Exa-MMAE-A)44. The targeting molecule-drug conjugate of formula (V) according to claim 42 or 43, wherein compound has the formula (V-Exa-MMAE-B)45. A method of manufacturing a targeting molecule-drug conjugate of formula (V) according to any one of claims 33 to 44, the method comprising the steps ofa) providing a compound of formula (I) according to any one of claims 1 to 32, b) providing a targeting molecule Ab, andc) reacting said compound of formula (I) according to any one of claims 1 to 25 with the targeting molecule Ab to provide the targeting molecule-drug conjugate according to any one of claims 33 to 44.

46. A compound of formula (V) according to any one of claims 33 to 44 for use in medicine, preferably for use in a method of treating cancer.